Role of AMP-protein kinase (AMPK) in regulation of perivascular adipose tissue (PVAT) function by Almabrouk, Tarek Ali Mohamed
  
 
 
 
 
 
 
Almabrouk, Tarek Ali Mohamed (2017) Role of AMP-protein kinase 
(AMPK) in regulation of perivascular adipose tissue (PVAT) function. PhD 
thesis. 
 
 
 
http://theses.gla.ac.uk/8178/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten:Theses 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
ROLE OF AMP-PROTEIN KINASE (AMPK) 
IN REGULATION OF PERIVASCULAR 
ADIPOSE TISSUE (PVAT) FUNCTION. 
 
 
Tarek Ali Mohamed Almabrouk                                                                       
MSc, MBChB  
 
 
Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy in 
the Institute of Cardiovascular and Medical Sciences,                                 
University of Glasgow 
 
Institute of Cardiovascular and Medical Sciences                                            
College of Medical, Veterinary and Life Sciences                                        
University of Glasgow 
 
 
 
 
©T. A. Almabrouk 2016
 II 
 
Author’s Declaration 
I declare that this thesis has been written solely by me with the research entirely generated 
by myself with the exception of the Western blots to study AMPK activation in adipose 
tissue and VSMCs and the PVAT confocal experiments. These were done in collaboration 
with Dr. Azizah Ugsman, Mr Omar Katwan and Alex Riddel. The research was carried out 
principally in the Institute of Cardiovascular and Medical Sciences at the University of 
Glasgow, under the supervision of Dr. Simon Kennedy and Dr.Ian Salt.  
T A. Almabrouk, 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 III 
 
Acknowledgments 
First and foremost I would like to thank my supervisors, Dr. Simon Kennedy and Dr. Ian 
Salt for all their support, guidance, advice and the opportunities I’ve had over the period of 
my PhD. I would also like to acknowledge the Libyan Government and my university for 
their support and funding of this project.  
There are many people whose help over the years has been invaluable and greatly 
appreciated, at the Universities of Glasgow. I would like to thank all the members of the 
Kennedy and Salt groups past and present for helping me with just about everything. A 
special thanks goes to Dr. Marie-Ann Ewart who has supported me in my first steps in this 
project over the last few years.  
A special thanks to my family. Words cannot express how grateful I am to my mother and 
for all of the sacrifices that you’ve made on my behalf. Your prayer for me was what 
sustained me thus far. I would also like to thank all of my friends who supported me during 
my PhD study. At the end I would like to express appreciation to my beloved wife who 
was always my support in the moments of difficulty and for her advice and 
encouragement.  I couldn’t have achieved it without you. 
 
 
 
 
 
 
 
 IV 
 
List of Contents 
Author’s Declaration ............................................................................................................. II 
Acknowledgments ................................................................................................................ III 
List of Contents ................................................................................................................... IV 
List of Figures ..................................................................................................................... IX 
List of Tables...................................................................................................................... XII 
List of Publications ........................................................................................................... XIII 
List of Abbreviations and definitions ................................................................................. XV 
Abstract .......................................................................................................................... XVIII 
Chapter 1 ................................................................................................................................ 1 
General Introduction .............................................................................................................. 1 
1.1 Obesity and Cardiovascular disease ........................................................................ 1 
1.2 Anatomy of cardiovascular system ......................................................................... 2 
1.2.1 Endothelium ..................................................................................................... 3 
1.2.2 Vascular smooth muscle layer ......................................................................... 3 
1.2.3 Adventitia (Perivascular adipose tissue) .......................................................... 3 
1.3 Adipose tissue (General Features) ........................................................................... 3 
1.4 Perivascular adipose tissue (PVAT) ........................................................................ 5 
1.4.1 PVAT function ................................................................................................. 6 
1.5 Mechanism of vascular myocyte contraction ........................................................ 13 
1.6 Mechanism of VSMCs relaxation and the role of K+ channels............................. 14 
1.6.1 Ca
2+
-activated K
+
 channels (BKCa channels) ................................................. 14 
1.6.2 Voltage-gated K
+
 channels (Kv) ..................................................................... 15 
1.6.3 ATP-sensitive K
+
 channels (KATP) ................................................................. 16 
1.7 Mechanism of anticontractile effect of the PVAT ................................................ 17 
1.7.1 Endothelium-dependent mechanism of PVAT action.................................... 18 
1.7.2 Endothelium-independent mechanism of PVAT action ................................ 19 
1.8 PVAT involvement in cell proliferation and migration ........................................ 20 
1.8.1 Pro-Atherosclerotic Properties of PVAT ....................................................... 20 
1.8.2 Anti-atherosclerotic properties of PVAT ....................................................... 23 
1.9 AMP-activated protein Kinase (AMPK) ............................................................... 25 
1.9.1 Background .................................................................................................... 25 
1.9.2 AMPK structure ............................................................................................. 25 
1.9.3 Activation of AMPK ...................................................................................... 26 
1.10 Downstream targets of AMPK .............................................................................. 33 
1.11 Role of AMPK in peripheral tissue ....................................................................... 34 
1.12 Vascular effects of AMPK .................................................................................... 35 
1.12.1 Role of AMPK in the vascular endothelium .................................................. 35 
 V 
 
1.12.2 Role of AMPK in vascular smooth muscle cells ........................................... 37 
1.13 Cross talk between PVAT and vascular layers and role of AMPK ....................... 38 
1.14 Role of AMPK in perivascular adipose tissue ....................................................... 41 
1.15 Hypothesis and Aims ............................................................................................. 41 
Chapter 2 .............................................................................................................................. 43 
Materials and Methods ......................................................................................................... 43 
Materials ............................................................................................................................... 44 
2.1 Animals ................................................................................................................. 44 
2.2 Chemical and Reagents ......................................................................................... 44 
Methods ................................................................................................................................ 45 
2.3 Genotyping ............................................................................................................ 45 
2.3.1 DNA Extraction ............................................................................................. 45 
2.3.2 Polymerase Chain Reaction for AMPKα1 Wild type (WT) and AMPKα1 
Knockout (KO) ............................................................................................................ 45 
2.4 Histology ............................................................................................................... 47 
2.4.1 Sample Preparation and Fixation ................................................................... 47 
2.4.2 Haematoxylin and Eosin staining .................................................................. 48 
2.4.3 Immunohistochemistry ................................................................................... 48 
2.5 Functional studies (wire myography) .................................................................... 50 
2.5.1 Preparation of the vessels ............................................................................... 50 
2.5.2 Cumulative Dose response curve ................................................................... 51 
2.5.3 PVAT releases bioactive molecules ............................................................... 53 
2.5.4 PVAT transfer experiment ............................................................................. 53 
2.5.5 Bioassay Experiment (Conditioned Media) ................................................... 53 
2.5.6 Effect of adiponectin on vascular relaxation .................................................. 54 
2.6 Secretory function investigation ............................................................................ 54 
2.6.1 Mouse Adipokine Array (Proteome Profiler) ................................................ 54 
2.6.2 Adiponectin ELISA ........................................................................................ 56 
2.7 AMPK activity determination ............................................................................... 57 
2.7.1 Vascular smooth muscle cell (VSMC) culture............................................... 57 
2.7.2 3T3-L1 adipocytes cell culture....................................................................... 58 
2.7.3 Western blotting ............................................................................................. 59 
2.7.4 PathScan® Intracellular Signalling Array Kit (Fluorescent Readout) ........... 60 
2.7.5 Quantification of expression of protein.......................................................... 62 
2.8 Determination of superoxide and nitric oxide availability .................................... 62 
2.8.1 Preparation of the PVAT samples .................................................................. 62 
2.8.2 Detection of superoxide ................................................................................. 62 
2.8.3 Detection of Nitric oxide ................................................................................ 62 
2.9 Statistical analysis ................................................................................................. 63 
 VI 
 
Chapter 3 .............................................................................................................................. 64 
Characterisation of the role of AMPKα1 in modulating PVAT function ............................ 64 
3.1 Introduction ........................................................................................................... 65 
3.2 Aims of the study .................................................................................................. 66 
3.3 Methods and Results ............................................................................................. 66 
3.3.1 Morphology of the PVAT .............................................................................. 66 
3.3.2 AMPK expression and activity ...................................................................... 70 
3.3.3 PVAT from AMPKα1 knockout mice enhances vascular contraction .......... 73 
3.3.4 PVAT enhances vascular relaxation to the AMPK activator AICAR ........... 75 
3.3.5 PVAT enhances vascular relaxation to cromakalim in wild type, but not 
AMPKα1 knockout aortic rings ................................................................................... 76 
3.3.6 Effects of PVAT on AICAR and cromakalim- induced vascular relaxation in 
abdominal aortic rings .................................................................................................. 78 
3.3.7 Transfer studies .............................................................................................. 81 
3.3.8 Wild type PVAT enhances relaxation in AMPKα1 knockout vessels ........... 83 
3.3.9 Conditioned media from WT aortic PVAT reduces contractility in vessels 
without PVAT .............................................................................................................. 85 
3.3.10 Conditioned media from WT mice enhances AICAR and cromakalim 
induced relaxation ........................................................................................................ 86 
3.3.11 Cromakalim does not activate AMPK in vascular smooth muscle cells or 
3T3-L1 adipocytes ....................................................................................................... 89 
3.3.12 AMPKα1 knockout mouse PVAT has altered adipokine release .................. 92 
3.3.13 AMPKα1 knockout PVAT releases less adiponectin .................................... 95 
3.3.14 Adiponectin is a potential PVAT derived vasodilator ................................... 95 
3.3.15 Effect of globular adiponectin and conditioned media on AMPK in VSMCs
 101 
3.4 Discussion ........................................................................................................... 102 
3.4.1 Effect of AMPKα1 subunit deletion on PVAT phenotype .......................... 102 
3.4.2 Effect of AMPKα1 subunit ablation on AMPK activity .............................. 104 
3.4.3 Effect of AMPK AMPKα1 subunit ablation on anticontractile effect of 
PVAT 105 
3.4.4 AMPKα1 knockout PVAT is assochied with adipocytokines release 
dysfunction ................................................................................................................. 106 
3.4.5 Adiponectin is a candidate for ADRF .......................................................... 107 
3.4.6 Role of KATP channels in anticontractile effect of PVAT ............................ 108 
3.5 Conclusion ........................................................................................................... 109 
Chapter 4 ............................................................................................................................ 110 
Role of AMPK in regulation of redox state of the PVAT and its effect on vascular function
 ............................................................................................................................................ 110 
4.1 Introduction ......................................................................................................... 111 
4.2 Aims of the study ................................................................................................ 113 
4.3 Methods & Results .............................................................................................. 113 
 VII 
 
4.3.1 Expression of superoxide anion in wild type and AMPKα1 KO PVAT ..... 113 
4.3.2 eNOS and NO levels in WT and KO PVAT ................................................ 116 
4.3.3 Effect of PVAT on Sodium nitroprusside-induced relaxation ..................... 120 
4.4 Discussion ........................................................................................................... 122 
4.4.1 Role of AMPK in regulation of ROS release from PVAT .......................... 122 
4.4.2 Effect AMPKα1 deletion on eNOS and NO levels ...................................... 124 
4.4.3 PVAT anticontractile effect in response to NO donor ................................. 125 
4.5 Conclusion ........................................................................................................... 125 
Chapter 5 ............................................................................................................................ 126 
Effect of a high fat diet on perivascular adipose tissue function and the role of AMPK... 126 
5.1 Introduction ......................................................................................................... 127 
5.2 Method and results .............................................................................................. 129 
5.2.1 High fat diet increased the weight of both wild type and AMPKα1 knockout
 129 
5.2.2 Effect of high-fat diet on vascular contraction ............................................. 131 
5.2.3 Effect of high-fat diet on the anticontractile effect of PVAT ...................... 132 
5.2.4 Effect of high-fat diet on the morphology of PVAT .................................... 135 
5.2.5 Effect of high-fat diet on AMPK level and activity ..................................... 137 
5.2.6 Effect of HFD on the inflammatory phenotype of PVAT............................ 140 
5.2.7 Effect of High-fat diet on adiponectin release ............................................. 142 
5.2.8 Effect of vascular injury on the PVAT phenotype ....................................... 142 
5.2.9 Inflammatory response of WT and KO PVAT to vascular injury ............... 144 
5.3 Discussion ........................................................................................................... 145 
5.3.1 Effect of HFD on anticontractile effect of PVAT ........................................ 145 
5.3.2 Eeffect of HFD on PVAT phenotype ........................................................... 146 
5.3.3 Effect of HFD on inflammatory phenotype of PVAT ................................. 147 
5.3.4 AMPK protects PVAT againest endovascular injury .................................. 149 
5.4 Conclusion ........................................................................................................... 151 
Chapter 6 ............................................................................................................................ 152 
General Discussion............................................................................................................. 152 
6.1 The hypothesis ..................................................................................................... 153 
6.2 The anticontractile effect of PVAT under basal conditions ................................ 154 
6.3 U46619 as contractile agent ................................................................................ 154 
6.4 Endothelium-independent relaxation to AICAR and PVAT ............................... 155 
6.5 Relaxation to cromakalim and the role of KATP channels ................................... 155 
6.6 Adiponectin as ADRF? ....................................................................................... 156 
6.7 Proposed mechanism of relaxation ...................................................................... 158 
6.8 Mechanism of PVAT dysfunction in obesity ...................................................... 159 
6.9 Potential physiological relevance and clinical implications ................................ 162 
 VIII 
 
6.9.1 Basal AMPK activity may act as vasculoprotective mechanism ................. 163 
6.9.2 Activation of AMPK in PVAT is a Potential therapeutic target .................. 164 
6.10 Limitations ........................................................................................................... 165 
6.11 Concluding remarks ............................................................................................ 166 
Chapter 7 ............................................................................................................................ 167 
List of References .............................................................................................................. 167 
Appendices ......................................................................................................................... 210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IX 
 
 
List of Figures 
Figure  1-1 Structure of the blood vessel. ............................................................................... 2 
Figure  1-2 Structure of Adiponectin. ................................................................................... 10 
Figure  1-3 Mechanism of adiponectin-induced vascular relaxation. ................................... 12 
Figure  1-4  Mechanism of leptin induced vasodilation and vasoconstriction. ..................... 18 
Figure  1-5 Structure of AMPK. ........................................................................................... 26 
Figure  1-6  Activation of AMPK. ........................................................................................ 33 
Figure  1-7 Demonstration of some downstream target proteins of AMPK involved in 
regulation of metabolism...................................................................................................... 34 
Figure  1-8 schematic presentation of how PVAT modulates the function of AMPK in both 
endothelium and vascular smooth muscle and how these affect vascular function. ............ 40 
Figure  2-1 AMPK colony genotyping. ................................................................................ 46 
Figure  2-2 Representative pictures of mouse aortic artery mounted in the small vessel wire 
myograph. ............................................................................................................................ 51 
Figure  2-3 Representative force myograph traces showing isometric tension (g) plotted 
against time in mouse thoracic aorta rings. .......................................................................... 52 
Figure  2-4 PVAT transfer experiment. ................................................................................ 53 
Figure  2-5 Proteome Profiler
 
Array Assay Principle. .......................................................... 56 
Figure  2-6 Principle of Adiponectin ELISA. ....................................................................... 57 
Figure  2-7 The PathScan Intracellular Signalling Array reaction. ....................................... 61 
Figure  3-1 Effect of AMPKα1 deletion on the morphology of PVAT. ............................... 68 
Figure  3-2 Immunohistochemical analysis of UCP-1 levels in PVAT in comparison with 
BAT and WAT for both wild type and AMPKα1 knockout mice. ...................................... 69 
Figure  3-3 UCP-1 levels in different PVAT depots............................................................. 70 
Figure  3-4 Total AMPKα levels in wild type and AMPKα1 knockout mouse thoracic aorta 
with intact PVAT. ................................................................................................................ 71 
Figure  3-5 Phospho-AMPKα Thr172 levels in wild type and AMPKα1 knockout mouse 
thoracic aorta with intact PVAT. ......................................................................................... 72 
Figure  3-6 AMPK levels and activity in PVAT. .................................................................. 73 
Figure  3-7 Effect of PVAT on thromboxane A2 receptor agonist U46619 (3x10
-8
 M) 
induced contraction. ............................................................................................................. 74 
Figure  3-8 Effect of PVAT on AICAR induced relaxation in wild type and AMPKα1 
knockout thoracic aorta. ....................................................................................................... 76 
 X 
 
Figure  3-9 Effect of PVAT on cromakalim-induced relaxation in wild type and knockout 
thoracic aorta. ....................................................................................................................... 77 
Figure  3-10 Effect of PVAT on AICAR-induced relaxation in wild type and knockout 
abdominal aorta. ................................................................................................................... 79 
Figure  3-11 Effect of PVAT on cromakalim-induced relaxation in wild type and knockout 
abdominal aorta. ................................................................................................................... 80 
Figure  3-12 Effect of addition of PVAT on cromakalim-induced relaxation in wild type 
and AMPKα1 knockout thoracic aortae. .............................................................................. 82 
Figure  3-13 Effect of PVAT transfer on AICAR and cromakalim induced vasorelaxation.
 .............................................................................................................................................. 84 
Figure  3-14 Effect of conditioned media on aortic ring contraction. ................................... 85 
Figure  3-15  Effect of PVAT-derived conditioned media on AICAR induced vascular 
relaxation in WT aortic rings. .............................................................................................. 86 
Figure  3-16 Effect of PVAT-derived conditioned media on cromakalim-induced vascular 
relaxation in wild type aortic rings....................................................................................... 87 
Figure  3-17 Effect of KO PVAT-derived conditioned media on AICAR-induced vascular 
relaxation in AMPKα1 knockout aortic rings. ..................................................................... 87 
Figure  3-18  Effect of KO PVAT-conditioned media on cromakalim-induced vascular 
relaxation in AMPKα1 knockout aortic rings. ..................................................................... 88 
Figure  3-19 Effect of cromakalim on AMPK phosphorylation and activity in VSMCs. .... 90 
Figure  3-20 Effect of AICAR and cromakalim on AMPK activity following different 
incubation times in 3T3 adipocytes...................................................................................... 91 
Figure  3-21 Adipocytokine levels in PVAT lysates of wild type and AMPKα1 knockout 
mice. ..................................................................................................................................... 93 
Figure  3-22 Adipocytokine levels in PVAT conditioned media of wild type and AMPKα1 
KO mice. .............................................................................................................................. 94 
Figure  3-23 Content of adiponectin in conditioned media from PVAT. ............................. 95 
Figure  3-24 Effect of adiponectin receptor 1 (AdipoR1) blocking peptide on PVAT-
enhanced relaxation in wild type mouse aorta. .................................................................... 97 
Figure  3-25  Effect of adiponectin receptor 1 (AdipoR1) blocking peptide on PVAT-
enhanced relaxation in AMPKα1 KO mouse aorta. ............................................................. 98 
Figure  3-26 Effect of globular adiponectin (1μg/ml) on U46619-induced contraction. ...... 99 
Figure  3-27 Effect of globular adiponectin on vascular relaxation induced by cromakalim.
 ............................................................................................................................................ 100 
Figure  3-28 Effect of globular adiponectin (gAd) and conditioned media on AMPK in 
VSMCs. .............................................................................................................................. 101 
 XI 
 
Figure  4-1 Representative Immunofluorescent images showing superoxide production by 
adipocytes in WT and KO thoracic PVAT, detected with dihydroethidium (DHE). ........ 115 
Figure  4-2 Nitrotyrosine expression in aortic PVAT from wild type and AMPKα1 
knockout mice. ................................................................................................................... 116 
Figure  4-3 eNOS expression and activity in PVAT. .......................................................... 117 
Figure  4-4  DAF-2 fluorescence in WT and KO thoracic PVAT. ..................................... 119 
Figure  4-5 Effect of PVAT on Na nitroprusside-induced relaxation in wild type and 
knockout thoracic aorta. ..................................................................................................... 121 
Figure  5-1 The average baseline weight of WT and KO mice before starting the HFD. .. 130 
Figure  5-2 Weight gain in response to high-fat diet in wild type and AMPKα1 knockout 
mice. ................................................................................................................................... 130 
Figure  5-3 Effect of high-fat diet on thromboxane A2 receptor agonist U46619 (3x10
-8
 M) 
induced contraction. ........................................................................................................... 132 
Figure  5-4 Effect of HFD on cromakalim-induced relaxation in WT thoracic aorta......... 133 
Figure  5-5 Effect of HFD on the cromakalim-induced relaxation in AMPKα1 KO thoracic 
aorta. ................................................................................................................................... 134 
Figure  5-6 Effect of high-fat diet on thoracic PVAT phenotype from both WT and KO 
mice. ................................................................................................................................... 135 
Figure  5-7 Effect of HFD on UCP-1 levels in PVAT. ....................................................... 136 
Figure  5-8 Effect of HFD on AMPKα levels in WT and KO PVAT................................. 137 
Figure  5-9 Effect of HFD on phospho-AMPKα levels in WT and KO PVAT. ................. 138 
Figure  5-10 Effect of high-fat diet on phosphorylation and activity of the AMPK in the 
PVAT. ................................................................................................................................ 139 
Figure  5-11 Effect of high-fat diet on inflammatory phenotype of WT and KO PVAT. .. 141 
Figure  5-12 Effect of HFD on adiponectin release. ........................................................... 142 
Figure  5-13 Effect of wire injury on carotid PVAT phenotype from both WT and KO mice.
 ............................................................................................................................................ 143 
Figure  5-14 Inflammatory response of WT and KO PVAT to vascular injury. ................ 144 
Figure  6-1 The proposed anticontractile mechanism of perivascular adipocytes on vascular 
myocytes. ........................................................................................................................... 159 
Figure  6-2 Hypothesis of the mechanism of PVAT dysfunction in obesity and the role of 
AMPK. ............................................................................................................................... 162 
 
 XII 
 
List of Tables 
Table  1-1 List of Adipocytokines released by PVAT ............................................................ 8 
Table  2-1 Composition of the high-fat diet (HFD). ............................................................. 44 
Table  2-2 RT-PCR reaction mixture for genotyping ........................................................... 45 
Table ‎2-3 list of DNA primers for genotyping..................................................................... 46 
Table  2-4 Sequence for processing samples for histological analysis ................................. 47 
Table  2-5 Primary and Secondary antibodies for Immunohistochemistry ........................... 50 
Table  2-6 Summary of antibodies and dilutions used for immunoblotting ......................... 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XIII 
 
List of Publications  
T.A.M. Almabrouk, M.A. Ewart, I.P. Salt and S. Kennedy (2014) Perivascular fat, AMP-
activated protein kinase and vascular diseases. British Journal of  Pharmacology, 171, 
595-617. 
T.A. Almabrouk, A.B. Ugusman, O. Katwan, I.P. Salt and S. Kennedy (2016) Deletion of 
AMPKα1 attenuates the anticontractile effect of perivascular adipose tissue (PVAT) and 
reduces adiponectin release. British Journal of Pharmacology, DOI:10.1111/bph.13633.  
Abstracts: 
T.A. Almabrouk, M.A. Ewart, I.P. Salt and S. Kennedy (2014) Regulation of vascular 
AMPK-activated protein kinase by Perivascular adipose tissue and its role in the regulation 
of vascular function. Scottish Cardiovascular Forum, Aberdeen (Oral communication). 
T.A. Almabrouk, M.A. Ewart, I.P. Salt and S. Kennedy (2015) Effect of perivascular 
adipose tissue on vascular function mediated via AMPK Scottish Cardiovascular Forum, 
Edinburgh (Poster). 
T.A. Almabrouk, M.A. Ewart, I.P. Salt and S. Kennedy (2015) AMP-activated protein 
kinase is critical for perivascular adipose tissue function. Maastricht AMPK meeting, 
Maasticht, Holand (Poster). 
T.A. Almabrouk, I.P. Salt and S. Kennedy (2015) Role of AMPK in the anticontractile 
effect of the perivascular adipose tissue.  British Pharmacology Society Meeting 
(Pharmacology 2015), London. pA2 online, 13(3), 271P. 
O. Katwan, T.A.M. Almabrouk, S. Kennedy and I.P. Salt (2016) The role of AMP-
activated protein kinase in perivascular adipose tissue modulates vascular function.  British 
Pharmacology Society Meeting (Pharmacological aspects of microvascular cell-cell 
signalling and CVS disease 2016), Oxford.   
T.A.M. Almabrouk, A. Riddell, A.B. Ugusman, I.P. Salt and S. Kennedy (2016) 
AMPKα1 knockout mice have dysfunctional perivascular adipose tissue (PVAT) and 
impaired vascular function. American Heart Association meeting, New Orleans, Louisiana, 
USA. (Accepted for poster presentation). 
 XIV 
 
A.B. Ugusman, T.A. M. Almabrouk and S. Kennedy (2016) Modulation of aortic 
perivascular adipose tissue function by peroxynitrite. British Pharmacology Society 
Meeting (Pharmacology 2016) (Accepted for poster presentation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XV 
 
List of Abbreviations and definitions  
PAI-1 Plasminogen Activator Inhibitor type-1 
A769662 6,7-Dihydro-4-hydroxy-3-(2′-hydroxy[1,1′-biphenyl]-4-yl)-6-oxo-thieno[2,3-
b]pyridine-5-carbonitrile 
ADMA Asymmetric Dimethylarginine 
ADAMTS Disintegrin and Metalloproteinase with Thrombospondin Motifs 
ADRF Adipocyte-Derived Relaxing Factor 
AdipoR1 Adiponectin Receptor 1 
ACC Acetyl-CoA carboxylase 
AMPK AMP-Activated Protein Kinase 
AICAR 5-Aminoimidazole-4-Carboxamide 1-β-D-Ribonucleoside 
AIS Autoinhibitory Sequence 
ASC C-terminal Sequence 
BAT Brown Adipose Tissue 
BH4 Tetrahydrobiopterin 
BMI Body mass index 
C/EBP CCAAT/Enhancer-Binding Protein  
cAd Collagenous Domain 
CAD Coronary Artery Disease 
CaMKKβ Calcium/Calmodulin-dependent Protein Kinase Kinase β 
CBM Carbohydrate-Binding Module 
CD68 Cluster of Differentiation 68 
cGMP Cyclic Guanosine Monophosphate 
CBS Cystathionine-β-Synthase 
CideA Cell Death-Inducing DFFA-like Effector A 
CPT1 Carnitine Palmitoyltransferase 1                              
CSE Cystathionine-Gamma-lyase Enzyme 
CTRPs C1q/TNF-Related Proteins 
CVD 
DHE 
Cardiovascular Diseases 
Dihydroethidium 
Dio2 Deiodinase Iodothyronine Type I 
ECM Extracellular Matrix 
eNOS Endothelial NO Synthase 
ERK1/2 Extracellular signal–Regulated Kinases 1/2 
FMN Flavin Mononucleotide 
FAD Flavin Adenine Dinucleotide 
FATP-1 Fatty Acid Transport Protein 1 
 XVI 
 
FFAs Free Fatty Acids 
FABP4 Fatty Acid Binding Protein 4 
gAd Globular Domain 
GLUT Glucose Transporter 
GPCR  G-Protein-Coupled Receptor 
GAPDH Glycerol 3-Phosphate Dehydrogenase 1 
GTP Guanosine Triphosphate 
H2O2 Hydrogen Peroxide 
H2S Hydrogen Sulphide 
HAECs Human Aortic Endothelial Cells 
HFD High Fat Diet 
HMG-CoA 
reductase 
3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A reductase 
HMW High-Molecular-Weight 
ICAM-1 Intercellular Adhesion Molecule 1 
IL-6 Interleukin 6 
iNOS Inducible NO synthase 
IRS-1 Insulin Receptor Substrate 1 
KCD N-terminal Kinase Katalytic Domain 
LKB1 Liver Kinase B1 
MCP-1 Monocyte Chemoattractant Protein 1 
MO25 Mouse Protein 25 
mTOR Mammalian Target for Rapamycin 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NMN Nicotinamide Mononucleotide 
NAMPT Nicotinamide Phosphoribosyltransferase 
nNOS Neuronal NO synthase 
NFk-B p65 Nuclear Factor-kappa B p65 
O2
.-
 Superoxide 
PDGF-BB Platelet-Derived Growth Factor BB 
PI3K Phosphatidylinositol-3-kinase 
PKB Protein kinase B 
PPARγ Peroxisome Proliferator-Activated Receptor γ 
Prdm16 PR Domain Containing 16 
PVAT Perivascular Adipose Tissue 
RORα Retinoic acid-related Orphan Receptor α 
S6K Protein S6 Kinase 
SAT Subcutaneous Adipose Tissue 
 XVII 
 
STRAD STE20-Related Adaptor Protein 
SVF Stromal Vascular Fraction 
T2DM Type 2 Ddiabetes Mmellitus 
TAK1 Transforming Growth Factor beta-Activated Kinase 1 
THP-1 Human acute monocytic leukemia cell line 
ROS Reactive Oxygen Species 
TNFα Tumor Necrosis Factor α 
TSC2 Tuberous Sclerosis Complex 2 
TZDs        Thiazolidinediones 
UCP-1 Uncoupling Protein 1 
VSMCs Visceral Adipose Tissue 
VCAM-1 Vascular Cell Adhesion Molecule 1 
VEGF-A Vascular Endothelial Growth Factor A 
WAT White Adipose Tissue 
ZMP   5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5′-monophosphate 
β-SID β subunit interacting domain 
  
                               
 
 
 
 
 
 
 
 
 XVIII 
 
Abstract 
This thesis, entitled: ‘Role of AMP-protein kinase (AMPK) in regulation of perivascular 
adipose tissue (PVAT) function’, has been submitted by author Tarek Ali Mohamed 
Almabrouk for a degree of Doctor of Philosophy (PhD) in the College of Medical, 
Veterinary and Life Sciences at the University of Glasgow, October 2016. 
 
Apart from the cerebral circulation, all vasculature is surrounded by layers of adipose 
tissue known as perivascular adipose tissue (PVAT). In health, PVAT can function as an 
endocrine organ to produce a wide range of adipocytokines which can attenuate vascular 
contraction. The exact mechanism of this anti-contractile effect is still ill-defined, although 
much evidence suggests that PVAT-released adipocytokines may activate K
+
 channels on 
VSMCs or eNOS on endothelial layer possibly via AMP-activated protein kinase (AMPK).  
However, obesity results in oxidative stress and inflammation of the PVAT leading to 
abnormal adipocytokine release and PVAT dysfunction. AMPK is a serine/threonine 
kinase with many potential physiological functions, including regulation of energy 
heamostasis. AMPK is expressed in the three layers of the blood vessel: smooth muscle 
(VSM), the endothelium and PVAT and it is known that activation of AMPK leads to 
vascular dilatation via both endothelium- and non-endothelium-dependent mechanisms. 
Although it is known that AMPK can modulate VSM and endothelial function, it is 
unknown whether AMPK can influence the anti-contractile activity of PVAT. Therefore, 
this project aimed to investigate the mechanism of the anticontractile effect of PVAT by 
determining the functions of AMPK within adipocytes, as well as to assess the importance 
of vascular AMPK to the PVAT anti-contractile function. 
Experiments were conducted using wild type (WT) and global AMPKα1 knockout (KO) 
mice aortae. The phenotypic features of the PVAT were assessed by both histological, 
immunohistochemical and immunofluorescent methods.  Secretory function of the PVAT 
was tested using an immunoblotting array and ELISA, whereas the anti-contractile effect 
of PVAT was studied using wire myography. Immunoblotting methods were used to test 
AMPK activity in the PVAT and VSMCs.   
Aortic rings from WT and KO mice were denuded of endothelium and mounted on a wire 
myograph in the presence and absence of PVAT. The responses to an AMPK activator 
(AICAR) and the AMPK-independent vasodilator cromakalim were subsequently assessed. 
Relaxation responses to AICAR or cromakalim in the Sv129 (wild type) mouse were 
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significantly enhanced in the presence of endogenous attached or unattached PVAT, an 
effect that was absent in vessels from KO mice. Furthermore, enhanced relaxation was 
observed in vessels from KO mice incubated with PVAT from Sv129 mice, whereas 
PVAT from KO mice had no effect on relaxation of vessels from Sv129 mice. 
Furthermore, conditioned medium (CM) transfer experiments demonstrated the presence of 
an anticontractile factor released from PVAT that was absent in KO mice. Adiponectin 
secretion was reduced in PVAT from KO mice and PVAT-enhanced relaxation was 
attenuated in the presence of adiponectin blocking peptide. Adipokine array and ELISA 
demonstrated that adiponectin release is significantly reduced in the KO conditioned media 
in comparison with wild type CM. Globular adiponectin restores the relaxation response in 
both wild type aortae without PVAT and in KO aortae with and without PVAT.   
High fat diet (HFD) fed mice showed a reduction in the relaxation response to cromakalim 
in wild type vessels with intact PVAT in comparison with animals fed a normal chow diet 
(ND). HFD animals had increased inflammatory infiltrates in the PVAT which were 
associated with reduced AMPK activity and adiponectin release in comparison with ND 
fed WT mice. In KO mice, AMPK activity was also reduced and increased inflammatory 
infiltration was observed in both ND and HFD mice. 
In conclusion, the current project demonstrates that AMPKα1 has a critical role in 
maintaining PVAT’s anti-contractile effect; likely mediated through altered adiponectin 
secretion or sensitivity, and through protection of PVAT against inflammation.  Marked 
reduction in AMPK activity in WT PVAT, accompanied with the reduction in the release 
of adiponectin in HFD and KO animal may explain the impaired vascular function 
observed in obesity.  
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1.1 Obesity and Cardiovascular disease 
Obesity has been recognized as one of the major global health issues by the World Health 
Organization (WHO) and its incidence is rapidly rising in both industrialised and 
developing nations (Antipatis and Gill, 2001). The WHO has estimated that more than 1.9 
billion adults in the world are overweight (body mass index (BMI) > 25.0 kg/m²); of which 
at least 600 million are obese (BMI >30.0 kg/m²) (World Health Organisation, 2014). 
Obesity is associated with increased risk of insulin resistance, type 2 diabetes mellitus 
(T2DM), hypertension, coronary artery disease (CAD), myocardial infarction (MI) and 
sudden death, congestive heart failure and stroke (reviewed in Almabrouk et al., 2014).The 
extent of this epidemic stresses the need for developing an approach for obesity 
management and a better understanding of the mechanism which links obesity and 
cardiovascular disease. 
Many studies have demonstrated that the regional distribution of adipose tissue in the body 
determines both the obesity phenotype and its complications. For instance, intra-abdominal 
and visceral fat depots have been associated with a higher risk of development of 
cardiometabolic disease and mortality linked with obesity (Fox et al., 2007, Gesta et al., 
2007). One of these regional fat depots is perivascular adipose tissue (PVAT) which is now 
proposed to be a link between obesity and metabolic syndrome development and diabetes 
as a result of the adverse effect which PVAT exerts on the vasculature in disease states. In 
health PVAT releases a range of adipokines such as adiponectin which are capable of 
modulation of metabolism and local vascular tone. However, in disease states, there is an 
alteration in adipokine release which results in vascular malfunction and development of 
metabolic syndrome. Furthermore, the elevated levels of inflammatory cytokines such 
TNFα in obesity may disrupt the interaction between PVAT and the vascular wall (Yudkin 
et al., 2005). 
AMP activated protein kinase (AMPK) regulates adipocyte metabolism, adipose biology 
and vascular function and as such AMPK activation is an attractive therapeutic target for 
metabolic disorders such as T2DM and the vascular complications associated with obesity 
and T2DM. Recent studies have identified AMPK as a potential regulator of PVAT and 
also a target of PVAT action in the blood vessel (Almabrouk et al., 2014). The studies 
described in this thesis will focus on the vasoactive properties of perivascular adipose 
tissue as mediated by adipokines and also the role of AMPK in the regulation of vascular 
function and metabolism. 
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1.2 Anatomy of cardiovascular system 
The cardiovascular system is composed of the heart and its associated blood vessels. The 
role of the blood vessels is to transport blood containing oxygen and nutrients from the 
heart via systemic circulation to the rest of the body before returning the blood back to 
heart and delivering it to the lung via the pulmonary circulation. Based on their 
physiological function, blood vessels can be divided into five types: arteries, arterioles, 
capillaries, venules and veins. The arteries transport blood away from the heart and 
progressively branch from muscular arteries to smaller arterioles and eventually to 
capillaries (site of substance exchange). Capillaries then coalesce to form bigger venules 
which progressively increase in size to form the large veins which return the blood back to 
the heart. 
The wall of all blood vessels except capillaries is composed of three layers: tunica intima, a 
layer of endothelial cells; media, the middle smooth muscle layer and adventitia. The 
adventitia consists of two layers: adventitia compacta, a layer of mainly fibroblasts and 
perivascular adipose tissue (PVAT) which surrounds most blood vessels. The wall of the 
capillaries consists of a single layer of endothelial cells on a basement membrane, which 
facilitates substance exchange between blood and tissue. Figure 1-1 illustrates the basic 
strucure of the blood vessel wall including PVAT. 
Adventitia 
Intima
Media
Adventitial fat = PVAT 
(adipocytes)
Adventitial compacta = 
(fibroblasts)
VSMCs
Endothelial Cells 
 
Figure ‎1-1 Structure of the blood vessel.  
Representative H&E stained mouse aorta showing the structure of the wall of blood vessels. The 
blood vessel wall is composed of three layers: tunica intima (endothelium), tunica media (VSMCs 
layer) and adventitia which includes PVAT. PVAT contains adipocytes, vasa vasorum and other 
cells (macrophages, adipocyte stem/progenitor cells, lymphocytes, fibroblasts, etc respectively).  
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1.2.1 Endothelium 
The vascular endothelium is a monolayer of cells that line the lumen of all vascular beds 
and mechanically and metabolically separates the vascular wall from the circulating blood 
and its components (Lerman and Zeiher, 2005). The role of the endothelium in the 
regulation of vascular function gained prominence in 1980 when Furchgott & Zawadski 
discovered that the relaxant effect of acetylcholine was lost in denuded vessels (Furchgott 
and Zawadzki, 1980). Furthermore, the endothelium is now known to release many 
bioactive substances which are involved in control of vascular function including 
regulation of vascular tone, proliferation, inflammation, platelet function and angiogenesis 
(Deanfield et al., 2007). 
1.2.2 Vascular smooth muscle layer 
This layer is composed principally of smooth (involuntary) muscle cells and elastic fibres 
arranged in roughly spiral layers. Arteries in comparison with veins tend to have a thicker 
medial layer. Smaller arteries and arterioles are termed resistance vessels which are 
important in the regulation of blood flow through changes in peripheral vascular resistance. 
Several mechanisms are involved in the regulation of vascular tone such as myogenic 
mechanisms, endothelium-derived factors, sympathetic adrenergic stimulation and 
hormones. Vasoconstriction and vasodilation is a function of myocytes and occurs in 
response to transmural pressure or stretch. Based on the demand of the tissue, perfusion is 
controlled by constriction or dilation of arteries which controls the blood flow to the tissue 
(Schubert and Mulvany, 1999). 
1.2.3 Adventitia (Perivascular adipose tissue) 
PVAT is a regional adipose tissue surrounding most of vasculature. PVAT is present 
throughout the body and has been shown to have a local effect on blood vessels 
(Almabrouk et al., 2014). The structure and function of the perivascular adipose tissue will 
be discussed in detail in section 1.4. 
1.3 Adipose tissue (General Features) 
All adipose tissue is composed of mature adipocytes containing lipid droplets, T 
lymphocytes, macrophages, collagen fibres, fibroblasts, preadipocytes, blood vessels and 
nerves. According to the size of the lipid vacuoles and the number of mitochondria, 
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adipose tissue is divided into two categories: brown adipose tissue (BAT) and white 
adipose tissue (WAT). Morphologically, WAT is composed of adipocytes with more than 
90% of their volume occupied by a single spherical lipid droplet separated from the 
cytoplasm by a non-membranous barrier containing functionally active proteins such as 
perilipin (Greenberg et al., 1991). WAT is also characterised by adipocytes containing a 
variable number of thin elongated mitochondria with short, randomly arranged cristae 
(Cinti, 2011). BAT differs from WAT essentially in the characteristics of the adipocytes, 
vascularity and rich nor-adrenergic innervation. Adipocytes in BAT have multiple lipid 
vacuoles and a larger number of mitochondria. The mitochondria in brown adipocytes have 
a spherical or oval shape and are rich in laminar cristae with a characteristic marker protein 
called uncoupling protein 1 (UCP-1), responsible for their thermogenic activity (Cinti, 
2011). The presence of a large number of mitochondria and rich vascularity is responsible 
for the brown colour of BAT.  
The distribution of WAT and BAT are to a large extent different depending on genetic 
background, age, gender, and environmental status (temperature, diet, exercise) (Cinti, 
2011). In small mammals both types of adipose tissue are located in subcutaneous and 
trunk depots surrounded by connective tissue capsules (Cinti, 2005). In small rodent 
adipose tissue (mice and rats), most of the intrascapular area is considered the classical 
BAT depot, whereas the posterior subcutaneous depot is mostly WAT. Mediastinal adipose 
tissues are largely BAT, especially in mice, whereas omental and mesenteric adipose are 
predominantly white. Depots including perirenal, periovarian and perivesical adipose 
tissue contain equal amounts of brown and white adipocytes. In males, the epididymal 
adipose depot is composed only of white adipocytes (Cinti, 2011).  
In the human body, BAT can be found in the trunk fat depot and that is likely due to 
differences in the thermogenic needs in comparison with small mammals which are based 
on different surface/volume ratio. WAT in humans is confined to subcutaneous with 
increased accumulation in mammary and gluteofemoral areas in female (Cinti, 2011). 
Furthermore, adipose tissue in humans and rodents has the same cellular composition, 
including distinct blood and nerve supply density in both WAT and BAT (Zingaretti et al., 
2009).  
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1.4 Perivascular adipose tissue (PVAT) 
PVAT differs from other fat depots due to the following specific features: 
PVAT is situated outside of the blood vessels and adventitia. It surrounds the adventitia, 
although no clear barrier separates the two and PVAT surrounds most systemic blood 
vessels, with the exception of cerebral blood vessels (Gao, 2007). In relation to the type of 
adipose tissue, PVAT is composed of either white adipose tissue, brown adipose tissue or 
both, depending on the type of the blood vessel. PVAT may be composed of WAT such as 
rodent mesenteric PVAT or mixed in aortic PVAT (Gao, 2007). Mixed aortic PVAT 
displays the morphological and gene expression features of BAT (Fitzgibbons et al., 2011), 
with its characteristic multilocular adipocytes and expression of UCP-1 while mesenteric 
PVAT contains white adipocytes that are lacking UCP-1 and are less vascularised (Cinti, 
2011).   
PVAT also differs from other adipose tissue in its secretory profile. Mouse aortic PVAT 
releases less adiponectin, leptin and resistin compared with subcutaneous adipose tissue 
(SAT) and visceral adipose tissue (VAT). Furthermore, regions of PVAT display a similar 
pattern of adipose tissue markers as BAT which includes CIDEA, UCP-1, Dio2, and 
Prdm16 (Fitzgibbons et al., 2011). PVAT expresses lower levels of lipid oxidation genes 
such as PPARγ, C/EBP, and FABP4 and lipid synthesis genes such as fatty acid synthase, 
glycerol 3-phosphate dehydrogenase 1 (GPDH), lipoprotein lipase, hormone-sensitive 
lipoprotein lipase, adipose triglyceride lipase, and perilipin (associated with the lipid 
droplet) in comparison with SAT and VAT (Chatterjee et al., 2009). Moreover, PVAT is 
different from other depots in the expression of immune and inflammatory genes. PVAT 
produces higher levels of interleukins (IL)-6, IL-8 and monocyte chemoattractant protein 1 
(MCP-1) (Chatterjee et al., 2009). However, a study by Fitzgibbons et al reported that 
PVAT showed lower expression levels of chemokines, T-cell receptor and macrophage 
markers (CD68 and F4/80) (Fitzgibbons et al., 2011). 
Depending on the vascular bed, there are differences in the profile of secretion and gene 
expression of proteins in PVAT. For example, the expression of renin–angiotensin system 
components by mesenteric and aortic PVAT in Wistar Kyoto (WKY) rats is characterised 
by higher angiotensin AT1a- and AT2 - receptor, chymase, and angiotensin II expression, 
and lower prorenin-receptor expression in mesenteric compared with aortic PVAT 
(Galvez-Prieto et al., 2008). 
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Adipocytes are the most abundant cell type in PVAT. Along with adipocytes, PVAT 
contains a stromal vascular fraction (SVF) which includes fibroblasts, mesenchymal stem 
cells, lymphocytes, macrophages and endothelial cells that line the vasa vasorum. The SVF 
has been suggested to be involved in the vasocrine function of the PVAT and also in 
disease states by enhancing the infiltration of inflammatory cells such as macrophages 
(Szasz et al., 2013). The extracellular matrix (ECM) of PVAT consists of collagen, laminin 
and fibronectin fibres along with ECM-processing enzymes, such as the matrix 
metalloproteinases, tissue inhibitors of metalloproteinases, and proteins from the 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family 
(Mariman and Wang, 2010). PVAT consists also of nerve fibres which are predominantly 
sympathetic. There is apparently no parasympathetic innervation of WAT (Giordano et al., 
2004, Giordano et al., 2006). 
1.4.1 PVAT function 
Adipose tissue was once considered to be a connective tissue with a traditional supporting 
structure involved in lipid storage (WAT) and nonshivering thermogensis (BAT). PVAT 
was also considered to act as scaffolding of nearby blood vessels and was removed during 
vascular function assessment because it was thought to impair diffusion of exogenous 
substances. However, accumulating evidence has led to the wide acceptance that adipose 
tissue including PVAT is not only a supporting structure but an important endocrine organ. 
It can release many bioactive molecules with various metabolic and vascular functions. 
In addition to its contribution to metabolism via release of free fatty acids 
(FFAs)/nonesterified fatty acids by lipolysis, adipose tissue secretes bioactive proteins that 
are collectively termed adipocytokines and have endocrine, autocrine and paracrine 
actions. They are termed adipocytokines because of their adipocyte origin and cytokine-
like effects. PVAT-released adipocytokines participate in the control of vascular function 
under normal physiological conditions (reviewed in Almabrouk et al., 2014). 
An extensive range of adipocytokines have since been identified and shown to have a wide 
spectrum of haemodynamic, metabolic and immunological effects (Trayhurn and Wood, 
2004, Trayhurn, 2005). Adipocytokines can be classified according to their effect on 
cytokine levels as either pro-inflammatory, such as leptin, or anti-inflammatory, such as 
adiponectin and adrenomedullin. As emerging vascular modulators, adipocytokines 
including adiponectin, omentin, nesfatin, vaspin and chemerin have been proposed to play 
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a role in the regulation of cardiovascular function (Table 1-1). The classification of some 
adipokines, such as resistin, can be somewhat blurred since it can be expressed by other 
cell types such as macrophages and participate in inflammation throughout the body 
(Jamaluddin et al., 2012). Others such as visfatin, originally considered as adipocytokines, 
may actually be produced in greater quantities by the stromal vascular tissue within PVAT 
(Stastny et al., 2012). Nevertheless, studies seem to indicate that generation of visfatin is 
elevated in obesity and metabolic syndrome and so it is likely to be an important pro-
inflammatory mediator in cardiometabolic disease.  
In addition to release of adipocytokines, adipocytes in PVAT also produce classical 
cytokines and chemokines including IL-6, IL-8, CCL2 (MCP-1) and plasminogen-activator 
inhibitor-1 (Thalmann and Meier, 2007, Rajsheker et al., 2010). Furthermore, 
inflammatory cells such as macrophages and T lymphocytes, fibroblasts and capillary 
endothelial cells, which are normally found in PVAT or attracted in response to 
inflammatory chemokines released by adipocytes, have also been demonstrated to 
contribute to the secretory profile of adipose tissue (reviewed in Szasz and Webb, 2012).   
In addition to classical adipocytokines, PVAT can also produce angiotensin peptides, 
which, along with angiotensinogen, angiotensin-converting enzymes and receptors, are part 
of the renin–angiotensin–aldosterone system (Lu et al., 2010). PVAT also releases reactive 
oxygen species (ROS), including superoxide (O2
.-
) (Gao et al., 2006), H2O2 (Gao et al., 
2007) and gaseous molecules such as H2S (Schleifenbaum et al., 2010). In denuded 
vessels, generation of H2O2 induces relaxation via activation of soluble guanyle cyclase 
sGC (Gao et al., 2007), whereas an enzyme present in PVAT, cystathionine γ-lyase, can 
generate H2S. The H2S induces relaxation by opening voltage-gated potassium channels in 
the vascular smooth muscle cells (VSMCs) to cause hyperpolarization (Schleifenbaum et 
al., 2010). In contrast, superoxide and angiotensin can potentiate vasoconstriction to 
electrical field stimulation in vitro (Gao et al., 2006, Lu et al., 2010). Another 
adipocytokine, apelin, has been found to induce NO-dependent vasorelaxation of 
peripheral and splanchnic human arteries both in vitro and in vivo (Salcedo et al., 2007, 
Japp et al., 2008). Table 1-1 illustrates the adipocytokines with known vascular effects and 
the mechanism of dysregulation.  
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Table ‎1-1 List of Adipocytokines released by PVAT 
Adipokines/ 
Cytokines 
Physiological 
effect 
Effect on vasculature Associated disease PVAT 
dysfunction 
Leptin Proatherogenic          
Proinflammatory 
Direct vasodilator, ↑VSMC 
proliferation/migration, 
↑Vascular permeability ,    
↑TNF-α, IL-6, IL-12, ROS 
Indirect vasoconstrictor 
 
Obesity, 
Hypertension, 
Atherosclerosis, 
Insulin resistance 
↑in obesity         
↓hypertension           
  
↑atherosclerosis 
Adiponectin Antiinflammatory  
Anti-atherogenic 
Direct vasodilator , ↓ VSMC 
proliferation/migration 
↓ IFN-γ, IL-6, NF-κB, TNF-
α phagocytosis, endothelial 
adhesion molecules, ↑IL-10,   
IL-1RA  
 
Obesity 
Hypertension 
Atherosclerosis 
Insulin resistance 
T2DM 
↓obesity            
diabetes 
↓Atherosclerosis  
Resistin  Proatherogenic ↑VSMC proliferation 
/migration, ↑Endothelial 
adhesion molecule,↑TNF-α, 
IL-6,NF-kB  
 
Atherosclerosis 
Insulin resistance  
T2DM 
↑Endothelial 
injury  
Visfatin Proatherogenic 
Proinflammatory 
↑VSMC proliferation 
/migration, vasodilatation 
↑TNF- α, IL-6, IL-8, 
↓Apoptosis 
 
Atherosclerosis 
Insulin resistance  
T2DM 
↑atherosclerosis 
Omentin Antiatherogenic 
Antiinflammatory 
↑eNOS, ↓ NF-κB  Atherosclerosis 
Metabolic syndrome 
↓atherosclerosis, 
obesity and 
metabolic 
syndrome 
 
Chemerin Antiatherogenic 
Antiinflammatory 
↓TNF-α-induced VCAM-1 
expression and ↓Monocyte 
adhesion  
 
Atherosclerosis ↓ atherosclerosis 
Nefastin Contractile Impair NO donor and SNP 
vasodilatation 
 
Hypertension 
Obesity 
 ↑hypertension 
and obesity 
Vaspin Antiinflammatory 
Antiatherogenic 
↓SMC migration  Atherosclerosis 
T2DM, Obesity 
↑atherosclerosis, 
obesity and 
diabetes milletus 
 
Apelin  Anticontractile 
Angiogenic 
↑ Glucose utilization in 
skeletal muscle Antagonize 
the effect of Ang II,↑NO 
production 
 
Obesity,Insulin 
resistance 
↑obesity and 
insulin 
resistance and 
heart failure  
 
Interleukins 
IL-1, IL-6, 
IL-8, CCL2 
 
Proinflammatory ↑Endothelial proliferation Atherosclerosis ↑atherosclerosis 
HGF Proinflammatory ↑Endothelial proliferation,  
↑Cytokines release from 
SMCs 
 
Obesity ↑obesity 
TNF-α Pro-inflammatory  Vasodilator, ↑ROS, 
↑ Endothelial dysfunction  
Obesity, 
Hypertension, 
Atherosclerosis, 
T2DM 
↑ obesity, 
hypertension, 
atherosclerosis 
and T2DM 
PVAT-derived factors with influence on vascular function and related cardiometabolic disorders. 
HGF, hepatic growth factor; NF-κB,‎ nuclear‎ factor‎ kappa-light-chain enhancer of activated beta 
cells; PVAT, perivascular adipose tissue; ROS, reactive oxygen species. 
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1.4.1.1 Adiponectin 
Adiponectin is a small protein of 30 kDa made of 247 amino acids. It consists of four 
domains: an amino-terminal signal sequence, a variable region, a collagenous domain 
(cAd), and a carboxy-terminal globular domain (gAd) (Figure 1-2) (Scherer et al., 1995). 
The collagenous domain is responsible for formation of high order complexs. These 
complexes have been identified as the high-molecular-weight (HMW) form (12–36 mer), 
low molecular weight (LMW) form (hexamer), and trimeric form (trimer). The essential 
mediator for formation of higher order complexes is a cysteine residue in the collagenous 
domain (Schraw et al., 2008). Based on its amino acid sequence and subunit domain 
structure, adiponectin is similar to C1q, which is a member of complement-related 
proteins. Furthermore, the globular domain of adiponectin has been found to be similar to 
the TNF-α family of proteins. C1q and TNFα are prototypical members of a growing 
family of paralogues known as C1q/TNF-related proteins (‘CTRPs’) (Davis and Scherer, 
2008).  
In general, adiponectin exists in two isoforms: full length and/or a smaller globular 
fragment (Kadowaki and Yamauchi, 2005, Kadowaki et al., 2006). Their mechanisms and 
extent of action of are still elusive. Adiponectin acts via two receptors, Adipo-R1 and 
Adipo-R2 (Yamauchi et al., 2003). Both receptors are composed of seven transmembrane 
domains although structurally and functionally they are distinct from G-protein-coupled 
receptors (GPCR) because the amino (N)-terminus of Adipo-R1 and Adipo-R2 is 
intracellular, and the C terminus is extracellular. The full length form acts via the R2 
receptor and the globular form via R1 (Yamauchi et al., 2003). There is an additional cell 
surface molecule, referred to as T-cadherin which has been identified (Hug et al., 2004) 
and although it binds adiponectin, it is not considered to be a signalling receptor because it 
has no intracellular signalling domain (Denzel et al., 2010). 
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Figure ‎1-2 Structure of Adiponectin.  
Full-length adiponectin is composed of 247 amino acids, including a collagen-like domain at the N-
terminus and a C1q-like globular domain at the C-terminus. Full-length adiponectin combines via 
the collagen domain and forms higher order complexs including trimers and hexamers, and a high-
molecular-weight (HMW) form. A smaller form of adiponectin composed of the globular domain 
also exists as globular adiponectin (adapted from Okamoto et al., 2006). 
 
Adiponectin is produced exclusively by adipose tissue. It forms 0.01–0.05% of plasma 
protein (usual range, 2–20 μg/ml). Adiponectin is a very stable protein in the circulation, 
with minimal degradation (36 hours) (Pischon et al., 2003). It has very short half-life (~45-
75 minutes) (Halberg et al., 2009) because it is cleared rapidly. The primary site of 
adiponectin clearance is the liver and although adiponectin is rapidly cleared, its plasma 
levels remain relatively constant (Halberg et al., 2009). The circulating adiponectin can 
bind pancreatic beta cells, vascular smooth muscle cells and some cell types in the heart 
and kidney where it elicits its effects (Turer and Scherer, 2012).  
Adiponectin concentration within plasma is affected by many factors including gender, 
pregnancy, and diseases (Combs et al., 2003). In general, females have more adiponectin 
than males and this level is increased during pregnancy (Combs et al., 2003). Decreased 
plasma adiponectin levels are observed in patients with diabetes, metabolic syndrome, 
coronary artery disease, and hypertension (Arita et al., 1999, Yamauchi et al., 2001, Chow 
et al., 2007, Kumada et al., 2003, Ouchi et al., 2003, Salmenniemi et al., 2004). High 
plasma levels of adiponectin have been reported to suppress development of 
atherosclerosis in apolipoprotein E-deficient mice by reducing vascular smooth muscle cell 
proliferation and migration. The mechanism involved has been suggested to be a direct 
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binding to platelet-derived growth factor (PDGF)-BB and inhibiting growth factor-
stimulated ERK signalling in vascular smooth muscle (Arita et al., 2002). In addition, 
adiponectin knockout mice are susceptible to development of diet-induced insulin 
resistance. This is likely through high TNFα expression decreasing muscle FATP-1 mRNA 
and IRS-1 mediated insulin signalling, predisposing to diet-induced insulin resistance 
(Maeda et al., 2002). High adiponectin concentration in the circulation is also associated 
with decreased risk of type 2 diabetes, and this is independent of abdominal fat deposition, 
suggesting a significant protective function of adiponectin against the development of type 
2 diabetes (Yamamoto et al., 2014). Furthermore, adiponectin has been reported to protect 
against cardiovascular diseases via inhibition of pro-inflammatory and hypertrophic 
responses, and stimulation of endothelial cell responses. These effects of adiponectin are 
mainly attributed to the modulation of signalling molecules, including AMP-activated 
protein kinase (AMPK) (reviewed in Shibata et al., 2009). Adiponectin also prevents 
development of atherosclerosis by regulating the main signalling pathways involved in the 
genesis of atherosclerosis. These involve PI3K-Akt, eNOS and AMPK (Shimada, et al. 
2004). Adiponectin appears to suppress monocyte adhesion to the vascular endothelium 
and promotes angiogenesis by stimulating crosstalk between Akt and AMPK in endothelial 
cells (Ouchi, et al. 1999).  
Adiponectin is also involved in regulation of vascular reactivity and thus is important in 
blood pressure regulation. It induces vascular dilatation via two distinct mechanisms 
(Figure 1-3): an endothelium-dependent mechanism via increased production of NO via 
increased AMPK and endothelial nitric oxide synthase (eNOS) activity (Chen et al., 2003, 
Cheng et al., 2007), and an endothelium-independent pathway by activation of potassium 
channels at the level of vascular smooth muscle cells (Lynch et al., 2013). Adiponectin 
stimulates production of NO in endothelial cells via a phosphatidylinositol-3-kinase (PI3K) 
pathway involving phosphorylation of eNOS at Ser1179 by AMPK (Chen et al., 2003). 
The importance of adiponectin in regulation of blood pressure was confirmed in 
adiponectin knockout mice which developed elevated blood pressure (Ouchi et al., 2003, 
Ouchi et al., 2006).  
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Figure ‎1-3 Mechanism of adiponectin-induced vascular relaxation. 
 
1.4.1.2 Nitric Oxide (NO) 
In 1980, Furchgott and Zawadzki proposed that vascular endothelium is essential to induce 
relaxation to acetylcholine in vitro using segments of rabbit aorta. Removal of the 
endothelial layer prevented relaxation to acetylcholine but the relaxation in response to 
glyceryl trinitrate was preserved (Furchgott and Zawadzki, 1980). This response was found 
to be due to an endogenous mediator termed endothelium-derived relaxing factor (EDRF) 
(Furchgott and Zawadzki, 1980) and which was later identified to be the gas nitric oxide 
(NO) (Ignarro et al., 1987, Palmer et al., 1987). NO is synthesized by conversion of the 
amino acid L-arginine to NO and L-citrulline via NO synthase enzyme (NOS) (Palmer et 
al., 1988). There are three NOS isoforms: neuronal isoform (nNOS) localized 
predominantly in the central and peripheral nerves but has also been detected in non-
neuronal cells, including myocytes, epithelial cells, mast cells, and neutrophils (Asano et 
al., 1994, Forstermann et al., 1998, Nakane et al., 1993, Wallerath et al., 1997) which 
produces NO to act as a neuronal messenger, inducible isoform (iNOS) initially identified 
in cytokine-induced macrophages, is now recognized as expressed in macrophages, 
neutrophils, platelets, and VSMCs, as well as in other nonvascular cells such as skeletal 
muscle and the hippocampus. Endothelial NOS (eNOS) isoform is largely expressed in 
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endothelial cells. However, it can be found in other cells including cardiac myocytes, 
platelets, certain brain neurons, and human placenta syncytio-trophoblasts and in LLC-PK1 
kidney tubular epithelium (Forstermann and Sessa, 2012).  
Activation of NOS requires binding to cofactors and dimerization. NOS binds to the 
cofactors flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), and 
tetrahydrobiopterin (BH4). BH4 along with L- arginine,,heme, nicotinamide adenine 
dinucleotide phosphate (NADPH) and molecular oxygen all act as cosubstrates which 
allows the NOS to dimerise and become activated. In the case of eNOS and nNOS, the 
dimer formed is in an inactive state in the absence of Ca
2+
 and is stimulated by elevated 
cytosolic Ca
2+
-calmodulin. In contrast to eNOS and nNOS, iNOS dimers are active at basal 
intracellular Ca
2+
 concentrations (reviewed in Liu and Huang, 2008). The enzyme function 
can also be regulated by phosphorylation which enables Ca
2+
 -independent activation of 
eNOS in endothelial cells by fluid shear stress. Shear stress stimulates a pathway involving 
PI3K and the serine/threonine kinase Akt, which phosphorylates eNOS. This 
phosphorylation directly increases eNOS activity at resting [Ca
2+
] (Fisslthaler et al., 2000). 
The synthesised NO diffuses through biological membranes into the underlying smooth 
muscle where it stimulates guanylyl cyclase to produce cGMP from guanosine 
triphosphate (GTP), stimulating vasorelaxation (Jin and Loscalzo, 2010). 
1.5 Mechanism of vascular myocyte contraction 
Vascular smooth muscle contraction is initiated by an increased concentration of 
intracellular Ca
2+
 mediated via opening of voltage-gated Ca
2+
 channels. Influx of Ca
2+
 
causes myocyte membrane depolarisation and initiation of contraction. The intracellular 
Ca
2+
 interact with calmodulin which activates myosin light chain kinase (MLCK) and 
phosphorylation of myosin light chain (MLC), leading to smooth muscle contraction 
(Webb, 2003). Elevation of cytosolic Ca
2+
 can also be mediated by activating 
phospholipase C, leading to formation of inositol 1,4,5-trisphosphate (IP3) to cause Ca
2+
 
release from the intracellular stores (sarcoplasmic reticulum) through IP3 receptors. 
Myocyte relaxation commences when cytosolic Ca
2+
 concentration is diminished. 
Reduction of intracellular Ca
2+
 leads to activation of MLC phosphatase, causing removal 
of the phosphate on the MLC kinase. Three subunits of MLC phosphatase has been 
identified; catalytic subunit, variable subunit, and a myosin-binding subunit. 
Phosphorylation of myosin-binding subunit abolishes the activity of MLC phosphatase, 
causing the light chain of myosin to remain phosphorylated, sustaining contraction. The 
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activity of MLC phosphatase is also regulated by small G protein RhoA and Rho kinase, 
the downstream target. MLC phosphatase is phosphorylated by Rho kinase, thereby 
inhibiting its activity and promoting the contraction via keeping MLC in the 
phosphorylated state (Webb, 2003). 
The increase of cytosolic Ca
2+
 concentration activates Ca
2+
 removal mechanisms to restore 
myocyte equilibrium. Ca
2+
 removal mechanisms involve Ca
2+
 uptake into the sarcoplasmic 
reticulum and through the plasma membrane via Ca, Mg-ATPase dependent mechanism. 
Ca
2+
 removal is also mediated via Na
+
/Ca
2+
 exchangers located on the plasma membrane 
which use the Na
+ 
electrochemical gradient to remove intracellular Ca
2+ 
ion (Webb, 2003). 
1.6 Mechanism of VSMCs relaxation and the role of K
+
 
channels.  
Vascular smooth muscle relaxation occurs in response to contractile stimuli removal or as 
a result of direct stimulation by a mediator or of a receptor or ion channel that triggers 
inhibition of the contractile response. The principle of VSMCs relaxation is alleviation of 
the contractile response by reducing the intracellular Ca
2+
 concentration. Reduction in 
cytosolic Ca
2+
 reverses the calcium-calmodulin-dependent contraction mechanisms. 
Induction of relaxation is mediated by stimulation of MLC dephosphorylation by MLC 
phosphatase and inhibition of MLC kinase.  
In general, contraction in VSMCs is connected to membrane potential. Depolarisation of 
the cell membrane is associated with opening of L-type voltage-dependent Ca
2+
 channels, 
influx of Ca
2+
 and cell contraction. However, hyperpolarisation reduces L-type Ca
2+
 
channel opening and the cell remains relaxed. Hyperpolarisation of the myocyte membrane 
is mediated by opening of K
+
 channels in the cell membrane allowing K
+
 efflux. 4 types of 
K
+
 channels have been identified: Ca
2+
-activated (KCa), voltage dependent (Kv), ATP-
sensitive (KATP) and inward rectifying (Kir) channels. This section will discuss some types 
of K
+
 channels. 
1.6.1 Ca2+-activated K+ channels (BKCa channels) 
This class of K
+
 channels are activated by an increase in intracellular Ca
2+
 concentration. 
This family include 3 subfamilies: large-conductance Kca (Big; BKCa), intermediate-
conductance (IKCa) and small-conductance (SKCa). SKCa and IKCa are voltage-independent 
channels activated by an increase in intracellular Ca
2+
. Their Ca
2+
 sensitivity is due to their 
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association with calmodulin (Xia et al., 1998, Fanger et al., 1999). Both SKCa and IKCa are  
thought to be essential for endothelium-dependent myocyte hyperpolarisation (Coleman et 
al., 2004). 
Large-conductance Ca
2+
-activated K
+ 
channels are the most common characterised type of 
KCa in VSMCs. It is activated in response to changes in intracellular Ca
2+
 and membrane 
depolarisation (Nelson and Quayle, 1995). It composed of a pore-forming α-subunit and a 
regulatory β-subunit (Tanaka et al., 1997). The α subunit comprises of seven 
transmembrane domains (S0-S6), including a voltage sensor (S4) and four hydrophobic 
domains located on the cytoplasmic surface. The S0 domain is a ubiquitous feature for the 
BKCa channels and facilitates the interaction with, and channel modulation by  subunits. 
The cytoplasmic tail (the C-terminus) has regulatory domains including regulator of 
conductance for K
+ 
1 (RCK1), RCK2 and a Ca
2+
 bowel (in RCK2) (Wei et al., 1994). 
There are four β subunit isoforms (β1-4). Each isoform consists of two transmembrane 
domains which may be linked to α-subunits. The β1 subunit is the most common isoform 
expressed in VSMCs (Ko et al., 2008). Overall, the function of the β subunit is to increase 
sensitivity of the channel to Ca
2+
, channel kinetics and pharmacological properties (Hanner 
et al., 1997, Meera et al., 1996). Activation of BKCa leads to K
+ 
efflux and 
hyperpolarisation of the cell membrane which reverses pressure- or chemical-induced 
depolarization and vasoconstriction (Ko et al., 2008). 
1.6.2 Voltage-gated K+ channels (Kv) 
Kv channels include 12 subfamilies (Kv1-12) (reviewed in Gutman et al., 2005). They are 
expressed in vascular smooth muscle cells (Caterson et al., 2004). Activation of Kv 
channels leads to opening of the channel and K
+ 
efflux in response to membrane 
depolarisation. This will result in repolarisation which causes the membrane potential to 
return to resting membrane potential. Membrane depolarisation in VSMCs has been 
reported to be associated with opening of L-type Ca
2+
 channels and Ca
2+
 influx resulted in 
contraction. Therefore, Kv channels act as a switch to maintain resting vascular tone by 
limiting membrane depolarisation (Nelson and Quayle, 1995, Sobey, 2001). They are 
composed from pore forming α-subunits and have cytoplasmic N- and C- termini formed 
from six transmembrane domains (S1–S6) with an S4 acting as the voltage-sensing 
transmembrane domain (Korovkina and England, 2002). The α subunit is linked with 
ancillary β subunits which define the properties of the channel (Bahring et al., 2001). It is 
worth noting that α subunits are characterised by heteromultimerization which mean that α 
Chapter 1 – General Introduction 
16 
 
subunits from different subfamilies can form functional channels with varying properties 
(McKeown et al., 2008). Depending on their voltage-dependence and pharmacological 
data, Kv channels expressed in VSMCs have been classified into two basic groups 
including rapidly activating/inactivating such as Kv4.2 and 4.3 and slowly activating; the 
delayed rectifiers such as Kv7.  
Kv7 channels have five subtypes: Kv 7.1-7.5 and are encoded by KCNQ1-5 genes; thus 
they are sometimes termed KCNQ channels and have various tissue localisations. Kv 7.1, 
7.4 and 7.5 have been demonstrated in VSMCs of rat aortic and mesenteric artery 
(Brueggemann et al., 2007, Mackie et al., 2008). They conduct a current that is slowly 
activating with a threshold -60 mV and is non-inactivating. Their activation threshold 
maintains the opening state of the channel during resting membrane potential, allowing 
conduction of the resting K
+ 
current in vascular myocytes (Xiong et al., 2008).  
1.6.3 ATP-sensitive K+ channels (KATP) 
KATP channels were initially chracterised in cardiac muscle and since then have been 
reported in many cells types including vascular smooth muscle (Nelson and Quayle, 1995). 
The single-channel conductances demonstrated for KATP channels in VSMCs are varied. 
However, it can be classified into two main categories: small/medium conductances and 
large conductances (Quayle et al., 1997). They are hetero-octameric complexes composed 
from 4 pore-forming Kir6 subunits and 4 regulatory sulphonylurea receptors (SUR) 
(reviewed in Cole and ClÉMent-Chomienne, 2003). The pore-forming subunits include 
two subtypes, Kir6.1 and Kir6.2 (Teramoto et al., 2006) with two transmembrane domains 
connected by an ion selectivity loop (Nichols, 2006). The sulfonylurea receptors (SUR) are 
an atypical ABC protein that binds to Kir6 subunits to form functional KATP channels. 
They belong to the ATP-binding cassette protein family. There are three isoforms of SUR 
(SUR1, SUR2A, and SUR2B). SURs have no role in pore-forming, but are important for 
surface expression of KATP and nucleotide-dependent activation of the KATP channel  (Hill 
et al., 2003). 
The KATP channel is activated in response to a decrease in the intracellular ATP/ADP ratio, 
causing K
+
 efflux from the cell, cell membrane hyperpolarization, and electrical activity 
suppression. The KATP channel can be inhibited by ATP (in the absence of Mg
2+
) by 
binding directly to Kir6 in a binding pocket located at the internal surface of the NH2- and 
COOH- ends (Hund and Mohler, 2011). In VSMCs, the current induced as a result of KATP 
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opening is both time and voltage-independent and can be inhibited by sulphonylurea 
compounds such as glibenclamide. The channel conductance in vascular myocytes via 
KATP is relatively small (20-50 pS) (Ko et al., 2008). Native KATP channels in VSMCs most 
likely have Kir6.1/SUR2B or Kir6.2/SUR2B with the Kir6.1/SUR2B being the 
predominant molecular entity (Koh et al., 1998, Cinti, 2005). However, it is worth noting 
that two different KATP channels may exist in the same type vessel. For example, it has 
been reported that both a small conductance and activated by nucleotide diphosphate and a 
larger conductance (50 pS) and inhibited by ATP are expressed in rat portal vein (Bolton 
and Imaizumi, 1996). Therefore, it is plausible to think that more than one type of KATP 
channels exists in the blood vessels.  
1.7 Mechanism of anticontractile effect of the PVAT 
Previously, vascular reactivity experiments were usually conducted in vessels with no 
attached PVAT. This practice was based on the traditional belief that PVAT only acted as 
scaffolding of the adjacent blood vessels. Additionally, PVAT was also removed as its 
presence was thought to affect reactivity either by impairing diffusion of the agents or 
metabolising some pharmacological agents added to the organ bath (reviewed in Oriowo, 
2015). However, in early 90s, the first evidence emerged suggesting modulation of 
vascular smooth muscle tone by PVAT was provided by Soltis and Cassis (Soltis and 
Cassis, 1991). They demonstrated that the presence of PVAT significantly attenuated 
noradrenaline-induced contraction of the rat aorta in comparison with vessels in which 
PVAT was removed. This effect was explained by uptake of noradrenaline into adrenergic 
nerves in the fat tissue, since PVAT had no effect on phenylephrine and KCl contractions 
(Soltis and Cassis, 1991). Lohn and co-workers confirmed the anticontractile effect of the 
PVAT on 5-HT and angiotensin II (Lohn et al., 2002). This finding would suggest that the 
anticontractile effect is not due to uptake into noradrenaline containing nerve fibres since 
angiotensin II is not a substrate for the uptake mechanism. Lhon et al suggested that the 
anticontactile effect of the PVAT is due to a transferable factor which is adipocyte-derived 
and they were the first to coin the term (ADRF) (Lohn et al., 2002). These early findings 
have been supported in many subsequent studies in different vascular beds and with 
different agonists (Verlohren et al., 2004, Dubrovska et al., 2004, Fesus et al., 2007, Gao et 
al., 2006, Gao et al., 2007, Lu et al., 2011b). PVAT released factors induce the 
anticontractile effect via modulation of vascular function either at the level of the 
endothelium or vascular smooth muscle layer by targeting certain effectors or receptors. 
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Therefore, the function of ADRFs can be classified into two main categories which will be 
discussed in the following section.  
1.7.1 Endothelium-dependent mechanism of PVAT action 
PVAT was reported to attenuate the contraction of rat thoracic aorta induced by 
phenylephrine (Gao et al., 2007). In this study, conditioned medium from donor PVAT-
intact  rat aorta induced relaxation in endothelium-intact vessels. Removal of the PVAT 
from the donor or the endothelium from recipient aortic rings led to loss of the relaxant 
effect of the PVAT. In the same study, transfer of conditioned medium from intact PVAT 
vessels to segments with denuded endothelium did not enhance the relaxation response of 
the vessels. These findings indicated that the PVAT is a source of transferable factors and 
its effect is dependent on the endothelium. This effect was proposed to be mediated via 
PVAT generated NO and subsequent activation of calcium-dependent K
+
channel 
activation in VSMC (Gao, 2007). Adipokines in the conditioned medium have therefore 
been proposed to underlie these actions of PVAT. 
Leptin is an adipokine released by adipose tissues including PVAT and is involved in 
regulation of appetite and energy metabolism. It also has vasoactive properties (Figure 1-2) 
mediating both vasodilatation (Vecchione et al., 2002) and vasoconstriction (Cooke and 
Oka, 2002). The vasodilation is reported to be mediated by activation of the AMPK 
signalling pathway, resulting in eNOS activation via Ser1177 phosphorylation (Vecchione 
et al., 2002). 
Cell membrane
Leptin Receptor 
Leptin
 
Figure ‎1-4  Mechanism of leptin induced vasodilation and vasoconstriction. 
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Adiponectin is another important  cardioprotective adipokine (Antoniades et al., 2009) that 
can also induce vascular relaxation via endothelium dependent mechanisms. It enhances 
production of NO from endothelial cells by increasing phosphorylation of eNOS at ser1177 
with involvement of PI3K-Akt and AMPK (Chen et al., 2003). This effect is mediated 
through binding to adiponectin type 2 receptor (rather than type1) or T-cadherin 
(Greenstein et al., 2009), and also binding of heat shock protein HSP90 (Xi et al., 2005) in 
which APPL1 acts as an immediate downstream modulator of adiponectin receptors 1 and 
2 (Cheng et al., 2007). In human endothelial cells, adiponectin reduced TNF-α-induced 
production of asymmetric dimethylarginine (ADMA), an L-arginine analogue that inhibits 
NO formation and impairs vascular function (Eid et al., 2007).  
Other adipokines that have been reported to influence endothelium-mediated vascular tone 
include omentin, visfatin and hydrogen peroxide (H2O2), Omentin is reported to induce 
endothelium-dependent vascular relaxation via eNOS phosphorylation and stimulated NO 
synthesis (Yamawaki et al., 2010) while visfatin, has been reported to activate Akt and 
cGMP-dependent protein kinase (Yamawaki et al., 2009) and H2O2  induces endothelium-
dependent vasodilation through COX-1-mediated release of PGE2 (Thengchaisri and Kuo, 
2003). 
1.7.2 Endothelium-independent mechanism of PVAT action 
In addition to being produced by vascular smooth muscle and heart tissue (Zhao et al., 
2001, Zhao and Wang, 2002), H2S is also generated by PVAT  from cysteine by 
cystathionine-gamma-lyase enzyme (CSE) (Fang et al., 2009). H2S induces a dose-
dependent vascular relaxation in both rat aorta and mesenteric arterioles that is not 
dependent on nitric oxide but is calcium-dependent (Zhao and Wang, 2002, Zhao et al., 
2001). The mechanism of relaxation is thought to be due to opening of ATP-sensitive 
potassium channel (KATP channel) and enhancing K
+
efflux (Zhao et al., 2001) since  Fang 
and co-workers demonstrated that the anticontractile effect of endogenous H2S from PVAT 
was abolished by blocking the KATP channel (Fang et al., 2009).  
PVAT has also been found to significantly attenuate vascular responsiveness of mesenteric 
arteries to several agonists, including serotonin, phenylephrine, and endothelin I. The 
mechanism of this anticontractile effect is reported to be mediated by activation of voltage-
dependent, delayed-rectifier K (Kv) channels that hyperpolarize the vascular smooth 
muscle cell membrane (Verlohren et al., 2004). 
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In 2007, Gao et al suggested that perivascular adipose tissue releases transferable factor(s) 
that can induce vascular relaxation both via endothelium-dependent and endothelium-
independent mechanisms. The endothelium-independent mechanism was suggested to be 
due to release of H2O2 with subsequent activation of soluble guanylate cyclase (sGC) (Gao 
et al., 2007). Hydrogen peroxide was also demonstrated to induce NO-independent 
vascular relaxation via activation of KCa channels (Thengchaisri and Kuo, 2003, Hattori et 
al., 2003). Furthermore, H2O2 has been reported to induce relaxation through activating 
voltage-dependent K
+
 channels (Iida and Katusic, 2000, Gao et al., 2003) and independent 
of phospholipase A2, cyclooxygenase, lipoxygenase, cytochrome P450 monooxygenase, 
adenylate or guanylate cyclase (Gao et al., 2003) or ATP-dependent K
+
 channels (Gao et 
al., 2003). 
1.8 PVAT involvement in cell proliferation and migration  
In addition to its role in regulation of vascular reactivity, PVAT has been proposed to be 
involved in development of atherosclerosis via its effect on vascular smooth muscle 
proliferation and migration (Engeli, 2005). It has long been known that endothelium and 
VSMC layers are the major contributors to the development of atherosclerotic lesions 
(Rudijanto, 2007, Davignon and Ganz, 2004). Furthermore, adventitia with its fibroblasts 
is involved in vascular remodelling and constriction of the external lamina by the 
accumulation of α smooth muscle-containing myofibroblasts in the injured area of the 
blood vessels (Scott et al., 1996, Wilcox and Scott, 1996). Furthermore, macrophage 
infiltration associated with plaque neovascularisation (Maiellaro and Taylor, 2007) and the 
profound inflammation of adventitia following balloon angioplasty of porcine coronary 
arteries is further evidence supporting the involvement of other layers of vasculature rather 
than just the endothelium and VSMCs (Sartore et al., 2001, Okamoto et al., 2001). The 
inflammatory response to arterial angioplasty has been demonstrated in the PVAT 
surrounding the treated arterial segment (Okamoto et al., 2001). These results suggest a 
potential role for PVAT in vascular remodelling and proliferation. However, the current 
view regarding the role of PVAT in atherosclerosis is that PVAT may have opposing 
effects; proatherosclerotic and antiatherosclerotic (Almabrouk et al., 2014). 
1.8.1 Pro-Atherosclerotic Properties of PVAT 
The major mechanism that promotes development of atherosclerosis is the inflammatory 
response in which PVAT may play a role via the recruitment and proliferation of 
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adventitial myofibroblasts (Okamoto et al., 2001). There are also many changes in PVAT 
which have been observed in response to endothelial injury. Wire or balloon injury to the 
lumen of mouse and rat vessels significantly increased the expression of pro-inflammatory 
adipocytokines and reduced adiponectin, an effect that was absent in TNF-α knockout 
(KO) mice and which could be replicated by TNF-α application to the perivascular area of 
the vessel. Furthermore, TNF-α KO mice had reduced neointimal formation, reinforcing 
the potential importance of PVAT-derived inflammatory mediators in vascular remodelling 
(Takaoka et al., 2010). Another study showed that the adipokine C1q/TNF-related protein-
9 attenuates neointima formation in the wire-injured obese mouse femoral artery (Uemura 
et al., 2013).  
Inflammatory responses in PVAT have also been demonstrated to occur not only due to 
injury but also as a response to high fat feeding (Chatterjee et al., 2009). The 
proinflammatory phenotype found in murine PVAT in response to high fat feeding is 
characterised by the markedly reduced secretion of anti-inflammatory adiponectin with 
increased secretion of the proinflammatory cytokines IL-6, IL-8, and the chemokine MCP-
1 in coronary perivascular adipocytes (Chatterjee et al., 2009, Henrichot et al., 2005). 
These findings suggest that PVAT has strong chemotactic activity which is mainly 
mediated via the secretion of chemokines IL-8 and MCP-1. These factors are likely to 
contribute to the infiltration of macrophages and T cells at the interface between human 
PVAT and the adventitia of atherosclerotic plaques in the aorta (Henrichot et al., 2005). 
Another study investigated the relationship between development of atherosclerosis and 
pro-inflammatory PVAT by transplantation of visceral fat to the mid-perivascular area of 
the carotid artery in apolipoprotein-E-deficient mice (Ohman et al., 2011). Transplant of 
visceral WAT (inflammatory fat with a higher macrophage content) stimulated 
development of atherosclerotic lesions in the carotid artery accompanied by an increased 
level of serum MCP-1 (also called CCL2) and enhanced endothelial dysfunction. Such a 
detrimental effect was not seen with transplantation of subcutaneous fat and could be 
ameliorated by an antibody to P-selectin glycoprotein ligand (Ohman et al., 2011). This 
important study demonstrates that the pro-inflammatory and pro-atherogenic properties of 
adipose tissue in the hypercholersterolaemic state can have an adverse influence on 
vascular function and plaque formation. 
PVAT may mediate cell growth and proliferation via release of bioactive adipokines. In 
addition to its function as a vasodilator, leptin has been reported to induce VSMCs growth 
and proliferation (Oda et al., 2001, Huang et al., 2010, Shan et al., 2008). Leptin regulates 
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VSMCs proliferation and migration by stimulating phosphorylation and activation of 
mitogen-activated protein (MAP) kinases, and also increased phosphatidylinositol (PI) 3-
kinase activity (Oda et al., 2001). High levels of serum leptin are observed in obese and 
diabetic patients and have been found to be associated with enhanced neointimal formation 
following femoral artery injury in both wild type and leptin-deficient mice treated with 
exogenous leptin and this was due to activation of the key regulator of protein and amino 
acid metabolism, mammalian target for rapamycin (mTOR) (Shan et al., 2008). Leptin also 
can stimulate VSMCs proliferation via increased phosphorylation of extracellular signal-
regulated kinase 1/2 (ERK1/2), and nuclear factor (NF)-kappa Bp65 (Huang et al., 2010).  
Visfatin has been identified as nicotinamide phosphoribosyltransferase (NAMPT) and is 
involved in the synthesis of nicotinamide mononucleotide (NMN) from nicotinamide 
(Wang et al., 2009a, Wang et al., 2011a). In comparison with subcutaneous fat, visfatin is 
mainly expressed in and secreted from visceral fat. The circulating visfatin level is 
correlated with obesity and its associated abnormalities (Fukuhara et al., 2005, Wang et al., 
2010a, Stastny et al., 2012). Visfatin has been also reported to be expressed in and released 
from aortic PVAT (Wang et al., 2009a). The expression of visfatin in rat thoracic aorta 
PVAT is higher in comparison with subcutaneous and visceral adipose tissue. Similar 
findings have been reported in adipose tissue samples derived from monkeys (Wang et al., 
2009a). Furthermore, visfatin has also been identified in conditioned medium from PVAT, 
demonstrating that this protein can be secreted by PVAT (Wang et al., 2009a). Visfatin has 
no effect on VSMC contraction (Wang et al., 2009a), however, PVAT-derived visfatin has 
been found to be a VSMC growth factor. PVAT-conditioned medium induces VSMC 
growth and proliferation which is inhibited by visfatin-specific neutralising antibodies. 
Application of exogenous visfatin enhances VSMC proliferation and this effect was 
abolished after co-incubation with FK866, a selective inhibitor of NAMPT activity (Wang 
et al., 2009a). In the same study, visfatin stimulated VSMC proliferation in a dose- and 
time-dependent manner mediated via extracellular signal-regulated kinase (ERK) 1/2 
signalling pathways (Wang et al., 2009a) and also attenuated VSMC apoptosis induced by 
H2O2. The knockdown of insulin receptors abolished insulin-induced Akt phosphorylation 
and VSMC proliferation but had no effect on the response to visfatin while the visfatin 
product NMN also stimulated proliferative signalling pathways and cell proliferation 
(Wang et al., 2009a). Visfatin also exhibits pro-inflammatory effects, stimulating iNOS 
and activation of the key proinflammatory transcription factor, NF-κB (Romacho et al., 
2009). 
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Epicardial adipose tissue thickness was reported to be associated with elevated plasma 
visfatin levels and local visfatin expression in CAD patients (Cheng et al., 2008) while 
increased visfatin expression has been detected in the PVAT of aortic and coronary vessels 
with atherosclerosis (Spiroglou et al., 2010). 
1.8.2 Anti-atherosclerotic properties of PVAT 
As well as the important role inflammation in atherosclerosis development, impaired 
energy metabolism in the blood vessels is also linked with atherogensis (Mayr et al., 2005). 
Temperature has long been recognized to influence energy metabolism, and one of the 
main roles of BAT is to provide adaptive thermogenesis via uncoupling of respiratory 
chain by UCP1 (Brown et al., 2014). BAT is involved in the regulation of energy 
expenditure in humans, and since some adipocytes within PVAT possess the 
morphological features of BAT, it might be anticipated that the fat surrounding the blood 
vessels can control the local energy metabolism of the vessel wall. Studies have shown that 
PVAT can generate heat, which helps in maintaining intravascular temperature and 
correlates with increased activity of metabolic enzymes in mice housed at 16°C (Chang et 
al., 2012). In this study, development of atherosclerotic plaques in the mice was attenuated 
and serum triglyceride concentrations decreased markedly. Peroxisome proliferator-
activated receptor γ (PPAR-γ) is a key regulator of white and brown adipocyte 
differentiation (Siersbaek et al., 2010) and in mice lacking smooth muscle PPARγ, an 
absence of PVAT was found, which caused endothelial dysfunction and temperature loss 
(Chang et al., 2012).  
It is well known that obesity-induced inflammation in periadventitial adipose tissue is 
associated with upregulation of inflammatory adipocytokines and downregulation of the 
antiinflammatory adipocytokine adiponectin (Takaoka et al., 2009). These changes were 
associated with enhanced neointima formation after endovascular injury. Endothelial injury 
induces adhesion and migration of leukocytes, macrophages, and bone marrow–derived 
progenitor cells into the vessel wall (Sata et al., 2000). Furthermore, pro-inflammatory 
cytokines have a fundamental role in mediating the initiation and progression of vascular 
lesion formation (Serrano et al., 1997, Libby, 2002). Takaoka et al provide direct evidence 
that PVAT may protect against neointimal formation after angioplasty in lean mice and 
that inflammatory changes in the periadventitial fat may have a direct role in the 
pathogenesis of vascular disease accelerated by obesity. They also suggested that 
adiponectin released from PVAT may play a protective role in neointima formation of the 
Chapter 1 – General Introduction 
24 
 
adjacent artery after vascular injury in lean mice (Takaoka et al., 2009). In this study, 
PVAT removal enhanced neointimal hyperplasia following endovascular injury in the 
femoral artery. Transplantation of subcutaneous fat from a normal mouse to surround the 
injured artery significantly reduced neointimal formation. In line with the previous 
findings, the protective effect of exogenous adipose tissue was lost when transplanted 
subcutaneous adipose tissue was derived from obese mice. This is likely related to 
phenotypic changes in adipose tissue associated with obesity. These changes include 
reduced production of anti-inflammatory adiponectin and increased pro-inflammatory 
adipokines; IL-6, MCP-1, tumour necrosis factor-α (TNF-α) and plasminogen activator 
inhibitor type-1 (PAI-1) in subcutaneous adipose tissue-conditioned medium from obese 
mice compared with that from normal mice (Takaoka et al., 2010). In the same study, the 
conditioned medium derived from the subcutaneous adipose tissue of normal mice 
attenuated VSMC proliferation stimulated by platelet-derived growth factor (PDGF)-BB 
(Takaoka et al., 2010). On the other hand, the conditioned medium from obese mice 
increased VSMC proliferation, which was attenuated by pretreatment with anti-TNF-α 
antibodies. Furthermore, the conditioned medium of adiponectin-deficient subcutaneous 
adipose tissue enhanced VSMC proliferation. These findings reveal that TNF-α secreted 
from adipose tissue increases VSMC growth, and that adiponectin secreted from adipose 
tissue inhibited VSMC growth in response to PDGF-BB stimulation (Takaoka et al., 2010).  
Further experiments revealed that adiponectin suppressed endothelial cell proliferation 
induced by a low dose of oxidized low density lipoprotein (Motoshima et al., 2004). 
Interestingly, exogenous adiponectin suppressed PDGF-BB-induced VSMC proliferation 
via AMPK activation (Igata et al., 2005). The AMPK pathway is central to many of the 
effects of adiponectin including: inhibiting the expression and activity of iNOS, secretion 
of adventitial infective factors, division, proliferation and translation of adventitial 
fibroblasts, change of adventitial fibroblasts to myofibroblasts, and oxidative/nitrative 
stress which reduces atherosclerotic plaque area and stabilizes the plaque (Cai et al., 2008). 
In the next part of the introduction, I will focus on AMPK and its role in the function of 
PVAT. 
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1.9 AMP-activated protein Kinase (AMPK)  
1.9.1 Background  
AMPK is a metabolic stress-sensing protein kinase that is involved in regulation of 
metabolism in response to energy requirements; phosphorylating key regulatory enzymes 
in different metabolic pathways as well as regulating gene expression (Kemp et al., 2003). 
AMPK was identified by ATP-dependent inhibitory activity observed during preparation 
of rat liver acetyl-CoA carboxylase (ACC) (Jeong et al., 2007) and purification of 3-
hydroxy-3-methylglutaryl coenzyme A from rat liver microsomes (Maenhaut and Van de 
Voorde, 2011). Later, both enzymes were found to be activated by AMP (Yeh et al., 1980, 
Ferrer et al., 1985). Carling et al found that ACC and the HMG-reductase kinases were 
identical and the name of AMPK was adopted (Greif et al., 2009). AMPK monitors 
cellular energy status by sensing increases in the ratios of AMP/ATP and ADP/ATP 
(Hardie, 2011). Therefore, a reduction in ATP/AMP ratio leads to activation of AMPK 
which acts to inhibit anabolic pathways such as fatty acid, triglyceride and cholesterol 
synthesis, protein synthesis and transcription and stimulate catabolic pathways including 
glycolysis and fatty acid oxidation (Kemp et al., 2003).  
In this section I will review the role of AMPK in physiological and pathophysiological 
function with particular emphasis on its role in the regulation of vascular function.  
1.9.2 AMPK structure 
AMPK is heterotrimeric serine-threonine protein kinase. The complex is composed of one 
catalytic α subunit, and two regulatory subunits (βand γ). There are multiple subunit 
isoforms in mammals (α1, α2, β1, β2, γ1, γ2 and γ3), which enables the formation of 12 
different heterotrimer combinations that are thought to possess distinct subcellular 
localization and signalling mechanisms (Hardie, 2007). Figure 1.2 illustrates the domain 
organizations of α, β and γ subunits of AMPK.  
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Figure ‎1-5 Structure of AMPK.  
The‎ figure‎ shows‎ the‎ components‎ of‎ the‎ AMPK‎ subunits.‎ The‎ catalytic‎ α-subunit can be 
phosphorylated at Thr
172
.‎ The‎ β-subunit contains a glycogen-binding‎ domain‎ (GBD).‎ The‎ γ-
subunits contain four nucleotide-binding modules (CBS domains) capable of co-operatively binding 
to AMP, ADP and ATP. AIS; autoinhibitory sequence,  β-SID; β‎ subunit‎ interacting‎ domain 
(adapted from Ewart and Kennedy, 2011). 
 
The α subunit (α1: 550 residues) is composed of an N-terminal kinase catalytic domain 
(KCD), followed by an autoinhibitory sequence (AIS) and complex-forming C-terminal 
domain (β-SID) which are separated by a region of predicted high flexibility. The β 
subunits act as targeting scaffolds that influence subcellular localization. Mammalian β1 
consists of an N-terminal (∼70 residue) sequence, followed by an internal carbohydrate-
binding module (CBM) related to the N-isoamylase domain subfamily and glycogen-
branching enzyme. The highly conserved C-terminal sequence (ASC) has been reported by 
genetic and structural studies to act as a tethering domain for both α and γ AMPK subunits. 
Each γ subunit comprises of four cystathionine-β-synthase (CBS) sequence repeats which 
are small motifs found in tandem pairs called Bateman domains. The CBS sequences act as 
structural elements which are required for binding the regulatory nucleotides AMP and 
ATP. In comparison with γ1, the γ2 and γ3 subunits have large extensions to the N-
terminus prior to their canonical pair of Bateman domains (reviewed in Oakhill et al., 
2009). 
1.9.3 Activation of AMPK 
1.9.3.1 Allosteric AMPK activation 
AMPK is a primary sensor of cellular energy change that responds to stresses that cause 
increases in the AMP:ATP ratio. Metabolic stresses including hypoxia, nutrient 
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deprivation, heat shock and metabolic poisoning, have been reported to activate AMPK 
(Salt et al., 1998, Hardie, 1999). Reduction in the cellular ATP sensed by a rise in AMP or 
ADP will increase AMPK activity by 10 fold. Binding of AMPK to AMP or ADP induces 
a conformational change that results in α-subunit Thr172 phosphorylation, as well as 
inhibition of Thr172 dephosphorylation by protein phosphatases (Hardie et al., 2011). 
AMP has been shown to support allosteric activation of AMPK that has already been 
phosphorylated on Thr172 of the α-subunit (Corton et al., 1995). 
1.9.3.2 Activation by upstream Kinases 
In addition to the allosteric activation due to changes in ATP/AMP ratio, AMPK can be 
activated at Thr127 on the catalytic α subunit by upstream kinases. Two major AMPK 
kinases have been identified and they are liver kinase B1 (LKB1) (Woods et al., 2003a) 
and Ca
2+
/calmodulin-dependent protein kinase kinase β (CaMKKβ) (Figure 1-3) (Hawley 
et al., 2005). 
LKB1 is the major Thr172 kinase that regulates mammalian AMPK and is the most 
thoroughly investigated (also referred to as serine/threonine kinase 11). LKB1 was 
originally identified as a tumour suppressor gene (Hemminki et al., 1998), which is 
mutated in Peutz Jeghers syndrome. This syndrome is characterised by the development of 
hamartomas (benign intestinal polyps) and development of high risk malignant cancers in 
other organs within the body (Hardie, 2005). Inactive LKB1 is located within the nucleus. 
However, when LKB1 is activated, it translocates to the cytoplasm forming a 
heterotrimeric complex with two supporting subunits, STE20-related adaptor protein 
(STRAD), and scaffolding mouse 25 protein (MO25) (van Veelen et al., 2011). STRAD 
functions as a blocker of the nuclear re-localization of LKB1 and Mo25 stabilizes LKB1-
STRAD-Mo25 complex. LKB1 is constitutively active and it has been suggested that the 
phosphorylation of AMPK by LKB1 is upregulated by physiological and pathological 
metabolic stress that affects the ATP/AMP ratio such as hypoxia, hypoglycaemia, 
ischaemia and exercise (Hawley et al., 2003). LKB1 phosphorylates AMPK on its α-
Thr172 residue, resulting in at least a 100-fold increase in AMPK activity (Hardie, 2011). 
Binding of AMP to AMPK stimulates LKB1-dependent phosphorylation of Thr-172 
through inhibition of dephosphorylation by causing a conformational change which makes 
the AMPK complex a less desirable substrate for protein phosphatases and produces a 
large effect on kinase activity by allosterically activating the phosphorylated form of 
AMPK (Viollet et al., 2010). In addition, LKB1 has also been identified as being essential 
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for the phosphorylation and activation of 13 other AMPK-related kinases (Lizcano et al., 
2004). However, their physiological functions have not yet been thoroughly defined and 
they do not appear to be regulated by metabolic stress (Lizcano et al., 2004). 
Although LKB1 was considered to be the major kinase responsible for activation of 
AMPK via an AMP-dependent mechanism, activation of AMPK via phosphorylation at 
Thr172 has been identified in cells lacking LKB1 (Woods et al., 2005, Hawley et al., 
2005). CaMKKs, as the name implies, were originally thought of  as acting upstream of 
Ca
2+
/calmodulin-dependent protein kinases, however they were also found to activate 
AMPK in vitro as early as 1995 (Hawley et al., 1995). Unlike LKB1, CaMKKs are tissue 
restricted and are mainly expressed in neurons, T cells and endothelial cells (Anderson et 
al., 2008, Tamas et al., 2006, Stahmann et al., 2006). CaMKKβ rather than CaMKKα 
phosphorylates and activates AMPK in response to increased levels of calcium influx into 
the cell (Hawley et al., 2005, Woods et al., 2005). In human endothelial cells, thrombin 
activates AMPK via an increase in Ca
2+
 and activation of CaMKKβ (Stahmann et al., 
2006). In the same type of cells, VEGF-B activates AMPK in a CaMKK-dependent 
manner and AMPK activitation is required for proliferation in response to either VEGF-A 
or VEGF-B and migration in response to VEGF-A (Reihill et al., 2011). 
TGF-β-activated kinase 1 (TAK1), was also proposed as an upstream kinase for AMPK 
based on a genetic screen for mammalian kinases. TAK1 was shown to activate the yeast 
orthologue of AMPK, Snf1 protein kinase, in vivo and in vitro and co-expression of TAK1 
and its binding partner TAB1 in HeLa cells stimulated phosphorylation of AMPK-Thr172 
(Momcilovic et al., 2006). Mice carrying a cardiac-specific dominant negative mutation for 
TAK1 had signs of the Wolff–Parkinson–White syndrome, which is similar to those 
associated with mutations in human AMPKγ2 (Xie et al., 2006). Moreover, TAK1-
deficient MEFs exhibit reduced AMPK activation by oligomycin, metformin and 5-
aminoimidazole-4-carboxamide 1-β-D-ribonucleoside (AICAR), leading the authors to 
propose that TAK1 has a pivotal role in the regulation of LKB1/AMPK signalling axis, an 
essential pathway in the regulation of cell metabolism (Xie et al., 2006). Despite this, no 
recent studies have further corroborated the action of TAK1 as an AMPK Thr172 kinase. 
1.9.3.3 Physiological modulators of AMPK 
AMPK is activated by metabolic stresses that inhibit catabolic generation of ATP such as 
glucose deprivation, hypoxia, ischaemia, and treatment with metabolic poisons or increases 
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ATP demand or consumption such as muscle contraction, thereby increasing cellular 
ADP:ATP (Oakhill et al., 2010, Oakhill et al., 2011) and AMP:ATP ratios (Hardie, 2007). 
1.9.3.4 Pharmacological modulators of AMPK 
In addition to physiological activation of AMPK by increases in the cellular AMP/ATP 
ratio (Ewart and Kennedy, 2011, Hardie, 2007), many pharmacological AMPK activators 
have been identified (Figure 1-4). 
Metformin is a commonly used medication in the treatment of type 2 diabetes that reduces 
hyperglycaemia (Kirpichnikov et al., 2002). Metformin is a biguanide that activates AMPK 
in intact cells and in vivo (Musi and Goodyear, 2002). Activation of AMPK by metformin 
is dependent on its uptake by organic cation transporter 1 (Shu et al., 2007), and recent 
studies have shown that metformin stimulates AMPK activity by increasing AMP levels 
(Hawley et al., 2010). Others have suggested that ROS and reactive nitrogen species are 
also involved in the activation of AMPK by metformin (Zou et al., 2004, Fujita et al., 
2010). However, many studies have revealed that metformin can induce anti-
gluconeogenic actions in an AMPK-independent manner via a decrease in hepatic energy 
state (Foretz et al., 2010), although it remains possible that AMPK activation underlies 
other effects of metformin.  
In the vasculature, metformin-induced AMPK activation has been reported to up-regulate 
eNOS phosphorylation to increase NO bioavailability (Calvert et al., 2008, Zhang et al., 
2011) and reduce SMC proliferation, migration and inflammatory responses (Kim and 
Choi, 2012). In cardiac tissue, metformin-induced AMPK activity sustains energy balance, 
cardiomyocyte function and myocardial viability (Cha et al., 2010, Fu et al., 2011). The 
reported cardioprotective effect is principally achieved by the reduction of hypertrophic 
cell growth and endoplasmic reticulum (ER) stress (Dong et al., 2010). 
Thiazolidinediones (TZDs) are another class of anti-diabetic drugs, including rosiglitazone, 
troglitazone and pioglitazone, which have been used to counteract insulin resistance in 
patients with T2DM by increasing the sensitivity of peripheral tissues to insulin (Krishan et 
al., 2015). They act by binding to PPARγ, which promotes the synthesis of glucose 
transporters and proteins regulating lipid metabolism, leading to storage of lipids in 
adipocytes rather than hepatocytes and muscle, protecting against lipotoxicity-driven 
insulin resistance (Semple et al., 2006, Burns and Vanden Heuvel, 2007). PPARγ receptors 
are nuclear hormone receptors that are expressed widely not only in adipose tissue but also 
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in skeletal muscle (Hevener et al., 2003), liver (Gavrilova et al., 2003) and macrophages 
(Hevener et al., 2003).  
TZDs exert pleiotropic effects in a manner similar to statins, and some of these effects are 
observed acutely and do not require gene transcription. The acute effects of TZDs have 
been proposed to be via activation of AMPK in adipose tissue, skeletal muscle and liver 
(LeBrasseur et al., 2006). The mechanism of AMPK activation is reported to be due to an 
increase in intracellular AMP/ATP ratio (Fryer et al., 2002). Similar to metformin and 
phenformin, TZDs have been demonstrated to act as inhibitors of complex 1 of the 
respiratory chain (Brunmair et al., 2004); thus, an increase in the AMP/ATP ratio may be 
the mechanism for AMPK activation in response to these drugs. Notably, this effect was 
reported to be independent of PPARγ (Guh et al., 2010). TZDs can also activate AMPK by 
stimulating adiponectin release from adipose tissue (Yamauchi et al., 2002) and this effect 
may be important in PVAT. Both rosiglitazone and pioglitazone have been reported to 
have beneficial anti-atherosclerotic and anti-inflammatory effects (Stocker et al., 2007), as 
well as an additional beneficial influence on endothelium via AMPK-dependent and 
PPAR-γ-independent mechanisms (Polikandriotis et al., 2005, Ceolotto et al., 2007). It has 
been also shown that rosiglitazone can stimulate NO synthesis in human endothelial cells 
via AMPK-mediated eNOS Ser1177 phosphorylation (Boyle et al., 2008). However, it 
should be noted that TZD use is associated with the risk of fluid retention which may 
exacerbate heart failure (Hannan et al., 2003). There is also a concern that rosiglitazone is 
associated with additional cardiovascular (MI and stroke) risk in patients with T2DM 
(Azimova et al., 2014). 
Statins are HMG-CoA reductase inhibitors used in the treatment of metabolic syndrome 
and hypercholesterolaemia. Besides their cholesterol-lowering effects, statins have also 
been reported to activate AMPK in human and bovine endothelial cells (Sun et al., 2006). 
Sun et al. also reported that while atorvastatin and lovastatin rapidly stimulate AMPK and 
eNOS in mouse myocardium and endothelial cells, they do not alter the cellular AMP/ATP 
ratio, suggesting a different pathway of AMPK activation (Sun et al., 2006, Goirand et al., 
2007). Two days of treatment with fluvastatin (at a concentration of 20 mM) has also been 
reported to stimulate eNOS and AMPK in human iliac endothelial cells. This effect was 
blocked by an eNOS inhibitor, implying that AMPK up-regulation was dependent on NO 
synthesis (Xenos et al., 2005). In another study conducted in rat aorta, simvastatin up-
regulated both AMPK and the upstream kinase LKB1. They also reported that this 
activation of AMPK was dependent on PKCζ-mediated phosphorylation of LKB1 (Choi et 
Chapter 1 – General Introduction 
31 
 
al., 2008). However, another study using HeLa cells expressing mutant LKB1 reported that 
phosphorylation of Ser431 on LKB1 was not required for AMPK up-regulation (Fogarty 
and Hardie, 2009). In addition to the beneficial effects of statins on endothelial function, 
which are likely due to eNOS up-regulation (Laufs et al., 2002, Laufs et al., 2000), statins 
exert anti-inflammatory (Cahoon and Crouch, 2007) and anti-atherogenic effects (Nissen et 
al., 2005). These observations all indicate that AMPK activation might be important in the 
pleiotropic effects of statins on cardiovascular protection. 
6,7-Dihydro-4-hydroxy-3-(2′-hydroxy[1,1′-biphenyl]-4-yl)-6-oxo-thieno[2,3-b]pyridine-5-
carbonitrile (A769662) is a member of the thienopyridone family that activates AMPK 
both allosterically and by inhibiting dephosphorylation of the kinase at Thr172 (Cool et al., 
2006). A769662 is dependent on the β-subunit carbohydrate-binding module and γ subunit 
(Guh et al., 2010) of AMPK and, notably, exclusively activates trimers containing the β1 
subunit (Scott et al., 2008). In in vitro studies, A769662 has been shown to stimulate 
phosphorylation of acetyl-CoA carboxylase (ACC) independently of the upstream kinases 
LKB1 and CaMKK (Cool et al., 2006, Goransson et al., 2007). In cell-free assays, it has no 
direct effect on the ability of LKB1 or CaMKK to phosphorylate AMPK. The mechanism 
of AMPK activation by A769662 is thought to be distinct from that of AMP, as A769662 
can still activate an AMP-insensitive AMPK containing a mutation in the γ subunit. In 
addition, A769662 activation of AMPK was inhibited by a mutation in the β1 AMPK 
subunit (Ser108 to Ala), which is an auto-phosphorylation site within the glycogen-binding 
domain; however, the same mutation only partially reduced AMPK activation by AMP 
(Cool et al., 2006, Sanders et al., 2007). A769662 stimulates AMPK directly in partially 
purified rat liver and suppresses fatty acid synthesis in primary rat hepatocytes. Short-term 
treatment of normal Sprague-Dawley rats with A769662 has been shown to reduce liver 
malonyl-CoA levels and the respiratory exchange ratio of CO2 production to O2 
consumption, indicating an increased rate of whole-body fatty acid oxidation (Cool et al., 
2006). Treatment with A769662 reduced plasma glucose, weight gain, and both plasma 
and liver triacylglycerol (triglyceride) levels in leptin-deficient ob/ob mice (Cool et al., 
2006).  
Another potent activator that binds to the same binding site of A769662 which has been 
identified to be a cleft located between the N-lobe of the kinase domain on the α subunit 
and the carbohydrate-binding module on the β-subunit (Calabrese et al., 2014) is 991 (also 
known as ex229). Discovered via high-throughput screens, 991, like A769662, shows 
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some selectivity for β1 complexes although it will activate β2 complexes at higher 
concentrations (Grahame Hardie, 2016).  
Another widely used AMPK activator is AICAR, also known as acadesine. AICAR is a 
pro-drug and analogue of adenosine that enters cells and stimulates AMPK, following its 
phosphorylation to its active nucleotide ZMP (5-aminoimidazole-4-carboxamide-1-β-D-
furanosyl 5′-monophosphate), which mimics AMP (Merrill et al., 1997). AICAR has been 
tested in human studies of ischaemic heart disease due its ability to block adenosine 
reuptake by cardiac cells, promoting stimulation of adenosine membrane receptors. In 
1997, treatment with AICAR before and during surgery was shown to alleviate early 
cardiac death, MI and combined adverse cardiovascular consequences, although whether 
the effects were via AMPK was not investigated at that time (Mangano, 1997). AICAR has 
been demonstrated to reverse many aspects of the metabolic syndrome in animal models 
such as the ob/ob mouse, the fa/fa rat and high fat-fed rat (Buhl et al., 2002, Iglesias et al., 
2002), and also in human subjects (Cuthbertson et al., 2007). AICAR has also been 
reported to stimulate release of adiponectin and inhibit release of cytokines such as TNF-α 
and IL-6, which have been implicated in the development of obesity-induced insulin 
resistance (Kern et al., 2001, Lihn et al., 2004). AICAR is not suitable for clinical use 
because of its short half-life, requirement for i.v. infusion and variable effectiveness. 
AICAR has also been reported to cause bradycardia and hypoglycaemia when 
administered intravenously (Young et al., 2005). 
In addition to galegine, several natural products derived from plants have been reported to 
activate AMPK. These include resveratrol from red grapes, ginsenoside from Panax 
ginseng, berberine from Coptis chinensis, epigallocatechin gallate from green tea, 
theaflavin from black tea and hispidulin from snow lotus (Hwang et al., 2009, Lin et al., 
2010). The role of these compounds in the activation of the AMPK was reasoned with the 
results that berberine can inhibit the respiratory chain (Turner et al., 2008) and resveratrol 
can inhibit the F1 ATP synthase (Gledhill et al., 2007), and thus they activate AMPK 
indirectly. By inhibiting mitochondrial ATP production and thus increasing cellular AMP: 
ATP and/or ADP: ATP ratios, they activate AMPK in a similar manner to the biguanides. 
Supporting this, AMPK activation by resveratrol, berberine, and quercetin was abolished in 
cells expressing the AMP/ADP-insensitive AMPK mutant (Hawley et al., 2010).  
Dorsomorphin (compound C) is an inhibitor of AMPK activity. Compound C binds the 
ATP-binding site of the AMPK kinase domain although it is poorly selective, inhibiting 
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several other protein kinases more effectively that AMPK. Despite this, compound C has 
been used to inhibit AMPK activity in muscle cells, several tumor cell types, and in 
angiogenesis studies in vivo (Nagata et al., 2003, Baumann et al., 2007, Dowling et al., 
2007, Isakovic et al., 2007).  
 
 
Figure ‎1-6  Activation of AMPK.  
AMPK‎ is‎activated‎by‎phosphorylation‎of‎ the‎α‎catalytic‎subunit‎at‎Thr172‎by‎LKB1‎or‎CaMKKβ.‎
Increased AMP or ADP/ATP ratio bind‎ to‎ the‎ regulatory‎γ‎subunit,‎allosterically‎activating‎AMPK‎
and inhibiting dephosphorylation of Thr172 by protein phosphatase (P-ase). Neither LKB1 nor 
CaMKKβ‎ are‎ ‎ regulated‎ directly‎ by‎ adenine‎ ATP,‎ AMP‎ or‎ ADP.‎ Increased‎ intracellular‎ Ca
2+
 
stimulates‎CaMKKβ-mediated AMPK activation. The antidiabetic drugs metformin and rosiglitazone 
(a TZD) increase AMP/ATP or ADP/ATP concentrations, thereby activating AMPK. Resveratrol, 
galgeine and berberine also activate AMPK by this mechanism. AICAR is phosphorylated to the 
nucleotide ZMP, which mimics AMP. A769662, salicylate and compound 991 are reported to 
activate‎AMPK‎complexes‎containing‎the‎β1‎subunit 
 
1.10 Downstream targets of AMPK  
Once activated, AMPK directly activates a number of downstream effectors that control 
energy metabolism and growth, or induce changes in gene expression that will result in 
long-term effects on metabolic function (reviewed in Kahn et al., 2005). In general, AMPK 
up-regulates catabolic pathways (e.g., glucose uptake in muscle, glycolysis, fatty acid 
oxidation and mitochondrial biogenesis) and down-regulates anabolic pathways (e.g., fatty 
acid, triglyceride, cholesterol, glucose (via gluconeogenesis) and glycogen synthesis) to 
maintain energy balance within the cells (reviewed in Kahn et al., 2005). Figure 1-5 
summarises the most well know downstream protein targets of AMPK.   
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Figure ‎1-7 Demonstration of some downstream target proteins of AMPK involved in 
regulation of metabolism.  
Target proteins and processes activated by AMPK activation are shown in Blue arrow, and those 
inhibited by AMPK activation are shown in red arrow. Abbreviations:‎ ACC1,‎ 1‎ (α)‎ of‎ acetyl-CoA 
carboxylase; eEF2, elongation factor-2; FAS, fatty acid synthase; GLUT1/4, glucose transporters; 
GS, glycogen synthase; HMGR, 3-hydroxy-3-methyl-CoA reductase; HSL, hormone-sensitive 
lipase; mTOR, mammalian target of rapamycin; GPAT, glycerol-3-phosphate acyltransferase; PFK-
2, 6-phosphofructo-2-kinase. 
 
1.11 Role of AMPK in peripheral tissue 
AMPK has a well-defined regulatory role in lipid metabolism. Activation of AMPK 
phosphorylates and inactivates ACC and HMGR, as well as reducing expression of fatty 
acid synthase (FAS). The net effect is a reduction in fatty acid and cholesterol synthesis 
(Kahn et al., 2005). In the liver, inactivation of ACC1 results in increased fatty acid 
transport and subsequent oxidation. In skeletal muscle, activated AMPK stimulates fatty 
acid oxidation by decreasing malonyl-CoA levels through the inhibition of ACC. This 
leads to an increase in carnitine palmitoyltransferase 1 (CPT1) activity and the subsequent 
activation of fatty acid oxidation (Kahn et al., 2005). AMPK has been suggested to inhibit 
lipolysis in adipocytes (Daval et al., 2005, Corton et al., 1995), thereby reducing the 
plasma level of fatty acids. Furthermore, AMPK activation stimulates and upregulates the 
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peripheral muscle expression of PPAR-γ coactivator-1α (PGC1α), which enhances 
mitochondrial biogenesis (Terada et al., 2002).  
AMPK is also involved in the regulation of glucose homeostasis. Activation of AMPK in 
skeletal muscle up regulates hexokinase II expression (Holmes et al., 1999). It also 
increases glucose uptake via cell membrane translocation of the glucose transporter 
GLUT4 and the stimulation of GLUT4 gene expression (Derave et al., 2000, Wright et al., 
2005). AMPK inhibits hepatic gluconeogenesis by repressing the transcription of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) 
(Lochhead et al., 2000). Furthermore, AMPK activation decreases glycogen synthesis via 
phosphorylation and inhibition of glycogen synthase (Wojtaszewski et al., 2002). 
Hypothalamic AMPK is also involved in regulation of peripheral tissue metabolism, 
indicating that AMPK is a crucial enzyme in regulation of the interaction between 
peripheral and central energy production. In a study by Perrin et al, intraventricular 
AICAR administration increased both insulin-mediated and non-insulin-mediated glycogen 
synthesis (Perrin et al., 2004), which implies a role for hypothalamic AMPK in muscle 
glycogen synthesis. The same study showed that AMPK is also involved in increasing 
muscle glycogen synthesis and this effect was blocked by the co-administration of glucose 
(Perrin et al., 2004). Activation of hypothalamic AMPK by central adiponectin 
administration decreases energy expenditure, possibly by a reducing the expression of 
UCP-1 in BAT (Kubota et al., 2007). On the other hand, central α-lipoic acid inhibits 
hypothalamic AMPK activity, thus increasing UCP-1 expression and energy expenditure in 
BAT (Kim et al., 2004). Central ghrelin treatment has been shown to increase glucose 
utilisation rate of white and brown adipose tissues (Theander-Carrillo et al., 2006). Ghrelin 
has been shown to abolish, at least in part the effects of central leptin treatment on fat 
weight, plasma glucose and insulin, the effects in which AMPK involved (Minokoshi et 
al., 2004). 
1.12 Vascular effects of AMPK 
1.12.1 Role of AMPK in the vascular endothelium 
Both α subunit isoforms of AMPK are expressed in endothelium (Fisslthaler and Fleming, 
2009), yet the total cellular activity of AMPK complexes containing α1 is higher than those 
containing α2 (Morrow et al., 2003). Despite this, it has been shown that mice lacking the 
α2 AMPK subunit isoforms have endothelial dysfunction characterised by excessive ROS 
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generation (Wang et al., 2010b). The α2 subunit isoform of AMPK is critical in 
maintaining endothelial cells in a normal, non-atherogenic phenotype as it is considered to 
be a physiological suppressor of NAD(P)H oxidase; the marker of oxidative stress and 
generation of ROS (Wang et al., 2010b). However, the role of the α1 subunit in endothelial 
cells has also been examined (Liu et al., 2010) and it was found that AMPK-mediated 
suppression of NF-κB, glucose deprivation and hypoxia-stimulated endothelial cell 
apoptosis was lost in mice lacking AMPKα1, suggesting that AMPKα1 is essential for 
AMPK to promote cell survival by NF-κB-mediated expression of anti-apoptotic proteins 
(Liu et al., 2010). AMPK activation has also been shown to alleviate endoplasmic 
reticulum stress (Dong et al., 2010). 
AMPK enhances release of NO from vascular endothelium. Activated endothelial AMPK 
phosphorylates eNOS at Ser1177, thereby enhancing NO production in human aortic 
endothelial cells (HAECs) (Morrow et al., 2003). AMPK activation may also stimulate 
eNOS association with heat shock protein 90 (Hsp90), which stimulates NO synthesis 
(Wang et al., 2009c, Davis et al., 2006). NO release leads to vasodilation in both conduit 
(Wang et al., 2009c) and resistance vessels (Bradley et al., 2010). Shear stress, statins and 
adiponectin have been found to increase NO bioavailability in the endothelial cells by 
activation of AMPK which phosphorylates eNOS at Ser1177 and also Ser663/635 (Chen et 
al., 2009). In the absence of Ca
2+
/calmodulin, AMPK phosphorylates eNOS at the 
inhibitory Thr495 site, in vitro, reducing the activity of eNOS (Chen et al., 1999). In 
addition the phosphodiesterase inhibitor cilostazol which activates AMPK via altering 
[AMP:ATP] ratio has been demonstrated to enhance NO production and restore 
endothelial function in diabetic rats (Suzuki et al., 2008).  
The lesions of atherosclerosis usually start with endothelial dysfunction and inflammatory 
cell adhesion events (Ross, 1999) and AMPK has been implicated in both of these events. 
In HUVECs, activated AMPK has been found to abolish TNFα stimulated leukocyte 
adhesion and migration via an NO-dependent mechanism associated with reduced MCP-1 
secretion and an NO-independent mechanism by decreasing the expression of adhesion 
molecule E-selectin (Ewart et al., 2008). Similarly, activation of AMPK by berberine 
significantly reduces monocyte (THP-1) adhesion to HUVECs by reducing the expression 
of the adhesion molecules ICAM-1 and VCAM-1 (Wang et al., 2009b). AICAR has been 
found to reduce leukocyte rolling and adhesion by both eNOS-dependent and -independent 
mechanisms. In those experiments, administration of AICAR 30 min prior to induction of 
ischaemic perfusion in mesenteric artery injury reduced inflammatory cell adhesion 
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independent of eNOS, whereas administration of AICAR 24 hours before induction of 
ischaemic perfusion injury abolished leukocyte adhesion in an eNOS-dependent manner 
(Gaskin et al., 2007). In addition, the statin fluvastatin has been reported to upregulate 
eNOS and AMPK and reduce adhesion molecule expression in cultured human iliac artery 
endothelial cells (Xenos et al., 2005).  
AMPK has been shown to control vascular redox balance in endothelial cells. Increased 
oxidant stress and/or defective antioxidant function are involved in endothelial dysfunction 
in atherosclerosis and following vascular injury caused by balloon angioplasty or stenting 
(Siersbaek et al., 2010). Activating AMPK in endothelial cells increases the expression of 
manganese superoxide dismutase (Kukidome et al., 2006) and reduces NF-κB-mediated 
transcription (Hattori et al., 2008). AMPK activating agents such as rosiglitazone and 
AICAR inhibit ROS generation in endothelial cells exposed to oxidant stress via increased 
glucose concentration (Ceolotto et al., 2007). Moreover, activated AMPK enhances 
uncoupling of protein-2 expression which supresses ROS formation and nitration of 
prostacyclin synthase (Xie et al., 2008). 
AMPK is also implicated in angiogenesis. Vascular Endothelial Growth Factor (VEGF), 
the key regulator of angiogenesis, induces differentiation, survival, migration, proliferation 
and vascular permeability (Ferrara et al., 2003). It does so via increasing NO synthesis via 
an AMPK-dependent mechanism (Reihill et al., 2007). 
1.12.2 Role of AMPK in vascular smooth muscle cells  
Many studies have provided evidence that AMPK is important in regulation of vascular 
smooth muscle function and its dysfunction leads to development of vascular disease such 
as hypertension and atherosclerosis.  
Both catalytic α isoforms are expressed in VSMCs, although the ratio of α subunits differs 
according to the type of the vessel (Rubin et al., 2005). Activation of AMPK in vascular 
smooth muscle using AICAR induces vascular relaxation in an endothelial- and eNOS-
independent mechanism mediated by AMPKα1 rather than AMPKα2 (Goirand et al., 
2007). AMPK has been also found to attenuate vascular smooth muscle contraction 
induced by phenylephrine via phosphorylating and inactivating myosin light chain kinase 
(MLCK) (Horman et al., 2008). Moreover, acetylcholine induces endothelial independent 
vascular relaxation by stimulating AMPK-LKB1 dependent mechanism. Activation of 
Chapter 1 – General Introduction 
38 
 
AMPK by LKB1 inhibits myosin light chain kinase and decreases phosphorylation of 
myosin light chain which might attenuate vasoconstriction (Lee and Choi, 2013). 
AMPK is also implicated in inhibition of VSMCs proliferation. This effect appears to be 
mediated by many different signalling mechanisms including regulation of the cell cycle 
and inhibition of protein synthesis, de novo fatty acid and cholesterol synthesis (reviewed 
in Motoshima et al., 2006). AMPK activation can induce G1 cell cycle arrest by 
upregulation of p53-p21 which inhibits VSMCs proliferation (Igata et al., 2005). Retinoic 
acid-related orphan receptor alpha (RORα) is implicated in reducing progression of 
atherosclerosis. RORα abolishes VSMCs proliferation through AMPK-induced mTOR 
suppression and ribosomal protein S6 kinase (S6K), thus alleviating VSMC proliferation 
(Kim et al., 2014). Vascular calcification is a complication associated with type 2 diabetes, 
peripheral and coronary artery disease and occurs due to disturbed osteoblastic 
differentiation (Snell-Bergeon et al., 2013). Activation of AMPK by adiponectin has been 
found to attenuate vascular calcification via AMPK-TSC2-mTOR-S6K1 signalling 
pathway. Furthermore, metformin activated AMPK supresses vascular calcification by 
AMPK-eNOS-NO pathway in rat aortic VSMCs (Zhan et al., 2014, Cao et al., 2013). 
Activation of AMPK abolishes VSMCs proliferation via direct inhibition of IGF-I (Ning 
and Clemmons, 2010). AMPK stimulates the phosphorylation of IRS-1 Ser794 which leads 
to reduced IRS-1 tyrosine phosphorylation and the association of the p85α subunit of PI3K 
with IRS-1 in response to IGF-I. The net effect will be diminished protein synthesis due to 
reduced phosphorylation of Akt at Ser473 (Ning and Clemmons, 2010).   
1.13  Cross talk between PVAT and vascular layers and 
role of AMPK 
PVAT, via its release of adipokines, may therefore affect vascular function via activation 
of AMPK in both endothelium and VSM layers. AMPK-stimulating adipokines, such as 
adiponectin, are potentially the principal mediators of the modulatory effect of PVAT on 
blood vessels. Adiponectin release is markedly reduced in obese PVAT and this has been 
reported to lead to inhibited vasorelaxation. Adiponectin receptor antagonism and the 
AMPK inhibitor compound C have been reported to attenuate vascular relaxation, whereas 
globular adiponectin failed to induce vascular relaxation in AMPKα2-deficient mice 
(Meijer et al., 2013). Furthermore, activation of adipocyte β3-adrenoceptors has been 
reported to stimulate release of a substance, assumed to be adiponectin that indirectly 
opens myocyte BKCa channels. This effect was reported to involve AMPK since it could be 
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mimicked by the AMPK activator, A-769662, and blocked by compound C (Weston et al., 
2013). The indirect activation BKCa by AMPK was demonstrated by blocking adipocyte-
dependent myocyte hyperpolarization induced by BKCa channel opener, NS1619 with 
glibenclamide and clotrimazole (Weston et al., 2013). PVAT has also been reported to 
induce vasodilatation in muscle resistance arteries by increasing secretion of adiponectin 
and activation of AMPK α2 in the blood vessels. Furthermore, this study reported that in 
obese db/db mice, PVAT mass increased dramatically in the muscle and was associated 
with loss of insulin-mediated vasodilation. Notably, the lack of insulin-induced vascular 
reactivity could be restored by JNK inhibition (Meijer et al., 2013). Figure 1-8 illustrates 
the mechanisms by which PVAT may induce vascular relaxation in both endothelium and 
VSMC layers.  
It has been suggested that adiponectin exerts beneficial effects via activation of AMPK and 
suppression of iNOS expression in the vascular adventitia (Cai et al., 2008). The same 
group tested the effects of adiponectin on adventitial fibroblast transition and migration. 
They reported that adiponectin induced AMPK phosphorylation and reduced the migration 
of fibroblasts, the expression of iNOS and the peroxynitrite marker nitrotyrosine in 
response to LPS treatment (Cai et al., 2010).  
Although this thesis focuses on the adiponectin as a potential PVAT derived 
adipocytokines, there are many others such as leptin, apelin and resitin and some gasiuos 
molecules such as H2O2, NO and H2S are ivolved in regulation of vascular function. Figure 
1-8 illustrates the mechanisms by which theses factors modulates vascular function.  
Chapter 1 – General Introduction 
40 
 
 
Figure ‎1-8 schematic presentation of how PVAT modulates the function of AMPK in both 
endothelium and vascular smooth muscle and how these affect vascular function.  
PVAT is a highly active organ secreting various adipokines and cytokines implicating in the 
regulation of vascular contractility via modulation of AMPK activity. ADRF, adipose tissue-derived 
relaxation factor; Ang1-7, angiotensin 1–7; BKCa, calcium-dependent big potassium channel; 
CAMKK, calcium/calmodulin-dependent protein kinase kinase; eNOS, endothelial NOS; HMG-
COA, 3-hydroxy-3-methylglutaryl-coenzyme A; LKB, liver kinase B; MAPK, mitogen-activated 
protein kinases; MnSOD, manganese superoxide dismutase; mTOR, mammalian target of 
rapamycin; PGI2, prostacyclin; ROS, reactive‎oxygen‎species;‎TAK1,‎transforming‎growth‎factor‎β-
activated kinase (Almabrouk et al., 2014). 
 
Activation of AMP-activated protein kinase (AMPK) phosphorylates tuberous sclerosis 
complex 2 (TSC2) which in turn inhibits of mTOR activity and limits protein synthesis 
(Inoki et al., 2003). Ma et al discovered that PVAT can induce vascular dysfunction via 
dysregulation of the AMPK/mTOR pathway in diet-induced obese rats, with mesenteric 
arterial rings incubated with periaortic fat from HFD rats showing reduced endothelium-
dependent relaxation and down-regulation of AMPK and eNOS in the aorta with a 
concurrent up-regulation of mTOR. This effect was absent in periaortic fat from rats on a 
chow diet. In the same study, co-culture of vascular SMCs with periaortic adipocytes from 
HFD animals also reduced AMPK phosphorylation and increased mTOR phosphorylation 
(Ma et al., 2010).  
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Cytokines generated from the PVAT (Figure 1-7) may induce vascular dysfunction 
indirectly via up-regulation of iNOS. 3T3 L1 adipocytes incubated with TNF-α showed a 
200-fold increase in iNOS gene expression (Digby et al., 2010). Furthermore, FFAs 
released by adipocytes increase iNOS expression and vascular dysfunction, as human 
vascular SMCs stimulated with a combination of conditioned media from adipocytes and 
oleic acid induced not only iNOS up-regulation and NO formation but also a proliferative 
response (Lamers et al., 2011). Activation of AMPK in adipose tissue has been found to 
suppress iNOS expression and NO production in cytokine (TNF-α, IFN-γ) treated 
adipocytes (Pilon et al., 2004, Centeno-Baez et al., 2011). 
1.14 Role of AMPK in perivascular adipose tissue  
AMPK is expressed in the three layers of the blood vessel: the endothelium, smooth 
muscle and PVAT and is known to induce vasodilatation by both endothelium and non-
endothelium dependent mechanisms. Furthermore, it is well known that AMPK exerts an 
anti-proliferative effect at the level of the endothelium and VSM. Although it is known that 
AMPK can modulate VSM and endothelial function, it is unknown whether AMPK can 
modulate the anti-contractile and anti-proliferative effects of PVAT, despite the expression 
of AMPK in endothelium, VSM and in perivascular adipocyte. 
At the start of these studies, the role of AMPK in PVAT function had not been examined. 
The studies described in this thesis test the hypothesis that AMPK in PVAT modulates the 
activity of vascular smooth muscle cells, and that this may underlie PVAT-mediated 
changes in vascular function and vessel remodelling in CVD (s).   
1.15 Hypothesis and Aims  
Perivascular adipose tissue (PVAT) surrounds most blood vessels and secretes numerous 
active substances, including adiponectin which produce a net anticontractile effect in 
healthy PVAT. The anticontractile mechanism of PVAT is still unclear, although it is 
generally proposed that PVAT can induce vascular relaxation via both endothelium and 
non-endothelium dependent mechanism. Although it is known that AMPK can modulate 
VSM and endothelial function, it is unknown whether AMPK can modulate the anti-
contractile effects of PVAT. Obesity is an independent risk factor for cardiovascular 
disease and is associated with altered arterial contractility. It is known that AMPK activity 
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in PVAT is reduced with obesity; however it is unknown whether the effects of AMPK on 
arterial contractility are modulated by obesity.  
Therefore, the hypothesis of this thesis is that AMPK expressed in the PVAT is essential in 
regulation of anti-contractile effect of the PVAT and that AMPK acts as a protective 
mechanism in case of HFD-induced obesity. Therefore, this study aimed to: 
i. Investigate the morphological features of PVAT in wild type mice and mice lacking 
AMPKα1. 
ii. Investigate the mechanism responsible for the anticontractile effects of PVAT, 
specifically:  
 The involvement of AMPK in the anticontractile effect of PVAT. 
 To investigate the role of PVAT-derived adiponectin in mediating the 
anticontractile effects of PVAT. 
iii. To determine the role of AMPK in regulation of redox state of PVAT, specifically: 
 To characterise any differences in ROS and RNS expression between wild type and 
AMPKα1 KO PVAT. 
 To define the role of AMPK in the NO-dependent anticontractile effect of PVAT. 
iv. To determine the effect of high fat diet on the function of the PVAT and AMPK, 
specifically: 
 To characterise the effect of high fat diet on the anticontractile effect of PVAT.  
 To determine the role of AMPK in high fat diet-induceed inflammatory response of 
PVAT. 
 To determine the whether wire-induced injury could affect AMPK function in the 
PVAT and thus the antiprolefertive response in mice carotid artery. 
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Materials 
2.1 Animals  
Wild type (Sv129) mice were originally purchased from Harlan Laboratories (Oxon, UK). 
AMPKα1 knockout mice were kindly supplied by Benoit Viollet (Institut Cochin, Paris, 
France) the generation of which has been described previously (Jorgensen et al., 2004). 
Mice were housed at the Central Research Facility at the University of Glasgow and 
maintained on 12 hour cycles of light and dark and at ambient temperature. Mice were fed 
a standard chow diet unless otherwise stated and allowed free access to both food and 
water. All experiments were conducted in accordance with the United Kingdom Animals 
(Scientific Procedure) Act of 1986. Where appropriate all experimentation was performed 
under the project licences, 60/4114 and 70/8572, held by Dr Simon Kennedy (University 
of Glasgow, U.K.). 
2.2 Chemical and Reagents 
All chemicals were supplied by Sigma-Aldrich (Poole, UK) unless otherwise stated. All 
cell culture reagents were obtained from Gibco  (Paisley, U.K.) unless otherwise stated. All 
Western blot materials were supplied by Life Technologies (Paisley, U.K.) unless 
otherwise stated. High-fat diet (Western RD) was purchased from SDS (SDS diets, U.K). 
The composition of the diet is illustrated in Table 2-1. 
Table ‎2-1 Composition of the high-fat diet (HFD). 
Specification % (W/W) Kcal/g % kcl 
Crude fat 21.4 1.93 42 
Crude Protein 17.5 0.70 15 
Crude Fibre 3.5 / / 
Ash 4.1 / / 
Carbhydrate 50.0 2.00 43 
Total AFE  4.63 100 
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Methods 
2.3 Genotyping  
The genotype of all wild type (Sv129) and AMPKα1 knockout mice was confirmed prior 
to inclusion in all studies. Genotypes were confirmed by reverse transcription polymerase 
chain reaction (RT-PCR) using the Go Taq amplification system (Promega, Southampton, 
U.K.), following DNA extraction from ear clips and immunofluorescence staining of the 
targeted sequence. Details of the technique are outlined below.    
 
2.3.1 DNA Extraction 
Ear notches from mice were obtained by staff from the Central Research Facility at 8 
weeks of age when animals were numbered. Samples were stored at -20
o
C until DNA was 
ready to be extracted using DNAreleasy (Anachem, Luton, UK). 10 µl of DNAreleasy was 
added to each ear notch and PCR was performed as follows: 75°C for 5min, 96°C for 2min 
and then kept at 20°C (until needed). 90µl of nuclease free dH2O was then added to the 
samples. Genotyping was performed by RT-PCR using the Go Taq amplification system 
(Promega, Southampton, UK) as per the manufacturer’s instructions, with reaction mixture 
details given in Table 1-1. 
Table ‎2-2 RT-PCR reaction mixture for genotyping 
Reaction Mixture 
TAQ(GO) HOT START GREEN MASTERMIX (Promega, Southampton, UK) which 
contains dNTPs, MgCl and load dye. 
FORWARD primer for both wild type and knockout sequence 
REVERSE primer for both wild type and knockout sequence 
Prepared DNA samples 
 
2.3.2 Polymerase Chain Reaction for AMPKα1 Wild type (WT) and 
AMPKα1 Knockout (KO) 
Details of the primers and their sequences, annealing temperatures and electrophoresis 
bands are showed in Table 2-2. All PCR cycles were subject to a hot-start 95 °C for 5min 
(enzyme activation), followed by 40 cycles of 95°C for 30 seconds (DNA denaturation), 
58°C for 40 seconds and 72°C for 1min (primer binding). Samples were subjected to 72°C 
for 10 min (primer extension) and then 4°C where they were stored until visualised. 
Samples were electrophoresed on a 2% (w/v) agarose/TAE (242g TRIS, 18.6g EDTA, pH 
8) gel and visualized with ethidium bromide (final concentration 0.1% (v/v)) using the 
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Alpha Innotech digital imaging system (San Leandro, CA, USA). The wild type and 
knockout animals were identified by the presence or absence of a targeted sequence in 
comparison with a 100 bp ladder (Promega, UK) run at the same time as shown in Figure 
2-1.   
Table  2-3 list of DNA primers for genotyping 
Target Primer Type Sequence‎(50΄‎-30΄‎) Annealing 
temp. (°C) 
Molecular weight 
(bp) 
Reaction 
product 
AMPKα1 wild-type 
 
 
 
 
 
knockout 
Forward 
primer   
 
Reverse 
primer 
 
Forward 
primer   
 
Reverse 
primer 
AGCCGACTTTGGTAAAGGAT
G 
 
CCCACTTTCCATTTTCTCCA 
 
 
GGGCTGCAGGAATTCGATAT
CAAGC                                    
 
CCTTCCTGAAATGACTTCTG 
62.9 
 
63.7 
 
72.7 
 
58.9 
6200 
 
5917 
 
7731 
 
6043 
WT 
 
 
 
KO 
 
 
 
 
WT DNA 
Primer
KO DNA 
Primer
Wild Type
AMPKα1 KO
Heterozygote
 
Figure ‎2-1 AMPK colony genotyping.  
Gel electrophoresis of amplified PCR products from ear notches taken from mice. A 100 bp DNA 
ladder is shown on the left. The upper half of the agarose gel shows DNA products from PCR 
reactions using primers specific to WT alleles (normal gene). The lower half of the agarose gel 
shows DNA products from PCR reactions using primers specific to KO alleles (gene construct). 
Examples of WT, KO and heterozgote genotypes are indicated. 
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2.4 Histology 
2.4.1 Sample Preparation and Fixation  
Thoracic aortae were dissected from the both AMPKα1 knockout and S129 control mice 
and divided into four rings. Two aortic rings per mouse were freed of PVAT and any 
connective tissue and the remaining aortic rings had PVAT left intact. All were fixed in 
10% acetic zinc formalin (Cell Path Ltd, UK) overnight. Tissues were processed through a 
gradient of ethanol solutions prior to Histoclear (a xylene substitute, Thermo Scientific, 
Loughborough, U.K.) with the terminal step into paraffin wax. Aortic ring processing was 
performed using a Citadel 1000 tissue processor (Thermo Shandon, Runcorn, U.K.). The 
sequence and the time of incubation is summarised in table 2-3.  
Paraffin-embedded wire-injured carotid arteries produced by a previous study in our 
laboratory were utilised in the current research. Endothelial wire injury was performed by 
Marie-Ann Ewart. Briefly, mice were anesthetized and endothelial injury of the left 
common carotid artery was performed with flexible nylon wire introduced through the left 
external carotid artery. The endothelium was damaged by passing the wire through the 
lumen of the artery several times (Grassia et al., 2010). Right carotid artery was spared and 
used as a control for the experiment in both strains of mice. A week after wire injury, mice 
were sacrificed and carotid arteries with surrounding PVAT were dissected and processed 
as previously described.  
                     Table ‎2-4 Sequence for processing samples for histological analysis 
 
 
 
 
 
 
Solution Length of incubation of sample 
70 % (v/v) ethanol 15 minutes 
85% (v/v) ethanol 15 minutes 
90% (v/v) ethanol 25 minutes 
100% (v/v) ethanol 25 minutes 
100% (v/v) ethanol 15 minutes 
100% (v/v) ethanol 15 minutes 
100% (v/v) ethanol 15 minutes 
Histoclear 30 minutes 
Histoclear 30 minutes 
Paraffin wax 30 minutes 
Paraffin wax 30 minutes 
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2.4.2 Haematoxylin and Eosin staining  
Haematoxylin and eosin (H&E) stain the nucleus and cytoplasm of cells respectively and 
were used to compare the gross histology of the perivascular adipose tissue around the 
aorta between WT and KO. Paraffin was removed from the cut sections by immersion in 
xylene and slides were rehydrated through an ethanol gradient of 100 % (v/v), followed by 
90 % (v/v) and 70 % (v/v) ethanol for 5 minutes each and washed in running water for a 
further 5 minutes. Sections were then stained with Harris haematoxylin (Raymond A Lamb 
Ltd, Eastbourne, U.K.) for 4 minutes and washed in running water before being placed in 
acid alcohol (1 % v/v HCl in ethanol) for 30 seconds. Slides were washed in water for 1 
minute, placed in 1 % (v/v) eosin (Raymond A Lamb Ltd, Eastbourne, UK) for 2 minutes 
before a further 5 minute wash in deionised water. Sections were then dehydrated by 
successive immersion in 70 % (v/v), 90 % (v/v) and 100 % (v/v) ethanol followed by 10 
minutes in Histoclear (National diagnostic, Hessle Hull, UK). Finally, cover slips were 
fixed over the section using DPX mounting medium (BIOS Europe, Lancashire, U.K.). 
Nuclei appeared blue/purple whereas cytoplasm was stained pink/orange. Sections were 
photographed using AxioVision microscope software (Zeiss, Germany) and analysed with 
Image J computer software.  
2.4.3 Immunohistochemistry  
The following steps were adopted as a general protocol for immunohistochemical staining 
for each of the antibodies unless otherwise stated:  
2.4.3.1 Antigen Retrieval   
Paraffin was removed from the cut sections using xylene and rehydrated through an 
ethanol gradient of 100 % (v/v), followed by 90 % (v/v) and 70 % (v/v) ethanol for 5 
minutes each and washed in running water. Heat-induced antigen retrieval was then 
performed with the sections incubated in 10 mM sodium citrate buffer (Tri-sodium citrate 
2.94g, 0.05% Tween20, pH 6.0) and heated to 95-100 °C for 10 minutes in a microwave 
oven. Antigen retrieval was not required for MAC-2 immunostaining. Sections were then 
allowed to cool to room temperature over 20 minutes in order to minimise epitope 
refolding then placed under running tap water for 10 minutes. 
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2.4.3.2 Blocking of Endogenous Peroxidases 
Endogenous peroxidase activity was blocked by incubation in 3 % (v/v) H2O2 in methanol 
for 20 minutes. Following this, sections were washed in running water for 10 minutes. 
2.4.3.3 Blocking of nonspecific binding 
Tissue sections were encircled using a Dako pen (Dako, Glostrup, Denmark) and incubated 
with 2.5 % (v/v) normal horse blocking serum from ImmPRESS REAGENT KIT (Vector, 
USA) in a humidified chamber for 1 hour at room temperature. For staining using anti-Mac 
2 antibodies, blocking buffer was composed of phosphate buffered saline (PBS) 
supplemented with 0.05% (v/v) Tween20 and 20 % (v/v) normal rat serum since this was 
the species in which the secondary antibody was raised. 
2.4.3.4 Primary and Secondary Antibody Incubation 
The arterial sections were then incubated overnight with the primary antibody diluted in 1 
% (w/v) BSA in PBS (Sigma Aldrich, Poole, U.K.) in a humidified chamber. A summary 
of the primary antibodies used along with dilutions and lengths of incubation are found in 
Table 2-4. A blank and negative control was carried out for each experiment using 1 % 
(w/v) BSA in PBS and rabbit IgG diluted in 1 % (w/v) BSA in PBS respectively.  
Following this, sections were washed twice in Tris buffred saline with tween 20 (Tris base 
3.03g, NaCl 8g, Tween20, 0.1% (v/v)) (TBS-T) for 15 minutes and incubated with 
ImmPRESS™ anti-rabbit Ig antibodies (Vector Laboratories, Peterborough, U.K.) for 1 
hour in a humidified chamber at room temperature. The exception from this protocol was 
sections stained for phosphorylated and total AMPK. These sections were incubated with a 
biotinylated secondary antibody followed by treatment with streptavidin-peroxidase 
solution using the Histostain®-Plus Bulk kit (Life Technologies, Paisley, U.K.), both for 
10 minutes at room temperature to improve the signal.  
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Table ‎2-5 Primary and Secondary antibodies for Immunohistochemistry   
Primary 
Antibody  
Supplier Species  & 
clonality  
Dilution IgG control Secondary 
antibody  
Dilution Blocking 
serum 
AMPKα Abcam 
#ab131512 
Rabbit 
polyclonal 
IgG 
1:100 rabbit IgG 
Vector Labs 
(I-1000) 
Biotinylated 
anti-rabbit Ig 
antibody 
Histostain®-
Plus Bulk kit 
# Blocking 
Solution 
Ready-to-use 
Histostain®-
Plus Bulk kit 
 
Phospho 
AMPKα 
Cell Signalling 
Technology 
#2535 
 
Rabbit 
polyclonal 
IgG 
1:100 rabbit IgG 
Vector Labs         
(I-1000) 
Biotinylated 
anti-rabbit Ig 
antibody 
Histostain®-
Plus Bulk kit 
# Blocking 
Solution 
Ready-to-use 
Histostain®-
Plus Bulk kit 
 
UCP1 Abcam 
#ab10983 
Rabbit 
polyclonal 
IgG 
1:500 rabbit IgG 
Vector Labs        
(I-1000)  
ImmPRESS™ 
anti-rabbit Ig 
antibody 
# 2.5 % (v/v) 
normal horse 
serum 
 
Mac2 Cedarlane 
#CL8942AP 
Rat 
Monoclonal 
IgG 
1:5000 Rat IgG2a 
Pharmingen 
BD (559073) 
Rabbit anti-rat  
Vector Labs 
(BA-4000) 
1:200 Normal 
Rabbit Serum 
Vector Labs 
(S-5000) 
Abbreviation: UCP1, Uncoupled protein 1; DFFA-like effector; Mac2, Galectin-3. (# = Ready to 
use). 
2.4.3.5 Antibody Complex detection  
To remove excess unbound secondary antibody, all sections were next washed twice in 
PBS-T for 15 minutes each. Then, sections were incubated with DAB chromagen solution 
(3,3-diaminobenzidine and hydrogen peroxidase solution, Vector Laboratories, 
Peterborough, U.K.) for immunoperoxidase staining for 2 to 5 minutes. Positive staining is 
indicated with the appearance of a dark brown colour. The reaction was stopped by 
washing the sections in water. Sections were then counterstained with haematoxylin to 
visualise the nucleus of the cells by incubation for 4 minutes followed by washing in warm 
water for 5 minutes to “blue” the nuclei. Finally, the sections were dehydrated in an 
ethanol gradient: 70 %, 90 % and 100 % (v/v) ethanol followed by 10 minutes in 
Histoclear. The sections were then mounted with coverslips using DPX mounting medium. 
Staining was visualised using a light microscope and positive immunostaining was seen as 
a brown/dark brown colour with nuclei appearing blue/purple. Sections were photographed 
using AxioVision microscope software (Zeiss, Germany).  
 
2.5 Functional studies (wire myography) 
2.5.1 Preparation of the vessels 
Both AMPKα1 knockout and Sv129 control mice were sacrificed by cervical dislocation 
and the aortae were collected in oxygenated physiological Krebs-Henseleit buffer solution 
with the following composition (in mM): 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 25 
mM NaHCO3, 1.03 mM KH2PO4, 11 mM glucose and 2.5 mM CaCl2, PH 7.4. Paired 
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aortic arterial rings (1-2 mm long), one with PVAT intact (PVAT+) and the other with 
PVAT removed (PVAT-) (Figure 2-3), were prepared from each artery and for both strains 
of mouse. The intimal layer of the artery was removed by gently rubbing the vessel with 
the back of forceps to remove and eliminate the action of the endothelium in the response. 
The vessels were then mounted on two stainless steel pins in a four-channel small vessel 
wire myograph (Danish Myo Technology, Aarhus, Denmark), with one of the wires 
connected to a force transducer and the other to an adjustable arm. Vessels were incubated 
at 37 °C in Krebs-Henseleit buffer and gassed continuously with 95% O2, 5 % CO2. The 
artery segments were equilibrated for at least 30 minutes at resting tension. A 
predetermined optimum tension of 1 g was then applied to the artery for a further 30 
minutes. Chart™ 5 Pro software (ADInstruments, Chalgrove, U.K.) was used to record and 
measure vessel responses to different reagents. At the beginning of each experiment, the 
arterial rings were challenged with two additions of 40 mM KCl (Ward et al., 2011) with 
washout in between at intervals of 30 minutes to establish the viability of the segments and 
also to sensitise the vessel before other pharmacological agents were added. 
 
 
A B
 
Figure ‎2-2 Representative pictures of mouse aortic artery mounted in the small vessel wire 
myograph.  
Segments (2 mm) of vessel were mounted on two pins with one connected to a force transducer 
and a computer to record the changes in vessels tone of the mounted arteries. The other wire was 
connected to an adjustable jaw for the application of the desired tension on the vessel. (A) Thoracic 
aorta with intact PVAT (B) Thoracic aorta with PVAT removed. 
 
2.5.2 Cumulative Dose response curve  
After the vessels had been sensitised, they were pre-constricted with the thromboxane A2 
mimetic, 9,11-dideoxy-11α,9α-epoxymethanoprostaglandin F2α (U46619, Sigma-Aldrich, 
Poole, U.K.) at a concentration of 3x10
-8
 M. The absence of endothelium was confirmed 
by the absence of a relaxation response to acetylcholine (10
-5 
M) in pre-contracted rings. 
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Cumulative concentration-response curves to the AMPK activator AICAR (Toronto 
research chemicals, Canada) were performed by addition of AICAR in increasing 
concentrations from 1x10
-4
 M to 2x10
-3
 M at 10 minute intervals. Cumulative 
concentration-response curves to the K
+
 channel opener cromakalim (Sigma-Aldrich, 
Poole, UK) were also constructed by addition of increasing concentrations from 1x10
-9
 to 
1x10
-6
 at 10 minute intervals and the nitric oxide donor sodium nitroprusside (Sigma-
Aldrich, Poole, UK) between 1x10
-9
 and 1x10
-6
 at 5 minute intervals, which acts directly 
on VSMCs (Schultz et al., 1977). Data were expressed as a percentage of loss in the 
vascular tone induced by U46619. 
 
 
Figure ‎2-3 Representative force myograph traces showing isometric tension (g) plotted 
against time in mouse thoracic aorta rings.  
(A)Represents a trace showing presence of intact endothelium demonstrated by a relaxation 
induced by 10
-5
 M acetylcholine.  (B) Represents a trace showing absence of endothelium 
demonstrated by a lack of relaxation to acetylcholine. 
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2.5.3 PVAT releases bioactive molecules 
To test the endocrine activity of the PVAT, PVAT was carefully dissected from both the 
thoracic aorta of wild type and AMPKα1 knockout mice. Once dissected, thoracic aortae 
devoid from PVAT were mounted in the wire myography and contracted to U46619. 
Dissected PVAT were then added to the myography chamber containing the vessels from 
which the PVAT had been dissected and then the dose response curve was constructed as 
previously described.    
 
2.5.4 PVAT transfer experiment 
To examine the ability of PVAT from mouse thoracic aorta to modify vascular tone, PVAT 
was carefully dissected and weighed. The isolated wild type PVAT was then transferred to 
the chamber containing AMPKα1 knockout thoracic aorta without PVAT and vice versa as 
shown in figure 2-4. After the equilibration and stabilization time both preparations were 
simultaneously contracted with U46619 and relaxed to cromakalim.  
 
Figure ‎2-4 PVAT transfer experiment.  
The figure illustrates a study protocol in which isolated wild type PVAT is transferred to AMPKα1 
knockout arteries devoid of PVAT and vice versa.   
 
2.5.5 Bioassay Experiment (Conditioned Media)   
To examine the paracrine function of the PVAT, bioassay experiments using conditioned 
media were carried out. In these experiments, PVAT from wild type mice was used to 
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produce conditioned media and this was added to PVAT− rings without endothelium. The 
same procedure was applied to the AMPKα1 knockout vessels. The conditioned media was 
prepared as following: PVAT from both mouse strains was carefully dissected and 
weighed. The dissected samples were then incubated in warm Krebs’ solution at 37 ˚C for 
one hour. The conditioned medium was transferred to the recipient chamber containing the 
vessels lacking PVAT. After equilibration and stabilization, aortic rings were successively 
contracted with U46619 and relaxed to cromakalim. At the end of every experiment, the 
conditioned media from both mouse strains was collected and stored at -80˚C to be used 
for further studies.   
2.5.6 Effect of adiponectin on vascular relaxation 
To test whether adiponectin is a potential PVAT-derived vasodilator, adiponectin blocking 
peptide against adiponectin receptor 1 (AdipoR1) (GeneTex, U.K.) (5µg/ml) was added to 
preconstricted vessels with and without PVAT. The response to exogenously applied 
globular adiponectin (1µg/ml) (Enzo Life Sciences Ltd, U.K.) was also assessed in arteries 
prior to contracting the arteries with U46619. Prior to application, globular adiponectin 
was diluted in sterile water containing 1% bovine serum albumin (BSA) which acts as 
carrier protein.  
2.6 Secretory function investigation 
Two methods were used to define the difference in secretory profile of PVAT from wild 
type and AMPKα1 knockout mice, described below: 
2.6.1 Mouse Adipokine Array (Proteome Profiler) 
The release of adipokines was assessed using a commercial adipokine array (ARY-013, 
R&D systems, Minneapolis, MN). The proteome profiler adipokine array is able to detect 
38 adipokines in duplicates that are captured on nitrocellulose membranes (Figure 2.5), 
with the manufacturer’s protocol summarised below.  
2.6.1.1 Preparation of tissue lysates 
Thoracic aorta PVAT from both wild type and AMPKα1 deficient mice was dissected, 
snap frozen and stored at -80˚C until use. PVAT was pulverised in liquid nitrogen using a 
mortar and pestle into a fine powder and re-suspended in ice-cold lysis buffer which 
consists of cell extraction buffer (Invitrogen, CA), supplemented with 1mM of protease 
 Chapter 2 – General Materials and Methods 
 
55 
 
inhibitor cocktail ( Sigma Aldrich, U.K.), 1mM phenylmethylsulfonyl fluoride (PMSF) and 
1mM dithiothreitol (DTT) (Sigma Aldrich, U.K.). Lysate samples were transferred into 
ice-cold centrifuge tubes and stored at -80°C until use.  
2.6.1.2 Protein concentration estimation 
PVAT lysates, aortae were centrifuged at 8000 rpm for 10 minutes in a Pico 17 Thermo 
Scientific Heraeus bench-top centrifuge (Fisher Scientific, Loughborough, U.K.). 
Supernatants were transferred to fresh ice-cold microcentrifuge tubes. Standard dilutions of 
bovine serum albumin (BSA) ranging from 0.1 mg/ml to 1mg/ml were used to generate a 
standard protein curve with distilled water as a blank. Protein samples from VSMCs and 
aortic PVAT were diluted in distilled water at a ratio of 5:1. Each sample (10 μl) and 
standards were added in triplicate to a 96 well plate followed by 100 μl DC™ Protein 
Assay Reagent (Bio-Rad Laboratories Ltd, Herts, UK). Absorbance was read at 595 nm 
using a FLUOstar OPTIMA microplate reader (BMG Labtech, Germany). The mean 
absorbance from each sample was generated in triplicate and the protein concentration was 
determined by comparison with the BSA standard curve.  
2.6.1.3 Array procedure  
Adipokine expression profiling was performed using an Adipokine proteome profiler, 
following the protocol provided by the manufacturer. In summary, membranes were 
blocked with a blocking buffer, and then 1 ml of pooled samples from PVAT and 
conditioned medium were incubated with a cocktail of biotinylated detection antibodies 
and incubated at 4°C overnight with the membranes. Membranes were washed with 
washing buffer. The membranes were then incubated with 2 ml of horseradish peroxidase–
conjugated streptavidin at room temperature for 30 min and the presence of adipokines was 
detected by chemiluminescence. The resultant film images were scanned with a 
densitometer and converted to densitometric units using Quantity One software (Bio-Rad 
Laboratories, Hercules, CA, USA). Data were analysed according to recommendations 
from R&D Systems. Data were imported into an Excel spreadsheet and normalized against 
an internal control, and final values were calculated and analysed via Graphpad Prism. 
Two arrays for each group, making a total of 4 independent arrays were analysed. The data 
presented represents the average of the four arrays over the two groups. 
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Figure ‎2-5 Proteome Profiler
 
Array Assay Principle.  
Capture adipocytokines antibodies have been spotted in duplicate on nitrocellulose membranes.  
Tissue lysates and conditioned media are diluted and mixed with a cocktail of biotinylated detection 
antibodies. The sample/antibody mixture is then incubated with the array over night. Any 
cytokine/detection antibody complex present is bound by its cognate immobilized capture antibody 
on the membrane. Streptavidin-Horseradish Peroxidase and chemiluminescent detection reagents 
are added. The produced signal is in proportion to the amount of adipocytokine present in the 
samples. Chemiluminescence detected is treated as a Western blot (Finkel et al., 2014). 
 
2.6.2 Adiponectin ELISA 
Adiponectin concentration was determined using a mouse adiponectin/Acrp30 Quantikine 
ELISA Kit (MRP300, R&D systems, Minneapolis, MN), designed to measure full-length 
mouse adiponectin concentrations.  
Samples of PVAT and conditioned media were prepared and protein concentration in the 
samples was estimated using the method described in section 2.6.1.2. Following the 
protocol provided by the vendor, the adiponectin concentration in the sample was 
determined. Briefly, 50 µl of assay diluent was added to each well in the microplate. 
Standard, PVAT lysate or conditioned media (50 µl) was then added to each well. The 
plate was then sealed and incubated at room temperature for 3 hours. After incubation, 
each well was aspirated and washed. Adiponectin antibody conjugate (100μl) was added, 
covered, and then incubated for 1hour at room temperature. Substrate solution (100 µl) was 
added and incubated at room temperature for 30 minutes away from light. Addition of 100 
µl of stop solution to each well resulted in the development of a yellow colour which 
indicates presence of the target protein. The absorbance of the ELISA plate at 450 nm was 
determined within 30 minutes with a wavelength correction set to 540 nm or 570 nm using 
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a FLUOstar OPTIMA microplate reader (BMG Labtech, Germany). The mean absorbance 
from each sample was generated in duplicate and the protein concentration was determined 
by comparison with the standard curve.  
Substrate
Adiponectin-specific Antibody 
Antigen
HRP-Conjugated-Adiponectin-
specific Antibody 
Blue
Yellow
Stop
 
Figure ‎2-6 Principle of Adiponectin ELISA.  
Uses a capture antibody and enzyme-linked (HRP) detection antibody to measure adiponectin 
concentration in CM. 
 
2.7 AMPK activity determination 
2.7.1 Vascular smooth muscle cell (VSMC) culture  
As a general rule, tissue culture was performed in sterile conditions in a biological safety 
class II vertical laminar flow cabinet. Tissue explants from experimental animals (see 
details in 2.7.1) were used as the source of material and cells were cultured at 37°C in an 
atmosphere of 5 % (v/v) CO2 and 95 % (v/v) air. 
Wistar Kyoto rat-derived VSMCs were supplied by Dr Augusto Montezano (Institute of 
Cardiovascular & Medical Sciences, University of Glasgow). VSMCs were maintained in 
Dulbecco’s modified Eagle medium (DMEM) (Gibco®-Life technologies, U.K.) 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen, U.K.) and pencillin/ 
streptomycin antibiotic combination (Sigma Aldrich, U.K.) and used for experiments at 
passage 4 to 5. Before each experiment, medium was discarded and cells were washed with 
PBS and incubated in serum-free medium for 2 hours.  
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2.7.1.1 Treatment of VSMCs 
Cells were incubated with AICAR (10
-2
-10
-3
M) or cromakalim (10
-8
-10
-6
M) for 45 
minutes. Medium was removed and 200µl of lysis buffer added into each well of a 6-well 
plate. Cell lysates were then scraped and transferred to microcentrifuge tubes. Lysates were 
incubated on ice for 30 minutes and then centrifuged at 8000 rpm for 10 minutes. 
Supernatants were collected and stored at -80 ̊C prior to use. 
2.7.2 3T3-L1 adipocytes cell culture 
Preadipocytes were maintained as fibroblasts (American Type Culture Collection, 
Manassas, USA) (passage 2-12) in DMEM supplemented with 10% (v/v) fetal bovine 
serum and 100 U/ml (v/v) penicillin and streptomycin. Cells were incubated at 37°C in a 
humidified atmosphere of 10% (v/v) CO2 and the media was replaced every 48 h. 
2.7.2.1  3T3-L1 differentiation protocol 
To differentiate 3T3-L1 fibroblasts into adipocytes, fibroblasts were grown to 70-80% 
confluent in DMEM containing 10% (v/v) FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin. At 48 hr post-confluence, cell medium was aspirated and replaced with 
differentiation medium consisting of DMEM containing 10% (v/v) FBS, 0.25 μM 
dexamethasone (Sigma-Aldrich Ltd, Gillingham, Dorset, UK), 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX) (Sigma-Aldrich Ltd, Gillingham, Dorset, UK), 5 μM troglitazone 
(Tocris Bioscience, Bristol, UK) and 1 μg/ml insulin. After 72 hour, this medium was 
changed with DMEM containing 10% (v/v) FCS, 5 μM troglitazone and 1 μg/ml insulin. 
The cells were incubated in this medium for three days before the medium was aspirated 
and replaced with DMEM containing 10% (v/v) FBS, in which the cells were then 
maintained. At 8-12 days post-induction of differentiation, cells were used for 
experimentation. 
2.7.2.2 Treatment of differentiated 3T3-L1  
Over a time course of 10 min and 30 min, 3T3-L1 were incubated with AICAR (2mM) 
alone, AICAR (2mM) + cromakalim (200μM) and cromakalim (200µM) alone. Medium 
was removed and 200µl of lysis buffer added into each well of a 6-well plate. Cell lysates 
were then scraped and transferred to microcentrifuge tubes.  Lysates were incubated on ice 
for 30 minutes and then centrifuged at 8000 rpm for 10 minutes. Supernatants were 
collected and stored at -80 ̊C prior to use. 
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2.7.3 Western blotting 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) and 
immunoblotting were conducted using a Novex® NuPAGE® gel electrophoresis system 
(Life Technologies, Paisley, U.K.), using the procedure described in the following 
sections.  
2.7.3.1 Preparation of the tissue lysates 
The full description of preparation of samples homogenate was discussed in detail in 
elsewhere (2.5.1.1).  
2.7.3.2 SDS PAGE 
Prior to protein loading, prepared protein samples were mixed with 7.5 μl of DTT and 12.5 
μl of NuPAGE® LDS sample buffer as a load dye, to a total volume of 50 μl and heated at 
70°C for 10 mins. Samples (10 μg) were then loaded on NuPAGE® Novex® 4-12 % Bis-
Tris mini gels (1.0 mm thick, 10 or 12 wells) with 10 μl Novex® sharp pre-stained protein 
standards in one lane. Gels were resolved for approximately 45 minutes in NuPAGE® 
MOPS SDS running buffer at 200V until the dye front reaches the bottom of the gel. At 
this stage, gel running was stopped and proteins were transferred onto a nitrocellulose 
membrane (Thermo scientific, Germany) at 30 V for 90 min in NuPAGE® transfer buffer 
containing 10 % (v/v) methanol. 
2.7.3.3 Immunoblotting 
Once the transfer of protein was complete, the nitrocellulose membranes were blocked for 
1 hour in 5 % (w/v) milk powder (Marvel) prepared in Tris-buffered saline (20mM Tris 
3.03g, 137mM NaCl 8g, PH 7.4) containing 0.1% (v/v) Tween-20 (TBST) at room 
temperature with continuous shaking. Membranes were then rinsed in TBST and incubated 
with primary antibody overnight at 4°C in 50% (v/v) TBS, 50% (v/v) Odyssey®-Block 
(LI-COR, USA). Membranes were then washed in TBST and incubated for 2 hours at 
room temperature with IRDye® 800CW Donkey anti-Rabbit IgG antibodies (Li-COR, 
USA) diluted in the same way as the primary antibody. Membranes were then washed in 
TBST prior to visualisation of immunolabelled bands using an Odyssey Sa Infrared 
Imaging System (LI-COR, USA) linked with Odyssey Sa Infrared Imaging System 
software (LI-COR, USA). A summary of the primary and secondary antibodies used along 
with dilutions are presented in Table 2-5. 
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Table ‎2-6 Summary of antibodies and dilutions used for immunoblotting 
Epitope Molecular 
weight 
Host Species Dilution Secondary 
antibody dilution 
Manufacturer and 
product number 
AMPKα 62kDa Rabbit 1:1000 1:5000 Cell Signalling 
Technology  
#2603  
 
Phospho-AMPKα‎
(Thr172) 
62kDa Rabbit 1:1000 1:5000 Cell Signalling 
Technology  
#2535  
 
ACC 280kDa Rabbit 1:1000 1:5000 Cell Signalling 
Technology  
#3676  
 
Phospho-ACC 
(Ser79)  
280kDa Rabbit 1:1000 1:5000 Cell Signalling 
Technology  
#3661  
 
AMPKα1 62kDa Human 1:1000 1:5000 Abcam         
Ab110036 
 
AMPKα2 62kDa Sheep 1:1000 1:5000 A generous gift from 
Prof. D.G. Hardie, 
University of 
Dundee, Dundee, 
UK. (Woods et al., 
1996)  
                        
eNOS (1177) 140kDa Mouse 1:1000 1:5000 BD Transduction 
Laboratories™ 
#612392 
 
Phospho-eNOS 
(1177) 
140kDa Rabbit 1:1000 1:5000 Cell Signalling 
Technology  
#9571 
 
UCP1 32kDa Rabbit 1:1000 1:5000 Abcam          
#ab10983 
 
GAPDH 37kDa Rabbit 1:2000 1:5000  Thermoscientific 
#PA1-988 
Primary and secondary antibodies were diluted in a mixture of 50% TBST  and  50 
% Odyssey® (TBS) (LI-COR, USA) incubated at 4 °C overnight and at room 
temperature for 2 hours respectively.  IRDye® 800CW Donkey anti-Rabbit and 
Donkey anti-sheep IgG (Li-COR, USA) was used secondary antibody. 
 
2.7.4 PathScan® Intracellular Signalling Array Kit (Fluorescent 
Readout) 
The effect of CM and adiponectin on AMPK activity on VSMCs, an Intracellular 
Signalling Array Kit (Cell Signalling Technology, U.K.) was used. The PathScan 
Intracellular Signalling Array is a slide based antibody which allows simultaneous 
detection of 18 important and well-characterized signaling molecules when 
phosphorylated. Following the protocol provided by the manufacturer. 
2.7.4.1 Preparation of the samples   
VSMCs were incubated with globular adiponectin (1µg/ml) and (100 ng/ml), WT CM 
(1ml) and KO CM (1ml). Untreated VSMCs were used as control for the current 
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experiment. Medium was removed and lysis buffer added into each well of a 6-well plate. 
Lysates were incubated on ice for 30 minutes and then centrifuged at maximum speed at 
4 ̊C for 15 minutes. Supernatants were collected and stored at -80 ̊C prior to use. 
2.7.4.2 Assay Procedure 
Following manufacturer’s protocol, the glass slides were blocked with a blocking buffer 
for 15 min and 75 µl diluted lysate (1mg/ml) added to each well and covered with sealing 
tape and incubated for 2 hours at room temperature over orbital shaker. Slides were then 
washed 4x5 min using washing buffer provided in the kit. Detection antibody cocktail was 
then added to each well and covered with sealing tape and incubated for 1 hour at room 
temperature on an orbital shaker. After that, slides were washed again using array wash 
buffer 4x5 min and incubated with DyLight 680™-linked streptavidin for 30 min away 
from the light. Following this, slides washed once for 10 second using deionised water and 
left to dry completely. Images of slides were captured using visualised using the LI-COR 
Odyssey® SA system. The intensity of each spot was calculated using ImageJ software. 
Data were imported into an Excel spreadsheet and normalized against an internal control, 
and final values were calculated and analysed via Graphpad Prism.  
Target 
Protein
Streptavidin-HRP
Detection Antibody Cocktail 
Capture Antibody
Glass Slide 
 
Figure ‎2-7 The PathScan Intracellular Signalling Array reaction.  
Capture antibodies have been spotted in duplicate on glass slide. Blocking buffer was added to the 
slide. The sample is then incubated with the array over for 2 hour. Any activated signalling 
molecule present is bound by its cognate immobilized capture antibody on the slide. Detection 
antibody cocktail will bound to target protein-antibody complex. Streptavidin-Horseradish 
Peroxidase was added. The produced signal is in proportion to the amount of activated signalling 
molecule present in the samples. 
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2.7.5 Quantification of expression of protein 
The relative expression of the protein of interest was determined using ImageJ software 
(version 1.47). The housekeeping protein, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as a protein loading control. Therefore, data were expressed as a ratio 
of protein of interest to the loading control or as a ratio of phosphorylated to the total 
amount of target protein present in the sample. 
2.8 Determination of superoxide and nitric oxide 
availability 
2.8.1 Preparation of the PVAT samples  
For the detection of nitric oxide and superoxide, segments of aortic PVAT samples were 
was stabilised in Krebs’ Henseleit buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 
25 mM KH2PO4, 11 mM glucose and 2.5 mM CaCl2) (KH) at 37°C for 30 minutes and 
incubated with dyes designed to detect the species of interest as described in 2.9.2 and 
2.9.3.  
2.8.2 Detection of superoxide  
Dihydroethidium (DHE) was used to assess superoxide levels. DHE is oxidised by O2
-.
in 
the cytosol to form the fluorescent product oxyethidium (Zhao et al., 2003). Once 
prepared, segments were incubated with 10
-5
 M DHE for 30 minutes at 37°C in the dark 
and then washed (2 x 15 min) in KH at 37°C. Negative controls were incubated with 15 
U/mL of superoxide dismutase (SOD) during exposure to DHE. Segments were fixed by 
immersion in acetic zinc formalin for 1 hour at room temperature, mounted on slides and 
visualised by confocal fluorescence microscopy, using the 488 argon line for excitation 
and 570 nm long-pass filter for detection. Data from 5 Kalman-averaged scans were 
collected using LaserSharp 2000 software (BioRad, UK) using set, tissue specific values of 
laser intensity, brightness and contrast, and the 20 X oil objective without zoom. The mean 
fluorescence intensity of each image was quantified using ImageJ software.  
2.8.3 Detection of Nitric oxide 
To assess NO production by PVAT, 4,5-diaminofluorescein diacetate (DAF- 2DA) was 
used. DAF-2DA is hydrolysed by cellular esterases to form 4,5-diaminofluorescein (DAF-
2) which subsequently reacts with cellular NO to form fluorescent triazolofluorescein 
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(Broillet et al., 2001). The preparation of sample was described in the previous section. 
PVAT samples were incubated in 10 μM DAF-2DA for 30 minutes. 0.1 mM Nω-nitro-L-
Arginine (L-NNA) and 15 U/L SOD were used also as negative and positive controls 
respectively. After fixation, samples were incubated in 1 μM SYTO 61 fluorescent nucleic 
acid stain (Thermo Fisher Scientific, U.K.) for 1 hour prior to mounting and confocal 
microscopy examination. DAF-2DA fluorescence was detected using the 488 nm argon 
line for excitation and 530 +/-30 nm filter for detection. Fluorescence from SYTO 61, 
detected using the 637 nm laser diode and 660 nm long pass filter, was used to aid image 
collection. 
2.9 Statistical analysis  
All results are expressed as mean ± standard error of the mean (SEM) where n represents 
the number of experiments performed or number of mice used. Data were analysed with 
GraphPad Prism 5.0 software (California, U.S.A.). When comparing three or more data 
groups, One-way ANOVA (analysis of variance) tests followed by Bonferroni post-hoc 
tests were used. When comparing two or more data groups (contraction data), two-way 
ANOVA (analysis of variance) tests followed by Newman–Keuls post hoc test was used. 
In all cases, a p value of less than 0.05 was considered statistically significant.  
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3.1 Introduction  
Perivascular adipose tissue (PVAT) which surrounds most arteries is now recognized as a 
major regulator of vascular tone. PVAT acts as an active endocrine organ producing a 
range of adipokines, inflammatory cytokines and other factors which influence vascular 
tone (Dubrovska et al., 2004, Gao, 2007, Malinowski et al., 2008, Weston et al., 2013). 
PVAT can induce vasodilatation via release of vasodilatory molecules such as adipocyte-
derived relaxing factor (ADRF) (Lohn et al., 2002, Verlohren et al., 2004, Galvez et al., 
2006), leptin (Vecchione et al., 2002), adiponectin (Fesus et al., 2007, Chen et al., 2003), 
angiotensin 1–7 (Ang 1-7) (Lee et al., 2009a), hydrogen peroxide (Gao et al., 2007), nitric 
oxide (NO) (Gil-Ortega et al., 2010) and hydrogen sulphide (H2S) (Fang et al., 2009). In 
addition to vasodilatory factors, PVAT can release vasoconstrictor factors such as 
angiotensin II (Ang II) (Galvez-Prieto et al., 2008) and superoxide anion (Gao et al., 2006). 
PVAT is composed of brown adipocytes, white adipocytes or both depending on the 
vascular bed (Gao, 2007, Fitzgibbons et al., 2011, Cinti, 2011). While all PVAT types have 
anticontractile properties (Lohn et al., 2002, Greenstein et al., 2009), the mechanism(s) by 
which this occurs remains uncertain.   
The anti-contractile effect of PVAT is proposed to be due to the release of an as yet 
undefined PVAT-derived relaxing factor(s) that are proposed to act via different pathways. 
These pathways are reported to include gated potassium (K) channels including the 
adenosine triphosphate (ATP) activated potassium channels (KATP) (Dubrovska et al., 
2004), the voltage-gated (KV) (Verlohren et al., 2004) and large conductance calcium-
activated potassium channels (BKCa) (Lynch et al., 2013). Gao and co-workers 
demonstrated that PVAT exerts its anti-contractile effects in rat aortic vessels through two 
distinct mechanisms: (1) by releasing a transferable relaxing factor which induces 
endothelium-dependent relaxation through NO release and subsequent KCa channel 
activation, and (2) by an endothelium-independent mechanism involving H2O2 and 
subsequent activation of sGC in vascular smooth muscle (Gao et al., 2007).  
AMP-activated protein kinase (AMPK) is now considered as a potential modulator of 
vascular function. Although recognized primarily as a cellular energy gauge and modulator 
of cellular metabolism (Hardie et al., 2003), the identification of its expression in vascular 
tissue and of its ability to respond to cellular energy state (Chen et al., 1999, Fleming et al., 
2005, Evans et al., 2005), hormonal changes (Cheng et al., 2007, Chen et al., 2003, Nagata 
et al., 2004), and drugs (Thors et al., 2004, Levine et al., 2007, Bilodeau-Goeseels et al., 
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2011, Ford et al., 2012) demonstrates an important role for AMPK in the regulation of 
vascular tone. Many studies have shown that activated endothelial AMPK enhances 
phosphorylation and activation of endothelial nitric oxide (NO) synthase (eNOS) at Ser
1177
 
(Chen et al., 2003, Morrow et al., 2003, Davis et al., 2006) and Ser633 (Chen et al., 2009) 
to increase NO availability and vascular relaxation (Chen et al., 2003, Morrow et al., 2003, 
Davis et al., 2006). In addition, the role of AMPK in endothelium-independent relaxation 
has been demonstrated in many vascular beds including porcine, mouse, and rat conduit 
arteries in response to AMPK activators such as hypoxia (Rubin et al., 2005), 5-
aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) (Goirand et al., 2007), and 
metformin (Majithiya and Balaraman, 2006). Furthermore AMPK activation has been 
documented to directly regulate myosin light-chain kinase (MLCK) leading to reduced 
sensitivity to intracellular calcium and induction of vascular relaxation (Horman et al., 
2008). Collectively, these findings suggest that AMPK may modulate vascular tone via 
both endothelium-dependent and -independent mechanisms. 
AMPK is expressed in the three layers of the blood vessel: the endothelium, smooth 
muscle (VSM), and perivascular adipose tissue (PVAT) (Ewart and Kennedy, 2011) and is 
known to induce vasodilatation by both endothelium-dependent and -independent 
mechanisms. Although it is known that AMPK can modulate VSM and endothelial 
function, it is unknown whether AMPK can modulate the anti-contractile effect of PVAT. 
Therefore, the hypothesis of the current study is that AMPK can act as switch which 
modulates the releasing profile of the PVAT to control vascular contractility. 
3.2 Aims of the study 
 To investigate the morphological features of aortic and mesenteric PVAT in normal 
mice and mice with a global knockout of the AMPKα1 subunit.  
 To investigate whether there is any functional difference between PVAT of normal 
mice and AMPKα1 knockout mice. 
3.3 Methods and Results  
3.3.1 Morphology of the PVAT 
To test the effect of AMPKα1 subunit deletion on the morphological features of the PVAT, 
haematoxylin and eosin-stained sections of PVAT, BAT and WAT from wild type (WT) 
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and AMPKα1 Knockout (KO) mice were examined. Thoracic arteries with intact PVAT 
were excised immediately and placed in 10% zinc formalin overnight. Arteries were 
processed through a gradient of alcohols to Histoclear and embedded vertically in paraffin 
wax before being cut into 5 μm sections. To compare the morphology of aortic PVAT with 
other fat depots, mesenteric PVAT, subscapular brown adipose tissue (BAT) and 
epididymal white adipose tissue (WAT) were also fixed and sectioned. H&E staining and 
immunohistochemical staining with anti-UCP-1 antibody was performed and sections were 
visualised under a microscope. There was no obvious difference in adipose tissue 
composition (Figure 3-1), whereby thoracic PVAT (E&F) appeared very similar to BAT 
(A&B), with round nuclei, and small, multilocular lipid droplets, whereas mesenteric 
PVAT (I&J) was very similar to WAT (B&D), with large single lipid vacuoles and 
marginal nucleus. Abdominal PVAT (F&G) showed features of both BAT and WAT in 
WT and KO (Figure 3-1).  
Immunohistochemical staining of the BAT marker uncoupling protein-1 (UCP-1) (Figure 
3-2) confirmed the results of H&E staining. The Intensity of UCP-1 staining was similar in 
adipose tissue depots including PVAT from WT and KO animals. Thoracic PVAT (Figure 
3-2 E&F) from both strains of animal exhibited relatively the same distribution of UCP-1 
in the BAT (Figure 3-2 A&B). The intensity of UCP-1 staining in the mesenteric PVAT 
(Figure 3-2 I&J) was very low regardless of AMPKα1 subunit deletion, likely due to the 
predominance of WAT in this depot (Figure 3-2 C&D). Abdominal aortic PVAT in both 
mouse strains showed similar distribution of both BAT and WAT as assessed by UCP-1 
staining (Figure 3-2 G&H).   
Next, UCP-1 levels were studied in PVAT and compared to that found in BAT 
(intrascapular area) and WAT (epididymal) from both WT and KO mice by 
immunoblotting. Quantitative analysis showed that PVAT shares a similar protein 
expression pattern with BAT, which includes high levels of UCP-1 (Figure 3-2) relative to 
the glycolytic protein GAPDH, regardless of AMPK deletion. These data indicate that 
thoracic PVAT has a similar phenotype to BAT, but is clearly different from WAT, 
suggesting that PVAT might have a similar function to BAT. Abdominal aorta showed no 
marked difference compared to thoracic PVAT. In contrast to these virtually identical 
protein levels between thoracic PVAT and BAT, mesenteric PVAT exhibited a similar 
phenotype to WAT. 
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Figure ‎3-1 Effect of AMPKα1 deletion on the morphology of PVAT.  
Representative H&E stained sections harvested from subscapular brown adipose tissue (BAT) 
(A&B), epididymal white adipose tissue (WAT) (C&D), thoracic perivascular adipose tissue (PVAT) 
(E&F), abdominal PVAT (G&H), and mesenteric PVAT (I&J) in wild type and AMPKα1 knockout 
mice. Nuclei appear blue/purple whereas cytoplasm is stained pink. Abbreviation: BAT; brown 
adipose tissue, WAT; white adipose tissue, Ao; aorta, MA;‎mesenteric‎artery.‎Scale‎bar;‎20‎μm,‎ 
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Figure ‎3-2 Immunohistochemical analysis of UCP-1 levels in PVAT in comparison with BAT 
and WAT for both wild type and AMPKα1 knockout mice.  
Representative histological sections of brown adipose tissue (BAT) (A&B), white adipose tissue 
(WAT) (C&D), thoracic PVAT (E&F), Abdominal (G&H) and Mesenteric PVAT (I&J) stained with 
anti UCP-1 and counterstained with haematoxylin. Positive immunoreactivity for UCP-1 is indicated 
by brown‎colour.‎Scale‎bar‎20‎μm 
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Figure ‎3-3 UCP-1 levels in different PVAT depots.    
Tissue lysates (n= 3) were prepared from WT and KO BAT, WAT, thoracic PVAT (TA), abdominal 
PVAT (AA) and mesenteric PVAT (MES). UCP-1 level is presented as a ratio of the density of the 
GAPDH band to adjust for protein loading. Western blotting was performed in BAT (brown adipose 
tissue); WAT (white adipose tissue); TA (thoracic aorta PVAT); AA (abdominal aorta PVAT); MES 
(mesenteric artery PVAT) from WT and KO. Blot shown are representative ***p<0.001 vs WT BAT; 
*p<0.05 vs WT BAT; ***p<0.001 vs WT BAT; ***p<0.001 vs WT BAT.  
 
3.3.2 AMPK expression and activity 
As AMPKα1 is one of two AMPKα subunit isoforms, the effect of AMPKα1 deletion on 
the total AMPKα and phospho-AMPKα Thr172 levels in PVAT was examined by 
immunohistochemistry and immunoblotting. There was reduced intensity of both total 
AMPKα and phospho-AMPKα Thr172 staining in AMPKα1 knockout thoracic aorta in 
both the PVAT and the medial vascular smooth muscle region (Figures 3-4 and 3-5). 
Immunoblot analysis further demonstrated that AMPK activity, reflected by the levels of 
phospho-AMPKα Thr172 (pAMPKα) and the AMPK substrate phospho-ACC Ser79 
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(pACC), was significantly reduced in AMPK-α1 knockout mice in comparison with wild 
type (Figure 3-6). 
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Blank  
Figure ‎3-4 Total AMPKα levels in wild type and AMPKα1 knockout mouse thoracic aorta with 
intact PVAT.  
Representative histological sections of thoracic aorta with intact PVAT from WT and KO mice 
stained with anti-AMPKα‎antibodies and counterstained with haematoxylin. (A, D) Positive staining 
is indicated by brown colour. (B, E) Negative control represents aortic rings with anti-AMPKα 
primary antibodies only; (C, F) Blank (untreated) represents aortic rings without treatment.  Scale 
bar‎20μm. 
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Figure ‎3-5 Phospho-AMPKα Thr172 levels in wild type and AMPKα1 knockout mouse 
thoracic aorta with intact PVAT.  
Representative histological sections of thoracic aorta with intact PVAT from WT and KO mice 
stained with anti-Phospho‎AMPKα‎Thr172‎antibodies‎and‎counterstained‎with‎haematoxylin. (A, D) 
Positive staining is indicated by brown colour. (B, E)  Negative control represents aortic rings with 
anti-AMPKα‎ primary‎ antibodies‎ only;‎ (C, F) Blank (untreated) represents aortic rings without 
treatment‎Scale‎bar‎20μm. 
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Figure ‎3-6 AMPK levels and activity in PVAT.  
Lysates of thoracic PVAT from wild type and AMPKα1 knockout mice were immunoblotted with the 
indicated antibodies. A) Representative Immunoblots are shown. (B,C) Quantitative analysis of 
immunoblots,‎ expressed‎ as‎ the‎ ratio‎ of‎ the‎ phosphorylated‎ and‎ total‎ form‎of‎AMPKα‎divided‎by‎
GAPDH (C). (D) Quantitative analysis of immunoblots, expressed as the ratio of the 
phosphorylated form of‎ the‎ enzyme‎ divided‎ by‎ total‎ AMPKα.‎ (E)‎ Quantitative analysis of 
immunoblots, expressed as the ratio of the phosphorylated form of ACC divided by GAPDH. 
**p<0.01 vs KO PVAT, n = 3; *p<0.05 vs KO PVAT, n = 3; *p<0.05 vs KO PVAT.  
 
3.3.3 PVAT from AMPKα1 knockout mice enhances vascular 
contraction 
To determine whether lack of AMPKα1 altered the contractile response of aortic rings in 
the presence or absence of associated PVAT, contractile responses to the thromboxane A2 
receptor agonist U46619 (3x10
-8
M) was assessed (Figure 3-7). The presence and absence 
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of PVAT did not affect the maximal tension induced by U46619. These results showed that 
the presence of PVAT did not pose a constraint on the ability of the aorta to contract, and 
the procedure used to remove PVAT or endothelium neither damaged nor affected the 
contractility of the aorta in both WT and KO animals. 
The magnitude of the U46619-induced vessel contraction was similar in the absence of 
PVAT in both mice strains (Figure 3-7). Wild type PVAT-free vessels contracted 1.49  
0.11 g (n = 29) versus 1.46  0.11 g for AMPKα1 knockout vessels without PVAT (n = 
31). The contraction in KO aortae devoid from PVAT was not significantly different from 
that with intact PVAT. The contraction of wild type aorta with intact PVAT was 1.15  
.0.11 g (n = 28) which was significantly less than that reported in WT vessels without 
PVAT (1.49 ± 0.11 g = 26; p<0.05 vs WT intact PVAT arteries). In addition, the 
contraction of wild type aorta with intact PVAT was significantly less than that seen in 
PVAT-containing aorta from knockout mice; 1.62  0.11 g (n = 32; p<0.001 vs WT 
vessels with PVAT), suggesting that WT PVAT has an anticontractile effect which is lost 
in KO mice.  
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Figure ‎3-7 Effect of PVAT on thromboxane A2 receptor agonist U46619 (3x10
-8
 M) induced 
contraction.  
Endothelium denuded, thoracic aortae with and without PVAT from WT and KO were stimulated 
with U46619 for approximately 30 min and contraction measured on a myograph. *p<0.05 vs WT 
aortic rings without PVAT, n = 31;   ***p<0.001 vs WT vessels with intact PVAT, n =28-32.  
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3.3.4 PVAT enhances vascular relaxation to the AMPK activator 
AICAR 
To test whether the presence of PVAT can augment relaxation, dose-response curves to a 
known vasodilator agent, the AMPK activating agent AICAR were constructed in 
endothelium-denuded thoracic aorta rings with (PVAT+) and without (PVAT-) associated 
PVAT as described in section 2.5. In wild type animals (Figure 3-8A), addition of AICAR 
to U46619-precontracted PVAT intact thoracic aortic rings resulted in a concentration-
dependent, slowly developing relaxation, which reached a maximum (Emax) of 49.7 ± 2.6% 
(n = 6). This was significantly greater in comparison to vessels with PVAT removed (Emax 
30.7 ± 0.3%, n = 6; p<0.001). AICAR also stimulated relaxation of U46619-precontracted 
AMPKα1 knockout thoracic aorta (n = 6), yet the presence of PVAT had no effect on the 
AICAR-induced relaxation (Figure 3-8 B). Addition of AICAR to PVAT intact thoracic 
rings resulted in a maximum relaxation response (Emax) of 29.3 ± 3.4% (n = 6), which was 
not different from that reported in aortic rings without PVAT (27.9 ± 4.9% (n = 6)).  
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Figure ‎3-8 Effect of PVAT on AICAR induced relaxation in wild type and AMPKα1 knockout 
thoracic aorta.  
Dose-response curves to AICAR were produced by wire myography in thoracic aortic rings with (+) 
and without (-) PVAT. All vessels were without endothelium. In wild type (A), PVAT significantly 
enhanced the relaxation to AICAR (n = 6, ***p<0.001 vs PVAT(-)). In AMPKα1 knockout mice (B), 
the presence of PVAT had no effect on vascular relaxation (n = 6, p =ns). 
 
3.3.5 PVAT enhances vascular relaxation to cromakalim in wild 
type, but not AMPKα1 knockout aortic rings 
To ensure that the anticontractile effect was due to the presence of PVAT and to rule out 
the possibility that activation of AMPK in vascular smooth muscle cells was responsible 
for the augmented relaxation to AICAR, we repeated the experiments using another 
vasodilator which does not activate AMPK (cromakalim). Cromakalim is a K
+
 channel 
opener which induces vascular relaxation via hyperpolarisation of the vascular smooth 
muscle membrane. The results are summarised in Figure 3-9. The maximum response to 
10
-4
M cromakalim produced by aortic rings from WT with intact PVAT (59.0 ± 12.3%, 
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n=7; Figure 3-9 A) was significantly greater than that produced by aortic rings without 
PVAT (27.6 ± 2.8%, n=7; Figure 3-9 B). In KO, maximal responses to cromakalim were 
not significantly different between vessels with or without intact PVAT (21.6 ± 1.6% vs. 
18.7 ± 4.0%; n=7; p=ns). 
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Figure ‎3-9 Effect of PVAT on cromakalim-induced relaxation in wild type and knockout 
thoracic aorta.  
Dose-response curves induced by cromakalim in thoracic aortic rings with (+) and without (-) 
PVAT. In wild type (A), the presence of PVAT enhanced the response to cromakalim (n=7, 
***p<0.001 vs. PVAT-). In AMPKα1 knockout (B), PVAT had no effect on vascular relaxation to 
cromakalim (n = 7, p =ns). 
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3.3.6 Effects of PVAT on AICAR and cromakalim- induced 
vascular relaxation in abdominal aortic rings 
To confirm that the ability of PVAT to enhance vasorelaxation was not depot specific, the 
experiments with AICAR and cromakalim were repeated in abdominal thoracic aortic 
rings. As with the thoracic aorta, WT PVAT enhanced the relaxation caused by AICAR. 
(Emax 53.3 ± 5.2% in PVAT(+) vs. 24.5 ± 5.7% in PVAT(-), n = 6; p<0.05) (Figure 3-10A). 
In KO mouse abdominal aorta, PVAT had no effect on the AICAR-induced relaxation 
(Emax 33.3 ± 2.8% vs. 30.9 ± 5.1%, n = 5; p=ns) (Figure 3.10B). 
The functional experiment in the abdominal aorta was repeated using cromakalim and the 
result showed the same pattern as with AICAR. In WT vessels with intact PVAT, 
maximum relaxation (Emax) was 50.9 ± 12.42%, (n = 6), significantly greater than 
abdominal aorta without PVAT (26.1 ± 8.3%, n = 6; p<0.05 vs. PVAT+) (Figure 3.11A). 
In KO animals (Figure 3.11 B), presence of PVAT had no effect on vascular relaxation 
induced by cromakalim (22.8 ± 5.8% vs. 17.4 ± 4.1%, n = 6). 
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Figure ‎3-10 Effect of PVAT on AICAR-induced relaxation in wild type and knockout 
abdominal aorta.  
Dose- response curves induced by AICAR in abdominal aortic rings with (+) and without (-) PVAT. 
In wild type (A), the presence of PVAT enhanced the response to AICAR (n=6, ***p<0.001). In 
AMPKα1 knockout (B), PVAT had no effect on vascular relaxation (n = 5, p =ns). 
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Figure ‎3-11 Effect of PVAT on cromakalim-induced relaxation in wild type and knockout 
abdominal aorta.  
Dose- response curves induced by cromakalim in abdominal aortic rings with (+) and without (-) 
PVAT. In wild type (A), the presence of PVAT enhanced the response to cromakalim (n=6, 
***p<0.001). In AMPKα1 knockout (B), PVAT had no effect on vascular relaxation (n = 6, p =ns). 
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3.3.7 Transfer studies  
To study whether the PVAT had to be attached to the vessel in order to augment 
relaxation, thoracic arteries without PVAT were preconstricted with U46619 (3 × 10
−8
M) 
and, once a stable constriction had developed, PVAT (unattached) was added to the 
myography bath and a dose-response curve to cromakalim was constructed. In wild-type 
vessels without PVAT (n = 5), addition of PVAT into the myography bath caused a 
significant increase in the relaxation (Emax 54.5± 8.3% vs. 15.9 ± 4.7%, Figure 3-12A). 
Contemporaneous control experiments with PVAT-intact WT arteries (n = 5) were 
performed which demonstrated that intact PVAT and added PVAT had a similar effect on 
augmenting relaxation to cromakalim (Emax 49.9 ± 6.7% vs. 30.1 ± 3.4%, Figure 3-12B). 
When the transfer experiments were repeated in AMPKα1 knockout vessels it was found 
that KO PVAT, either attached or added to the myograph bath did not influence the 
relaxation induced by cromakalim (Figure 3-12 C&D). 
 Chapter 3 - Characterisation of AMPKα1 role in PVAT 
 
82 
 
A
-1 0 -9 -8 -7 -6 -5
0
2 0
4 0
6 0
8 0
P V A T (+ )
P V A T (- )
***
L o g  [C ro m a k a lim ][M ]
R
e
la
x
a
ti
o
n
(%
 l
o
s
s
 o
f 
U
4
6
6
1
9
-i
n
d
u
c
e
d
 t
o
n
e
)
B
-1 0 -9 -8 -7 -6 -5
0
2 0
4 0
6 0
8 0
P V A T (+ )
P V A T (- )
**
L o g  [C ro m a k a lim ][M ]
R
e
la
x
a
ti
o
n
(%
 l
o
s
s
 o
f 
U
4
6
6
1
9
-i
n
d
u
c
e
d
 t
o
n
e
)
C
-1 0 -9 -8 -7 -6 -5
0
2 0
4 0
6 0
8 0 P V A T (+ )
P V A T (- )
L o g  [C ro m a k a lim ][M ]
R
e
la
x
a
ti
o
n
(%
 l
o
s
s
 o
f 
U
4
6
6
1
9
-i
n
d
u
c
e
d
 t
o
n
e
)
D
-1 0 -9 -8 -7 -6 -5
0
2 0
4 0
6 0
8 0
P V A T (+ )
P V A T (- )
L o g  [C ro m a k a lim ][M ]
R
e
la
x
a
ti
o
n
(%
 l
o
s
s
 o
f 
U
4
6
6
1
9
-i
n
d
u
c
e
d
 t
o
n
e
)
 
Figure ‎3-12‎Effect of addition of PVAT on cromakalim-induced relaxation in wild type and 
AMPKα1 knockout thoracic aortae.  
Dose- response curves induced by cromakalim in endothelium-denuded thoracic aortic rings with 
(+) and without (-) PVAT. Data are expressed as percentage loss of vascular tone induced by 
U46619. (A) Addition of unattached PVAT enhanced the response to cromakalim in wild type 
vessels without (-) PVAT (n=5, ***p<0.001 vs WT PVAT(-) vessels). (B) A contemporaneous 
control experiment comparing vessels with intact PVAT (+) and without PVAT (-) in wild type mice 
(n=5, **p<0.01 vs WT PVAT(-) vessels). (C) Addition of unattached PVAT did not enhance the 
response to cromakalim in AMPKα1 knockout mice aortic rings (n=5, p = ns vs KO PVAT(-) 
vessels). (D) A contemporaneous control experiment comparing vessels with intact PVAT (+) with 
those without PVAT in AMPKα1 knockout mice (n=5, p = ns vs KO PVAT(-) vessels).    
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3.3.8 Wild type PVAT enhances relaxation in AMPKα1 knockout 
vessels 
To further investigate the function of the PVAT, and whether it is the PVAT or the medial 
smooth muscle cells which are compromised in KO mice, “cross over” studies were 
conducted. These experiments involved addition of unattached PVAT from WT mice to 
myography chambers containing aortic rings from AMPKα1 knockout and vice versa. 
After addition of the PVAT, thoracic arteries were preconstricted with U46619. Once a 
stable constriction had developed dose-response curves to AICAR and cromakalim were 
constructed.  
It was found that WT PVAT significantly enhanced the AICAR-induced vasodilatation in 
KO arteries without PVAT (p<0.001, Figure 3-13A), and increased the Emax of AICAR 
from 27.7 ± 4.9 % to 52.7 ± 12.4% (p<0.001). In contrast, KO PVAT had no significant 
effect on AICAR-induced vasodilatation in wild type arteries without PVAT (p = ns, 
Figure 3-13B). 
The same studies were repeated using cromakalim and the results were consistent with 
AICAR. Addition of WT PVAT (n = 6) significantly augmented relaxation in KO aortic 
rings to cromakalim. Wild type PVAT increased the Emax of cromakalim from 18.7 ± 4.0 % 
to 46.3 ± 12.4% (p<0.001, Figure 3-13C), whereas KO PVAT had no effect on the 
relaxation of WT thoracic aorta in which the PVAT was removed (Figure 3-13D). 
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Figure ‎3-13 Effect of PVAT transfer on AICAR and cromakalim induced vasorelaxation.   
Dose-response curves were constructed to AICAR and cromakalim in endothelium-denuded 
thoracic aortic rings. Data are expressed as percentage loss of U46619-induced contraction. (A) 
Addition of WT PVAT enhanced the response to AICAR in KO vessels without PVAT (n=5, 
***p<0.001 vs KO PVAT(-) vessels). (B) KO PVAT did not affect AICAR induced relaxation in WT 
vessels without PVAT (n=5, p = ns). (C) Addition of WT PVAT enhanced the response to 
cromakalim in KO vessels without PVAT (n=6, ***p<0.001 vs KO PVAT(-) vessels). (D) KO PVAT 
did not affect cromakalim-induced relaxation in WT vessels without PVAT (n=6, p = ns). 
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3.3.9 Conditioned media from WT aortic PVAT reduces 
contractility in vessels without PVAT 
To ascertain whether augmented relaxation caused by PVAT is due to release of a 
transmissible factor, solution transfer (conditioned media) studies were performed. Control 
experiments with intact PVAT from wild-type and knockout arteries were performed in 
parallel to determine whether the conditioned media is as effective as attached PVAT in 
augmenting aortic relaxation. Conditioned media was prepared by incubation of PVAT in 
Krebs’ solution at 37 ̊C for 1 hour. In all experiments, conditioned media was added to the 
vessels without PVAT before pre-constriction to U46619 to ensure that the transferred 
solution would have the same effect as the attached (intact) PVAT vessels and also to 
determine whether there was any effect on U46619 induced contraction.  
Conditioned media from WT PVAT significantly attenuated contraction induced by 
U46619 (Figure 3-14). Addition of WT conditioned media to WT aortic rings (n = 12) 
without PVAT reduced the maximum contraction from 1.19 ± 0.1 g to 0.86 ± 0.1 g 
(p<0.05). In contrast, conditioned media from KO PVAT had no effect on U46619-induced 
contraction of KO aortic rings (2.8 ± 1.4 vs 2.33 ± 1.3 PVAT (-), n =12, p = ns).  
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Figure ‎3-14 Effect of conditioned media on aortic ring contraction.  
Conditioned media from WT and KO PVAT was added to endothelium-denuded thoracic aortic 
rings from WT and KO mice respectively in the absence of PVAT.  Contraction to U46619 is 
expressed in g. *p<0.05 vs WT PVAT(-) vessels, n =12; p =ns vs KO PVAT(-) vessels, n =12. 
 Chapter 3 - Characterisation of AMPKα1 role in PVAT 
 
86 
 
3.3.10 Conditioned media from WT mice enhances AICAR 
and cromakalim induced relaxation 
To investigate the ability of PVAT-secreted substances to modulate vasorelaxation, 
conditioned media from KO and WT PVAT were prepared and incubated with 
corresponding PVAT (-) vessels. To test the ability of conditioned media to enhance the 
relaxation to AICAR or cromakalim and that the enhanced relaxation was due to the 
conditioned media rather than decreased viability of the vessels over time, control 
experiments with intact PVAT were conducted concurrently. Prior to induction of 
contraction, vessels without PVAT from WT and KO mice were incubated with the 
conditioned media and once a stable constriction had developed in response to U46619, 
dose response curves for both AICAR and cromakalim were constructed.  
Conditioned media from WT PVAT significantly increased the Emax of WT aortic rings 
without PVAT in response to AICAR (Figure 3-15A) and cromakalim (Figure 3-16A) 
from 38.9 ± 8.2% to 53.2 ± 8.2% (n=8) and 25.2 ± 2.2% to 52.4 ± 10.3% (n=6) 
respectively. Conditioned media derived from PVAT of AMPKα1 KO mice had no 
significant effect on the relaxation of WT aortic rings to either AICAR (Figure 3-17) or 
cromakalim (Figure 3-18), suggesting that dysfunction of the PVAT anticontractile 
response is related to AMPKα1 subunit deletion. 
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Figure ‎3-15  Effect of PVAT-derived conditioned media on AICAR induced vascular 
relaxation in WT aortic rings.  
Dose-response curves were constructed to AICAR in endothelium-denuded WT thoracic aortic 
rings incubated with conditioned media from WT PVAT. Data are expressed as percentage of loss 
of U46619-induced tone.  ***p<0.001 vs WT PVAT(-) vessels, n = 8 and  ***p<0.001 vs WT PVAT(-
) vessels.  
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Figure ‎3-16 Effect of PVAT-derived conditioned media on cromakalim-induced vascular 
relaxation in wild type aortic rings.  
Dose-response curves were constructed to AICAR in endothelium-denuded WT thoracic aortic 
rings incubated with conditioned media from WT PVAT. Data are expressed as percentage of loss 
of U46619-induced tone. ***p<0.001 vs WT PVAT(-) vessels and, n = 7 and ***p<0.001 vs WT 
PVAT(-) vessels, n =7.  
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Figure ‎3-17 Effect of KO PVAT-derived conditioned media on AICAR-induced vascular 
relaxation in AMPKα1 knockout aortic rings.  
Dose-response curves were constructed to AICAR in endothelium-denuded WT thoracic aorta 
incubated with conditioned media from PVAT of KO mice. Data are expressed as percentage loss 
of U46619-induced tone. p = ns vs KO PVAT(-) vessels and, n = 6 and p = ns vs KO PVAT(-) 
vessels, n =6.  
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Figure ‎3-18  Effect of KO PVAT-conditioned media on cromakalim-induced vascular 
relaxation in AMPKα1 knockout aortic rings.  
Dose-response curves were constructed to cromakalim in endothelium-denuded KO thoracic aorta 
incubated with conditioned media from PVAT of KO mice. Data are expressed as percentage loss 
of U46619-induced tone. Data shown are representative p = ns vs KO PVAT(-) vessels; n = 6 and  
p = 0.ns vs KO PVAT(-) vessels, n =6.  
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3.3.11 Cromakalim does not activate AMPK in vascular 
smooth muscle cells or 3T3-L1 adipocytes  
To rule out the possibility that vasodilation to cromakalim is compromised in KO mice 
because chromakalim has AMPK-dependent actions, cultured rat vascular smooth muscle 
cells and 3T3-L1 adipocytes were incubated with AICAR (AMPK activator used as a 
positive control) or cromakalim. Western blotting (Figure 3-19A) demonstrated that 
cromakalim did not increase phosphorylation of AMPK in the vascular smooth muscle 
cells (n = 3, p=ns, Figure 3-19B). In addition, cromakalim had no effect on the 
phosphorylation of the AMPK substrate ACC (Figure 3.19C), a kinase downstream of 
AMPK. AICAR stimulated an increase in AMPK activity (n = 3, p<0.05) at a 
concentration of 10
-3
 M, as assessed by ACC phosphorylation but this was not observed 
with 10
-2
M AICAR. 
To examine whether cromakalim influenced adipocyte AMPK activity, the 3T3-L1 
adipocyte cell line was utilised (Figure 3-20). Over a time course of 10 min and 30 min, 
adipocytes were incubated with AICAR (2mM) alone, AICAR (2mM) + cromakalim 
(200μM) and cromakalim (200µM) alone. In all experiments, neither AICAR nor 
cromakalim alone affected AMPK phosphorylation (n =3, p = ns) (Figure 3-20C&D). 
AICAR and cromakalim in combination also did not enhance the activity of AMPK in 
adipocytes as assessed by ACC phosphorylation (n =3, p = ns) (Figure3-20D&F). 
However, stimulation of 3T3-L1 adipocytes with AICAR alone did show a trend toward 
enhanced ACC phosphorylation, although this did not reach statistical significance.  
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Figure ‎3-19 Effect of cromakalim on AMPK phosphorylation and activity in VSMCs. 
Cultured rat VSMCs were stimulated with AICAR (A) or cromakalim (CK), lysates prepared and 
subjected to immunoblotting with the indicated antibodies. (A) representative immunoblots are 
shown). Quantification of (B) phospho-AMPKα Thr172 relative to total AMPKα‎ levels‎ or‎ (C)‎
phospho-ACC Ser79 relative to total ACC levels, normalised to control (vehicle-treated) cells. 
***p<0.001 vs control (untreated). This data was generated in collaboration with Azizh Ugusman. 
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Figure ‎3-20 Effect of AICAR and cromakalim on AMPK activity following different incubation 
times in 3T3 adipocytes.  
3T3 adipocytes were treated with AICAR, AICAR+ cromakalim and cromakalim alone over 10 min 
(Figs A, C, E) and 1 hour time interval (Figs B, D, F). Cells were then lysed and immunoblotting 
was performed. Graphs are expressed as the fold change of the phosphorylated form of each 
enzyme divided‎by‎the‎total‎AMPKα‎(C&D)‎and‎total‎ACC (E&F) to measure the activation of the 
enzyme. Blots shown are representative (A&B). p = ns vs control (untreated), n = 3. This data was 
generated in collaboration with PhD student Omer Katwan. 
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3.3.12 AMPKα1 knockout mouse PVAT has altered adipokine 
release 
To assess the tissue levels and secretion of adipokines by PVAT of wild type and 
AMPKα1 knockout mice, homogenised PVAT and conditioned medium was assayed using 
a Proteome Profiler Adipokine array from R&D systems as screening test which detects 38 
different adipocytokines. As shown in Figure 3.21 the comparative analysis of 
homogenised PVAT adipokine levels reveals that AMPKα1 knockout PVAT has reduced 
levels of adiponectin (Acrp30/AdipoQ), C-Reactive Protein (CRP), Dipeptidyl peptidase-4 
(CD26/DPP4), ICAM-1 (CD54), Insulin-Like Growth Factor Binding Protein 2 (IGFBP-
2), Insulin-Like Growth Factor Binding Protein 5 (IGFBP-5), Insulin-Like Growth Factor 
Binding Protein 6 (IGFBP-6), Lipocalin-2 (NGAL), Pentraxin 2 (PTX2/SAP), and Retinol 
binding protein 4 (RBP4), and higher levels of Fetuin A, Fibroblast Growth Factor 1 (FGF-
1), Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3), Pentraxin 2 (PTX2/SAP) and 
Resistin. Factors including Angiopoietin-like 3 (ANGPT-L3), Endocan (ESM-1), Insulin-
like growth factor 2 (IGF-II), Insulin-Like Growth Factor Binding Protein 1 (IGFBP-1), 
and Receptor for Advanced Glycation Endproducts (RAGE) were below the detection limit 
of the Array in the AMPKα1 knockout in comparison with wild type PVAT. 
In addition, to levels within homogenised PVAT, the same Proteome Profiler Adipokine 
array was used to detect adipokines in the conditioned medium derived from both wild 
type and AMPKα1 knockout PVAT. As can be seen in Figure 3.22, conditioned media 
derived from AMPKα1 knockout PVAT releases lower quantities of some adipokines in 
comparison with wild type PVAT. The release of factors including adiponectin, CRP, 
CD26/DPP4, Fetuin A, FGF-1, IGFBP-3, IGFBP-5, IGFBP-6, Lipocalin-2, Pentraxin 2, 
RBP4 and Resistin were reduced while higher levels of PAI-1 and VEGF-A were found in 
the KO conditioned media compared to that from wild type PVAT. 
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Figure ‎3-21 Adipocytokine levels in PVAT lysates of wild type and AMPKα1 knockout mice.  
PVAT samples from both WT and KO were lysed and the array was performed. Chemiluminescent 
reaction spots on the adipokine profiler membranes represent various adipokines (A). The 
comparative expressions of adipokines corrected for protein content (in mean pixel density) 
obtained from densitometric analysis of the chemiluminescent reaction spots are presented in 
figure (B) (n=2). 
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Figure ‎3-22 Adipocytokine levels in PVAT conditioned media of wild type and AMPKα1 KO 
mice.  
PVAT‎ from‎ both‎ WT‎ and‎ KO‎ mice‎ was‎ incubated‎ in‎ Krebs’‎ solution‎ at‎ 37‎̊C‎ for‎ 1‎ hour‎ and‎
conditioned medium collected. Adipokine levels in conditioned medium were assessed by array. 
(A) Representative array showing chemiluminescent reaction spots on the adipokine profiler 
membranes. (B) Comparative levels of adipokines corrected for protein content (in mean pixel 
density) obtained from densitometric analysis of the chemiluminescent reaction spots (n=2). 
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3.3.13 AMPKα1 knockout PVAT releases less adiponectin 
Since the array data above indicated reduced adiponectin release by KO PVAT, an ELISA 
was used to quantify this. As can be seen in Figure 3-23, the concentration of adiponectin 
in KO conditioned media was significantly (p<0.05) lower than WT conditioned media 
(32.9 ± 3.3 ng/ml, n = 5 vs 47.5 ± 1.2 ng/ml, n = 5). These results are consistent with data 
from the adipokine array shown previously in Figure 3-22. 
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Figure ‎3-23 Content of adiponectin in conditioned media from PVAT.  
Conditioned media samples were collected from WT and KO PVAT and an adiponectin ELISA 
performed. **p<0.01 vs KO CM, n = 5. CM; conditioned media.  
 
3.3.14 Adiponectin is a potential PVAT derived vasodilator  
To further investigate the role of adiponectin in PVAT-induced relaxation, endothelium-
denuded thoracic aortic rings with and without PVAT from both wild type and AMPKα1 
knockout mice were preconstricted with U46619 and incubated with an AdipoR1 receptor 
blocker peptide. Dose response curves were then constructed using AICAR and 
cromakalim. Application of AdipoR1 receptor blocker attenuated the relaxation induced by 
AICAR and cromakalim in wild type PVAT intact aortic rings but not in AMPKα1 
knockout aortic rings with PVAT. In wild type aortic rings, adipoR1 blocking peptide 
reduced PVAT-induced relaxation to AICAR from 53.5 ± 2.8% to 30.1 ± 3.9% (n=6, 
p<0.05) (Figure 3-24A). The effect of PVAT on cromakalim-induced relaxation was also 
reduced by the adipoR1 blocking peptide (65.6 ± 14.2% to 39.9 ± 11.6%; n=6, p<0.05) 
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(Figure 3-24C). There was no obvious effect on aortic rings without PVAT when treated 
with AdipoR1 blocker prior to relaxation with AICAR or cromakalim (Figure 3-24B&D). 
In AMPKα1 KO aortic rings, addition of the AdipoR1 blocker to vessels without PVAT 
did not affect the relaxation induced by either AICAR or cromakalim (Figure 3-25 C&D). 
Additionally, Adiponectin receptor blocking peptide had no effect on the relaxation to 
AICAR or cromakalim in KO vessels with PVAT (37.8.2 ± 5.4% vs 32.5.8 ± 3.4%, n = 6, 
p = ns) and (29.6 ± 10.1% vs 19.2 ± 3.1%, n = 6, p = ns) respectively.  
Addition of globular adiponectin to wild type and AMPKα1 knockout vessels did not 
affect the baseline contraction to U46619 as shown in Figure 3-26. In the presence of 
globular adiponectin, an enhanced relaxation to cromakalim was observed in endothelium-
denuded wild type thoracic aortic rings without PVAT and in AMPKα1 knockout thoracic 
aortic rings in the presence and absence of PVAT (Figure 3-27). Aortic rings from wild 
type mice without PVAT (Figure 3-27A) (n = 5) dilated significantly from (33.6 ± 8.4%, n 
= 5) to (58.2 ± 9.9%) after addition of adiponectin in comparison with those with no added 
adiponectin (33.6 ± 8.4%, n = 5). Interestingly, addition of globular adiponectin caused 
relaxation in the presence and absence of PVAT in knockout aortic rings (Figure 3-27B). 
In thoracic aortic rings without PVAT, globular adiponectin increased the cromakalim-
induced relaxation from 30.2 ± 4.7% to 58.6 ± 12.5%, n = 6, p<0.05 vs PVAT (-). 
Additionally, globular adiponectin caused an enhanced relaxation response to cromakalim 
in knockout aortic rings with intact PVAT (47.1 ± 14.4%, n =5) in comparison with intact 
PVAT aortic rings with no added adiponectin (20.1 ± 1.8%, n = 5; Figure 3-27C).    
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Figure ‎3-24 Effect of adiponectin receptor 1 (AdipoR1) blocking peptide on PVAT-enhanced 
relaxation in wild type mouse aorta.  
Wild type aortic rings (A,C) with or (B,D) without PVAT were preconstricted with U46619, incubated 
with AdipoR1 blocking peptide and dose-response curves constructed to (A,B) AICAR or (C,D) 
cromakalim. Data are expressed as a percentage of loss of the U46619-induced tone. ***p<0.001 
relative to absence of AdipoR1 blocking peptide, n = 6. 
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Figure ‎3-25  Effect of adiponectin receptor 1 (AdipoR1) blocking peptide on PVAT-enhanced 
relaxation in AMPKα1 KO mouse aorta.  
KO aortic rings (A,C) with or (B,D) without PVAT were preconstricted with U46619, incubated with 
AdipoR1 blocking peptide and dose-response curves constructed to (A,B) AICAR or (C,D) 
cromakalim. Data are expressed as a percentage of loss of the U46619-induced tone. p = ns 
relative to absence of AdipoR1 blocking peptide, n = 6. 
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Figure ‎3-26 Effect of globular adiponectin (1μg/ml) on U46619-induced contraction.  
WT and KO thoracic aortic rings with and without PVAT were contracted with U46619, washed and 
then incubated with globular adiponectin for 10 min. Rings were then contracted a second time with 
U46619. Data are expressed in g tension to U46619 before and after addition of globular 
adiponectin. n = 5. 
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Figure ‎3-27 Effect of globular adiponectin on vascular relaxation induced by cromakalim.  
Dose-response curves to cromakalim before and after addition of gAd to thoracic aorta from WT 
and KO mice. Data expressed as percentage of loss of U46619 induced tone. (A) Dose-response 
curve to cromakalim in WT vessels without PVAT ***p<0.001 vs WT PVAT(-) vessels, n = 5. (B) 
Dose-response curve to cromakalim in KO vessels without PVAT ***p<0.001 vs KO PVAT(-) 
vessels, n = 5. (C) Dose-response curve to cromakalim in KO vessels with intact PVAT ***p<0.001 
vs KO PVAT(+) vessels, n = 5.  
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3.3.15 Effect of globular adiponectin and conditioned media 
on AMPK in VSMCs 
To investigate whether adiponectin modulates vascular smooth muscle function through 
activation of AMPK, a VSMC cell line was utilised (Figure 3-28). Over a time course of 
10 min and 1 hour, VSMCs were incubated with 1μg globular adiponectin, 100μg globular 
WT conditioned media and KO conditioned media. In all experiments, neither globular 
adiponectin nor conditioned media affected AMPK phosphorylation at 10 min (n =3, p = 
ns; Figure 3-12A) and 1 hour (n = 3, p = ns; Figure 3-28B).   
A
C
o
n
tr
o
l
g
A
d
 1

g
 
g
A
d
 1
0 0

g
 
W
T
 P
V
A
T
 C
M
 
K
O
 P
V
A
T
 C
M
 
0 .0
0 .5
1 .0
1 .5
R
e
la
ti
v
e
 F
lu
o
re
s
c
e
n
c
e
 U
n
it
 (
R
F
U
)
B
C
o
n
tr
o
l
g
A
d
 1

g
 
g
A
d
 1
0 0

g
 
W
T
 P
V
A
T
 C
M
 
K
O
 P
V
A
T
 C
M
 
0 .0
0 .5
1 .0
1 .5
R
e
la
ti
v
e
 F
lu
o
re
s
c
e
n
c
e
 U
n
it
 (
R
F
U
)
 
Figure ‎3-28 Effect of globular adiponectin (gAd) and conditioned media on AMPK in VSMCs.  
Cultured rat VSMCs were incubated with globular adiponectin or conditioned media (CM) from WT 
and KO PVAT over 10 min and 30 min, lysates prepared and subjected to Western blotting with the 
anti phosphoAMPKα (thr172) antibody. Data are expressed as relative fluorescence units (RFU) to 
control (untreated). (A) Effect of globular adiponectin and CM on AMPKα phspohorylation at 10 min 
(n‎=3,‎p‎=‎ns).‎(B)‎Effect‎of‎globular‎adiponectin‎and‎CM‎on‎AMPKα‎phosphorylation at 1 hour (n 
=3, p = ns). 
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3.4 Discussion 
The key observations in this chapter are that PVAT releases a substance(s) that can 
enhance the relaxation of preconstricted arteries and which appears to be mediated by the 
activation of KATP channel when using K
+
 channel opener cromkalim. The effect was not 
dependent on the endothelium and may be mediated by stimulation of the AdipoR1 
receptor. The results also showed that adiponectin augemted the relaxation respose to 
vasodiling agents.. The impaired anticontractile effect in the AMPKα1 knockout mice may 
be due to reduced adiponectin release by PVAT since the blunted vasodilation with KO 
PVAT was restored by globular adiponectin. These findings suggest that in KO PVAT, 
dysfunctional secretion may be related to lack of AMPKα1 in the PVAT.     
3.4.1 Effect of AMPKα1 subunit deletion on PVAT phenotype 
The first aim of this chapter was to study the effect of AMPKα1 ablation on morphological 
features of the PVAT by looking at phenotypic characteristics and comparing them with 
corresponding wild type littermates. This was performed by directly comparing the 
histological appearance of thoracic, abdominal and mesenteric PVAT to mouse 
interscapular BAT and epididymal WAT using H&E and UCP-1 as a marker for BAT. 
Examination of the tissue with standard histological staining (Figure 3-1) indicated 
structural similarity between thoracic aorta PVAT and brown (BAT) depots and between 
abdominal aorta PVAT and mesenteric PVAT and white (WAT) depots in both WT and 
KO. UCP-1 expression results (Figure 3-2 &3-3) showed that thoracic PVAT and BAT are 
virtually identical. This appears different from abdominal aorta PVAT, which showed an 
intermediate phenotype between white and brown adipose in histological appearance and 
analysis of BAT marker expression. Mesenteric PVAT is composed mainly of WAT as 
confirmed from the histological analysis and reduced UCP-1 expression. The results 
suggest that AMPKα1 catalytic subunit deletion had no effect on phenotypic features of the 
PVAT regardless of the PVAT depot type. Results from WT and KO mice are consistent 
with previous findings from other studies in Sv129 mice strain (Frontini and Cinti, 2010, 
Cinti, 2011) and also from other mice and rat strains (Cannon and Nedergaard, 2004, 
Fitzgibbons et al., 2011, Padilla et al., 2013) which reported that thoracic PVAT is 
composed mainly of a BAT like phenotype and that surrounding the abdominal aorta 
consists mainly of WAT. However, it is worth noting that these previous studies 
demonstrate that PVAT can have characteristics of both BAT and WAT but this largely 
depends on the anatomical context, animal strain and disease state.  
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Understanding the factors responsible for the difference in the PVAT phenotype 
throughout the arterial tree is an area of intense investigation. This is because phenotypic 
differences in PVAT depots may contribute to differences in disease risk in blood vessels. 
Several studies have reported a relationship between PVAT volume and the severity of 
vascular disease (Greif et al., 2009, Jeong et al., 2007). Studies have also indicated that 
PVAT can have a detrimental effect on vascular function and this effect is markedly 
exacerbated in disease such as obesity (Payne et al., 2010) which was also reported in the 
aortae (Ma et al., 2010) and mesenteric vessels (Ketonen et al., 2010) of obese rodents. In 
general, an increase in adipose tissue mass occurs due to adipocyte hyperplasia and/or an 
increase in triglyceride deposition in the preexisting adipocytes. It has been reported that 
lack or deficiency of AMPK activity may lead to development of obesity (Ruderman et al., 
2003). Previous studies reported that lack of catalytic subunits of AMPK is associated with 
increased adipose tissue mass. For example, studies of AMPKα2-knockout mice fed a 
high-fat diet showed increased adipose tissue mass compared with wild-type mice, due to 
increased adipocyte size, with no change in cell number (Villena et al., 2004). The role of 
AMPK in the determination of PVAT phenotype was investigated in a study by Ma et al 
who demonstrated that high fat diet reduced activating Thr172 phosphorylation of AMPK 
in thoracic aortic PVAT, which was associated with not only increased intimal thickness 
but also increased adipocyte size (Ma et al., 2010). However, the adipocyte size changes 
reported in these previous studies may be due to reduced FA oxidation and a concomitant 
increase in lipogenesis resulting from ablation of AMPK in adipose tissue. In addition, the 
animal models utilized in these studies have a global knockout of  AMPKα2 isoform, such 
that the observed effects may not be a direct effect of reduced AMPK activity in adipose or 
adipocytes alone.  
Brown adipocytes contain high numbers of mitochondria and characteristically express 
UCP-1, which allows thermogenesis (Tam et al., 2012, Marzolla et al., 2012).  AMPKα1 
has been reported to be the dominant isoform of the catalytic α subunit of AMPK and is 
expressed in BAT more than other organs such as liver, suggesting a potential regulatory 
role for AMPK in BAT (Mulligan et al., 2007). AMPK activity in BAT is increased by 
cold exposure (Mulligan et al., 2007, Vucetic et al., 2011) and as a result of AICAR or β3 
adrenergic stimulation (Sakaue et al., 2003, Hutchinson et al., 2005, Pulinilkunnil et al., 
2011) and this results in increased glucose transport and fatty acid oxidation. Furthermore, 
it has been reported that AMPK is involved in the regulation of brown adipocyte 
differentiation. In differentiating brown pre-adipocytes in vitro, AMPK activity increases 
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during differentiation after induction of adipogensis, and siRNA targeted to AMPK 
inhibited differentiation into mature brown adipocytes, accompanied by a reduction in 
UCP-1 expression. Additionally, continuous intra peritoneal AICAR administration in 
mice increased browning of WAT (Vila-Bedmar et al., 2010). This study suggests that 
AMPK may play a role in differentiation into FA-oxidizing BAT, leading to greater energy 
expenditure. However, in the current study there was no difference in the expression of 
UCP-1 between AMPKα1 deficient mice and wild type littermates which might be 
explained by a compensatory effect of the AMPKα2 subunit isoform, although there was 
no obvious enhanced expression of the α2 subunit or reduced AMPKα and ACC 
phosphorylation in KO PVAT. Indeed this has been suggested in other studies which 
reported that AMPKα1 deficient mice showed no alteration in cold tolerance or acute non-
shivering thermogenesis, and that a compensatory increase in AMPKα2 expression may 
explain this lack of effect (Bauwens et al., 2011).   
The absence of any difference in BAT markers between WT and KO PVAT may be related 
to a reduction of mitochondrial biogenesis PGC1α expression as a result of AMPK 
dysfunction. β3-aderenoceptor stimulation in adipocytes results in increased 
phosphorylation of AMPK and ACC and induced expression of the transcriptional co-
activator and master regulator of mitochondrial biogenesis PGC1α (Wan et al., 2014), 
which regulates UCP-1 transcription (Xue et al., 2005). These effects were reduced in 
epididymal adipose tissue from AMPKβ1 KO mice which was also accompanied with a 
reduction in mitochondrial protein content, including a reduction of PGC1α (Wan et al., 
2014). Taking these findings together, the absence of a difference in UCP-1 expression 
between WT and α1 KO adipose tissue including PVAT and the findings from other studies 
suggest the possibility that AMPK’s role in determining adipose tissue phenotype might 
depend on AMPK subunit type, animal strain, age and/or disease state.  
3.4.2 Effect of AMPKα1 subunit ablation on AMPK activity 
Another important question that was addressed in the present study was whether deletion 
of AMPKα1 subunit affects the activity of the AMPK in the PVAT, perhaps through 
compensation by another isoform of AMPK. Results showed reduced phosphorylated and 
total AMPK in PVAT (Figure 3-5) which correlated with data from immunoblots showing 
reduced phosphorylation of the downstream kinase ACC (Figure 3-6). There was no 
obvious compensatory upregulation in the AMPKα2 isoform. These data suggest the 
reduced activity of AMPK is due to the α1 subunit deficiency and that the α1 subunit might 
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be essential for regulation of AMPK function in adipose tissue. These results are in 
agreement with other studies demonstrating that the catalytic α1 subunit is the major 
catalytic subunit isoform expressed in adipose tissue and is also responsible for the major 
part of AMPK activity (Lihn et al., 2004, Daval et al., 2005).  
3.4.3 Effect of AMPK AMPKα1 subunit ablation on anticontractile 
effect of PVAT 
The current study investigated the effect of AMPKα1 subunit deficiency on the 
anticontractile effect of the PVAT. The studies have been carried out in thoracic and 
abdominal aortae from both wild-type mice and mice with a global AMPKα1 subunit 
knockout and using two relaxing agonists acting via different mechanisms.  One of these 
agents is AICAR which known to activate AMPK. In the cytoplasm, AICAR is 
phosphorylated by adenosine kinase and converted to the active metabolite AICAribotide 
(ZMP), which mimics AMP and activates AMPK (Corton et al., 1995). AICAR is known 
to target both AMPKα1 and AMPKα2 and is able to induce aortic relaxation in mice in an 
endothelium and eNOS independent manner (Goirand et al., 2007). The other agonist used 
was cromakalim with has not previously been reported to have any effect on AMPK 
activity. Cromakalim acts via opening of ATP sensitive K
+
 channels modulator (K
+
ATP) 
(Glavind-Kristensen et al., 2004) and hyperpolarising the VSMC membrane. In the current 
study, presence of PVAT augmented the relaxation induced by both agonists (Figure 3-8A 
&Figure 3-9A). Furthermore, the lack of AMPKα1 caused the PVAT to lose its 
anticontractile effect and its augmentation of relaxation to cromakalim and AICAR. These 
findings suggest the AMPKα1 isoform is likely involved in the anticontractile effect of 
PVAT. The difference in relaxation response between WT and KO is unlikely to be due to 
AMPK activation at the medial layer by AICAR and cromakalim as cromakalim had no 
effect on AMPK expression or phosphorylation in VSMCs (Figure 3-19) or cultured 
adipocytes (Figure 3-20). Furthermore, conditioned medium from WT PVAT was able to 
enhance relaxation of aortic rings from WT mice or KO mice with similar efficacy, 
suggesting the defect is at the level of the PVAT.  
The present data support and add to the plethora of evidence that PVAT has an 
anticontractile effect in different vascular beds including human subcutaneous vessels, 
internal mammary artery, rat mesenteric, and rat aorta (Gao et al., 2005b, Greenstein et al., 
2009) and also attenuates contraction to many agents including phenylephrine, 5-HT, 
angiotensin II and U46619 (Lohn et al., 2002, Verlohren et al., 2004, Gao et al., 2005a). 
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The mechanism for the attenuation of contraction by PVAT has been proposed as release 
of transferable relaxation factor(s) with unknown identity, termed adventitia-derived 
relaxation factor (ADRF) (Lohn et al., 2002). Results from the current study agree with 
this in that transfer of CM from WT mice augmented relaxation of aortic rings with PVAT. 
In addition, it was not necessary for the PVAT to be in contact with the vessel to exert an 
anticontractile effect. In the protocol CM was added prior to contraction of the vessel ring 
with U46619 and it was found that WT but not KO CM attenuated aortic contraction. This 
strongly suggests a transmissible factor is responsible for attenuating contraction and 
augmenting relaxation which is produced by aortic PVAT and in the KO mice this factor is 
reduced or absent and these findings are in agreement with many other studies (Lohn et al., 
2002, Verlohren et al., 2004, Gao et al., 2005b, Malinowski et al., 2008, Greenstein et al., 
2009).  
3.4.4 AMPKα1 knockout PVAT is assochied with adipocytokines 
release dysfunction 
PVAT is known to release many adipokines which can act in a paracrine fashion toward 
the blood vessels (Maenhaut and Van de Voorde, 2011). In 2002, Lohn and coworkers 
showed that the anticontractile effect of the PVAT is due to release of a transferable factor, 
termed ADRF (Lohn et al., 2002). Since then, many studies have revealed numerous 
adipokines that are involved in regulation of vascular tone (reviewed in Almabrouk et al., 
2014). The adipokines with vasodilatory properties are adiponectin (Fesus et al., 2007), 
omentin (Yamawaki et al., 2010) and visfatin (Yamawaki et al., 2009). The contractile 
adipokines include Ang II (Soltis and Cassis, 1991) and resistin (Walcher et al., 2010). 
Adipokines with both contractile and anticontractile properties are reactive oxygen species 
(Fang et al., 2009, Gao et al., 2007), leptin (Nakagawa et al., 2002), TNF-α (Brian and 
Faraci, 1998) and apelin (Japp et al., 2008).  
The release of the vasorelaxing factors (ADRF) has been reported to be dependent on Ca
2+
 
and is regulated by intracellular signalling pathways involving tyrosine kinase and protein 
kinase A and independent of perivascular nerve endings (Dubrovska et al., 2004). This is 
in contrast to the study by Weston et al. which proposed that under basal, noncontracted 
conditions, β3- stimulation in rat mesenteric PVAT induces release of an adipocyte- 
derived hyperpolarizing factor that is probably adiponectin (Weston et al., 2013). There are 
very few studies where the role of AMPK in release of ADRFs has been investigated. A 
study by Lihn et al indicated that the AMPK activator AICAR stimulated adipose tissue 
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AMPKα1 activity and adiponectin gene expression and reduced the release of TNF-α and 
IL-6 (Lihn et al., 2004). These cytokines have been shown to have inhibitory effects on 
adiponectin gene expression and release (Fasshauer et al., 2002, Maeda et al., 2002, 
Greenberg et al., 1991), such that activity of AMPK in the PVAT could regulate 
adiponectin expression (Lihn et al., 2004). Similarly, the PPARγ agonist troglitazone 
which also activates AMPK has a positive effect on adiponectin expression in mature 
adipocytes (Phillips et al., 2003, Sell et al., 2006). However, other studies using cultured 
3T3-L1 adipocytes found that prolonged exposure to the AMPK activating agent 
metformin actually causes a significant reduction in adiponectin protein content of the 
adipocytes (Huypens et al., 2005). Another study reported that metformin had no effect on 
serum adiponectin concentration or adipocyte adiponectin content in type 2 diabetic 
patients (Phillips et al., 2003, Tiikkainen et al., 2004). In human adipose tissue, activation 
of AMPK by AICAR also reduces the expression and release of TNFα and interleukin-6 
(IL-6) (Lihn et al., 2004, Sell et al., 2006). Furthermore, as it has been demonstrated that 
TNFα inhibits adiponectin expression (Kappes and Loffler, 2000), reduced TNFα 
expression results in up-regulation of adiponectin expression, such that the effects of 
AICAR on adiponectin may be indirect (Daval et al., 2006). To clarify how AMPKα1 KO 
affects the secretion of adipocytokines by aortic PVAT, an adipokine array was performed. 
Results showed that KO PVAT exhibits secretory dysfunction and the most striking 
difference was a reduction in adiponectin in KO PVAT and CM (Figure 3-21 &3-22). 
Quantitative studies using ELISA further confirmed a significant reduction in adiponectin 
in KO CM (Figure 3-23). Since adiponectin is a vasodilator (Fesus et al., 2007), it could 
account for the lack of an anticontractile effect in KO PVAT. These findings support 
previous indications that AMPK might be involved in regulation of adiponectin secretion 
(Lihn et al., 2004, Phillips et al., 2003), yet the mechanism of regulation needs further 
investigation. 
3.4.5 Adiponectin is a candidate for ADRF 
In the present study, the anticontractile effect of thoracic PVAT in wild type mice was 
abolished using a peptide blocking the effect of adiponectin (Figure 3-24), thereby 
suggesting that adiponectin might be responsible. This has also been demonstrated 
previously in human gluteal arteries (Fesus et al., 2007) and mice mesenteric arteries 
(Lynch et al., 2013). Furthermore, contractility studies conducted on AMPKα1 knockout 
mice demonstrated that PVAT was unable to attenuate contractility to U46619 as was 
observed with WT PVAT. It can therefore be proposed that impaired PVAT action is due 
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to the reduction in the release of adiponectin from the PVAT. The current study also 
demonstrated the ability of vessels to respond to exogenous globular adiponectin (Figure 3-
27). The globular adiponectin used for this study is known to have a higher affinity for 
AdipoR1 and low affinity for AdipoR2 (Kadowaki et al., 2006, Ketonen et al., 2010, 
Lynch et al., 2013). Since all rings were denuded of endothelium, an effect of adiponectin 
on the endothelium or generation of endothelium-derived mediators can be ruled out and 
the action is likely mediated by the vessel media (Weston et al., 2013). Additionally, 
vascular relaxation was seen in both wild type and AMPKα1 knockout vessels suggesting 
that adiponectin can act directly on vascular smooth muscle cells through AdipoR1 and 
that the AMPK expressed in these vessels may not involved. In the array experiment, 
neither globular adiponectin nor conditioned media was able to phosphorylate AMPKα in 
cultured vascular smooth muscle cells which further suggests that adiponectin can induce 
effects in vascular smooth muscle cells directly (Figure 3-28). This is in contrast to the 
study by Lynch et al which demonstrated that adiponectin induces an anticontractile effect 
in an endothelium-independent manner which involves activation of AMPK in the vascular 
smooth muscle layer and subsequent BKCa channel activation (Lynch et al., 2013). 
Furthermore, adiponectin receptor antagonism and the AMPK inhibitor compound C have 
been reported to attenuate vascular relaxation, whereas globular adiponectin failed to 
induce vascular relaxation in AMPKα2-deficient mice (Meijer et al., 2013). Such results, 
together with the findings from the current study, indicate that adiponectin may be the 
potential vasodilator molecule released by PVAT and that AMPK may regulate its release.  
3.4.6 Role of KATP channels in anticontractile effect of PVAT 
Two different vasodilators have been used in this study; AICAR which is a known AMPK 
activator and the KATP channel opener cromakalim. Indeed, PVAT enhanced the relaxation 
response induced by both agents. However, it is difficult to draw the conclusion that the 
observed AICAR-enhanced relaxation is due to PVAT as stimulation of VSMCs and 3T3-
L1 adipocytes with AICAR increased AMPK activity. Therefore, the data with AICAR as 
a vasorelaxant should be treated with caution and need to be investigated further. As stated 
previously, PVAT also enhances the relaxation response to the KATP channel activator, 
cromakalim, which suggests the involvement of vascular smooth muscle KATP channels. 
The role of this channel in the endothelium-independent vascular relaxation induced by 
PVAT has been suggested in a previous study by Lohn et al. in which the PVAT 
transferable factor was not identified (Lohn et al., 2002). Vascular ATP-dependent K
+
 
channels are activated by a number of conditions such as ischaemia and hypoxia and the 
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mechanism may be mediated by a fall in the intracellular ATP concentration or by a rise in 
the intracellular ADP concentration. Opening of KATP channels results in cell membrane 
hyperpolarisation and subsequent inactivation of voltage gated Ca2+ channels. This will 
lead to a decrease in intracellular free Ca
2+
 of the smooth muscle cells and thus to a 
dilation of the artery. As these channels are accompanied by efflux of Ca
2+
 into VSMCs, it 
is logical to think that will result in activation of AMPK in the medial layer of the artery. 
To rule out this issue, studies conducted using VSMCs treated with cromakalim and 
AICAR showed that treatment with cromakalim was not associated with either increased 
phosphorylation or activity of AMPK in VSMCs. Hypoxic vasodilation in isolated, 
perfused guinea pig hearts can be prevented by glibenclamide, a blocker of adenosine 
triphosphate (ATP)-sensitive potassium channels, and can be mimicked by cromakalim, 
which opens ATP-sensitive potassium channels. (Daut et al., 1990). These channels have 
been found to be involved in regulation of basal vascular tone in a number of vascular bed 
including the coronary circulation (Samaha et al., 1992) and mesenteric vessels (Nelson 
and Quayle, 1995) and inhibition of this channel by glibenclamide has been found to 
attenuate coronary and cerebral autoregulation (Narishige et al., 1993, Hong et al., 1994). 
In the current study, PVAT enhanced the relaxation induced by cromakalim and that 
suggests PVAT can induce endothelium-independent relaxation which may involve the 
KATP channel or perhaps increasing the sensitivity of the channel. However, the role and 
the mechanism of activation needed to be further investigated.  
3.5 Conclusion 
This study has shown that PVAT has a profound anticontractile effect on mouse aortic 
rings. The effect may be due to release of adiponectin by the PVAT and this release is 
regulated by the activity of AMPKα1. In mouse aortic rings, adiponectin augments 
relaxation to cromakalim in an endothelium-independent manner although other effects of 
adiponectin on the endothelium cannot be ruled out. The study also demonstrated 
perivascular adventitial adipose tissue elaborates an adiponectin factor that acts at least in 
part by an effect on ATP-dependent K
+
 channels. Clinically, there is evidence that PVAT 
becomes dysfunctional in obese humans and plasma adiponectin is reduced 
(Aghamohammadzadeh et al., 2015). Alterations in AMPK activity in the PVAT may be 
behind this effect.  
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4.1 Introduction 
Many studies have demonstrated that PVAT or conditioned media can attenuate vessel 
contraction to various agonists including phenylephrine, 5-HT, angiotensin II and U46619 
in the mouse aorta, rat mesenteric arteries and human internal thoracic arteries (Lohn et al., 
2002, Verlohren et al., 2004, Gao et al., 2005b, Gao et al., 2005a). The mechanisms for the 
attenuation of contraction by PVAT are not fully understood, but the release of transferable 
relaxation factor(s) with unknown identity, termed adventitium-derived relaxation factor 
(ADRF), has been proposed. Several candidates have been suggested including adiponectin 
(Fesus et al., 2007), angiotensin-(1-7) (Lu et al., 2010), H2O2 (Gao et al., 2006), leptin 
(Galvez-Prieto et al., 2012), H2S (Fang et al., 2009), methyl palmitate (Lee et al., 2011). 
Many of these transferable vasoactive factors induce an anti-contractile effect through 
increasing NO synthesis and release by the endothelium (Galvez-Prieto et al., 2012) and/or 
targeting K
+
channels in vascular smooth muscle (Gao et al., 2007). It was also recently 
shown that PVAT from the thoracic aorta expresses the endothelial isoform of NO 
synthase (eNOS) (Araujo et al., 2015, Xia et al., 2016) and releases NO itself. PVAT-
derived NO contributes to relaxation in both endothelium-intact and denuded thoracic 
aortic rings, indicating NO as a potential ADRF in this vessel (Xia et al., 2016).  
On the other hand, a few studies have identified a procontractile effect of PVAT. Soltis and 
Cassis showed data indicating a contraction of PVAT-intact rat aorta in response to 
electrical field stimulation which was absent in tissues without PVAT (Soltis and Cassis, 
1991). Similar findings were also reported in rat mesenteric arteries (Gao et al., 2006). This 
effect is thought to involve production of superoxide (O2
.-
) by stimulation of NADPH 
oxidase in PVAT adipocytes (Gao et al., 2006). PVAT is a potential source of reactive 
oxygen species (Gao et al., 2006), which are by products of many reactions including 
cyclooxygenase-mediated production of prostanoids and uncoupling of eNOS from making 
NO (Mayr et al., 2005). There are two common ROS species that have been reported to 
affect vascular contractility; O2
.-
 and H2O2. Apart from H2O2, which is a vasodilator (Gao 
et al., 2007), ROS can induce vasoconstriction via many mechanisms including: increasing 
the degradation of NO, formation of peroxynitrite, a strong cytosolic oxidant generated by 
the reaction of the O2
.-
 with NO which inactivates PGI synthase and shifts the production 
of prostacyclin to that of other vasoconstrictor prostanoids or directly targeting the vascular 
smooth muscle layer by either induction of depolarisation or inhibition of ATP-sensitive 
potassium channels (KATP), voltage-activated potassium channels (Kv) and large 
conductance calcium-activated potassium channels (BKCa) (Wong and Vanhoutte, 2010). 
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The physiological significance of PVAT-derived O2
-
 is still elusive, although there is some 
evidence suggesting that O2
.-
 may affect vascular tone. It has been reported that O2
.-
 
released from mesenteric PVAT can potentiate the contraction of blood vessels to electric 
field stimulation (Gao et al., 2006). In denuded vessels, scavenging of O2
-
 with exogenous 
superoxide dismutase (SOD) reduced contraction to phenylephrine in aortic arteries with 
intact PVAT but not those devoid of PVAT (Gao et al., 2007).  
AMPK is a key regulator of cellular energy homeostasis and is activated in response to 
changes in energy status (Rubin et al., 2005, Adams et al., 2004). Activation of AMPK 
subsequently modifies the balance between energy generating and consuming metabolic 
pathways, enabling conservation of cellular energy status (Hardie and Carling, 1997). One 
of the vasculoprotective roles of AMPK is the control of vascular redox status. Oxidative 
stress and disturbed antioxidant defence is associated with endothelial dysfunction in 
vascular injury and atherosclerosis (Siersbaek et al., 2010, Sata et al., 2002). Increased 
production of oxidant species in the diseased vascular wall is associated with reduced NO 
production and further formation of damaging species such as peroxynitrite (Sata et al., 
2000). The role of AMPK in alleviation of disturbed redox balance has been addressed in 
many studies. AMPK activation in HUVECs with AICAR was found to increase levels of 
superoxide dismutase (SOD), the enzyme responsible for removal of O2
-
 (Kukidome et al., 
2006). AICAR activation of AMPK in HUVECs also causes uncoupling of protein-2 
expression which diminishes O2
.-
 production and prostacyclin synthase nitration in diabetes 
(Serrano et al., 1997). In contrast, some studies have reported that AMPK is itself activated 
by ROS. Metformin has been proposed to activate AMPK via an increase in mitochondrial 
reactive nitrogen species (Zou et al., 2004). Additionally, Coi et al reported that statins 
induced ROS generation and that peroxynitrite was responsible for AMPK activation (Choi 
et al., 2008). Similarly, activation of AMPKα1 in HUVECs with low O2 concentrations 
occurred as a result of mitochondrial ROS and was responsible for increased expression of 
antioxidant genes such as catalase and SOD (Colombo and Moncada, 2009). Furthermore, 
silencing of AMPKα1 was associated with enhanced oxidative stress, reduced expression 
of antioxidant defence genes such as catalase and SOD and diminished expression of NO 
generating enzyme eNOS (Colombo and Moncada, 2009). 
Comparatively little is known about AMPK function in PVAT, although given its role in 
other tissues, AMPK signalling is likely to be integral to PVAT function (Almabrouk et al., 
2014, Ewart and Kennedy, 2011). Loss of AMPK may increase PVAT inflammation and 
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shift its redox status towards a pro-oxidative environment. Together this could lead to 
increased PVAT ROS production, reduced NO availability and an impaired ability of 
PVAT to enhance relaxation. In support of this is the relationship between PVAT oxidative 
stress and PVAT dysfunction which has been demonstrated previously (Ketonen et al., 
2010, Greenstein et al., 2009). Impaired anti-contractile properties of PVAT from obese 
mice was found to be restored by pre-incubation with free radical scavengers (Ketonen et 
al., 2010). In another study, PVAT obtained from obese humans had a compromised anti-
contractile function which could be improved by treatment with SOD (Greenstein et al., 
2009). Results from chapter 3 showed that PVAT from AMPKα1 KO mice exhibited 
reduced anti-contractile properties. The mechanisms underlying PVAT dysfunction in 
AMPKα1 KO mice are currently elusive. Therefore, the current hypothesis is that the 
anticontractile dysfunction may be related to the loss of protective AMPK in the  PVAT 
which shifts the redox balance from NO production by eNOS to ROS production causing 
an increases in oxidative stress in the PVAT. Taken together, this chapter will investigate 
the role of AMPK in regulation of redox state of PVAT and how this affects its 
anticontractile function.   
4.2 Aims of the study 
 To characterise any differences in ROS and RNS expression between wild type and 
AMPKα1 KO PVAT 
 To define the role of AMPK in the NO-dependent anticontractile effect of PVAT 
4.3 Methods & Results 
4.3.1 Expression of superoxide anion in wild type and AMPKα1 
KO PVAT  
To test whether AMPKα1 knockout resulted in enhanced production of O2
.-
, 
immunofluorescence confocal microscopy was used. Briefly, thoracic aortic PVAT from 
WT and KO was dissected and rapidly placed into Krebs-Henseleit solution previously 
gassed. Segments were incubated with 10
-5
 M DHE for 30 minutes at 37°C in the dark and 
then washed (2 x 15 min) in KH at 37°C. Negative controls were incubated with 15 U/mL 
of SOD during exposure to dihydroethidium (DHE). Segments were fixed by immersion in 
acetic zinc formalin for 1 hour at room temperature, mounted on slides and visualised by 
confocal fluorescence microscopy. Representative images are shown in Figure 4-1. The 
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production of intracellular O2
.- 
in adipocytes of PVAT was confirmed by the presence of 
dark red fluorescent staining. Upon visual appraisal (Figure 4-1), an enhanced fluorescence 
intensity seemed to be present in KO PVAT (B) in comparison with wild type (A). 
However, image analysis of the mean fluorescence intensity (MFI) showed only a non-
significant trend toward increased MFI in KO PVAT (Figure 4-1E). The MFI in KO was 
43.4 ± 12.6, n = 3 in comparison with 38.8 ± 5.6 n = 5 in WT, (p = ns). The production of 
O2
.-
 was reduced by the scavenger enzyme SOD (15 U/mL) in both WT and KO PVAT; 
the reduction in intensity was more apparent in WT PVAT compared to KO PVAT 
although analysis of MFI showed that these differences were non-significant (Figure 4-1 
C&D) with KO PVAT showing high variability in response to SOD (Figure 4-1E). 
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Figure ‎4-1 Representative Immunofluorescent images showing superoxide production by 
adipocytes in WT and KO thoracic PVAT, detected with dihydroethidium (DHE).  
PVAT was labelled with DHE (10
-5
M), which emits red fluorescence when oxidized by superoxide. 
Representative confocal images of WT and KO PVAT showing O2
.-
 level (A,B) and the effect of 
treatment with SOD (C,D). (E) Quantitative fluorescence measurement of DHE in the presence and 
absence of SOD. Scale‎bar‎20μm. 
 
The production of O2
.-
 by PVAT of each genotype was also evaluated by comparing the 
levels of nitrotyrosine using immunohistochemical staining with nitrotyrosine antibody. 
Aortic rings with attached PVAT were dissected from WT and KO and  processed as 
detailed in Section 2.3.3. Briefly, WT and KO thoracic aortae were were excised 
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immediately after death and placed in 10% acetic zinc formalin overnight. Arteries were 
processed through a gradient of alcohols to Histoclear and embedded vertically in paraffin 
wax before being cut into 5 μm sections. Peroxynitrite reacts with protein tyrosine residues 
to form stable nitrotyrosine moieties which can be detected with specific antibodies and is 
used as a marker for peroxynitrite activity (Libby, 2002). Polymer-based 
immunohistochemistry was used to evaluate nitrotyrosine expression in PVAT from WT 
and KO mice. Figure 4-2 shows representative images of WT and KO aortic PVAT stained 
with nitrotyrosine antibody. Upon visual assessment, diffuse nitrotyrosine expression was 
apparent in the aortic PVAT of both strains. The intensity of antibody staining appeared 
greater in PVAT from AMPKα1 KO mice (n=3). 
 
A B
ED F
C
Blank Nitrotyrosine (Positive) Nitrotyrosine (Positive)
Wild type
AMPKα1 KO
 
Figure ‎4-2 Nitrotyrosine expression in aortic PVAT from wild type and AMPKα1 knockout 
mice.   
Representative histological sections of thoracic aorta with intact PVAT from WT and KO mice 
stained with anti-nitrotyrosine antibody and counterstained with haematoxylin. Positive staining is 
indicated by brown colour (B,C,E,F) and blank (untreated) is represented in A&D. Scale bar 20μm 
(A, B, D, E), 10μm (C,F). 
 
 
 
 
 
 
4.3.2 eNOS and NO levels in WT and KO PVAT 
To determine the effect of AMPKα1 deletion on NO production by PVAT, two approaches 
were used. Firstly, the effect of AMPKα1 ablation on the protein levels and 
phosphorylation state of eNOS in the PVAT was assessed. Expression of eNOS was 
measured by Western blot analysis as detailed in Section 2.7. Briefly, WT and KO PVAT 
samples were dissected free and lyastes were prepared. Protein content analysis from these 
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lysates was performed and protein was added at 10 μg per well. Immunoblotting was 
performed with antibodies against phospho-eNOS, total-eNOS and GAPDH which was 
used as a loading control. Membrane visualisation of immunolabelled bands was carried 
out using an Odyssey Sa Infrared Imaging System (LI-COR, USA) linked with Odyssey Sa 
Infrared Imaging System software (LI-COR, USA) (all antibody dilutions found in Table 
2.5). Densitometric analysis of the blots demonstrated that the ratio of phosphorylation (p-
eNOS)(ser1179) relative to total eNOS (t-eNOS), was significantly reduced in AMPK-α1 
knockout PVAT in comparison with wild type (p<0.05, n = 3) (Figure 4-3B). Similarly, 
total eNOS was also reduced in KO PVAT in comparison to WT PVAT (p<0.01, n = 3 vs 
KO PVAT) (Figure 4-3C)  
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Figure ‎4-3 eNOS expression and activity in PVAT.  
PVAT samples from wild type and AMPKα1 knockout were lysed and immunoblotting for total and 
phospho-eNOS (Ser1179) was performed. (A) Representative immunoblots are shown. (B) 
Densitometric analysis of immunoblots, presented as ratio of phosphorylated eNOS relative to total 
eNOS and ratio of total eNOS divided by by GAPDH (C). *p<0.05 vs KO PVAT, n = 3; **p<0.01 vs 
KO PVAT, n = 3.  
 
The difference in the production of NO in aortic PVAT between WT and KO was also 
evaluated with the fluorescent dye DAF-2DA using immunofluorescence confocal 
microscopy. Preparation of PVAT samples was described in section 2.8.1. PVAT samples 
were incubated in 10 μM DAF-2DA for 30 minutes. 0.1 mM Nω-nitro-L-Arginine (L-
NNA) and 15 U/L SOD were used as negative and positive controls respectively. After 
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fixation, samples were incubated in 1 μM SYTO 61 fluorescent nucleic acid stain (Thermo 
Fisher Scientific, UK) for 1 hour prior to mounting and confocal microscopy examination. 
Representative images of which are shown in Figure 4-4.  
There was no difference in basal DAF-2DA fluorescence intensity between WT and KO 
(Figure 4-4 A, D). Incubation with the NOS inhibitor L-NNA visually reduced the 
fluorescence intensity in both genotypes (Figure 4-4B, E), yet this was not significant 
(Figure 4-4 G). In the presence of SOD, the fluorescence intensity was increased as 
assessed visually in both WT and KO (C, F). Statistical evaluation of the mean 
fluorescence intensity showed a non-significant trend toward increased enhanced 
production of NO in the presence of SOD (Figure 4-4 G). 
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Figure ‎4-4  DAF-2 fluorescence in WT and KO thoracic PVAT.  
PVAT was labelled with DAF-2DA (10 μM), which is hydrolysed to the impermeable 4,5 - 
diaminofluorescein (DAF-2) by cellular esterases. DAF-2 subsequently reacts with cellular NO to 
form the fluorescent triazolofluorescein. PVAT samples were then treated with either L-NNA (0.1 
mM) or SOD (15 U/L). Representative confocal images of WT and KO PVAT showing NO 
production (A,D) and the effect of treatment with L-NNA (B,E) and SOD (C,F). (G) Quantification of 
DAF-2 mean fluorescence intensity in presence and absence of L-NNA or SOD. Scale bar 20μm. 
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4.3.3 Effect of PVAT on Sodium nitroprusside-induced relaxation  
To determine the influence of AMPK in the PVAT on mediating relaxation of aortic rings 
to exogenous NO, concentration-response curves to the NO donor sodium nitroprusside 
were constructed. Denuded aortic rings with and without PVAT were dissected from WT 
and KO mice and cut into 2 mm segments and mounted on two 40 μm diameter wires in a 
small artery wire myograph as detailed in Section 2.4. Arterial rings were maintained in 
Krebs’ solution at 37 °C and gassed continuously with 95 % O2 and 5 % CO2. Following a 
30 minute equilibration period, the vessels were set to 1g optimal tension of. Viability of 
arterial rings was evaluated with 40 mM KCl. Following this, the artries were washed and 
pre-constricted with U46619 for a further 30 minutes. Cumulative dose-response curves to 
increasing concentrations nitric oxide donor sodium nitroprusside were constructed. Data 
were expressed as a percentage of loss in the vascular tone induced by U46619. 
In rings from both WT and KO mice, the presence of thoracic PVAT had no effect on the 
relaxation induced by sodium nitroprusside (Figure 4-5 A&B). However, in wild type 
vessels without PVAT, sodium nitroprusside produced a maximum relaxation (Emax) of 
36.2 ± 6.6%, (n = 6) which was approximately double the Emax observed in the KO (20.7 ± 
5.5%, n = 9, p <0.05) suggesting a dysfunctional vascular smooth muscle layer in 
AMPKα1 knockout mice (Figure 4-5C).  
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Figure ‎4-5 Effect of PVAT on Na nitroprusside-induced relaxation in wild type and knockout 
thoracic aorta.  
Dose-response curves to Na nitroprusside (SNP) were produced by wire myography of thoracic 
aortic rings from (A) WT or (B) KO mice with (+) and without (-) PVAT. All vessels were without 
endothelium. (C) Comparison of effect of SNP in vessels from each genotype lacking PVAT. (n = 6, 
***p<0.001). 
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4.4 Discussion  
The aim of this chapter was to investigate the role of AMPK in regulation of the redox 
state in PVAT. The results presented show that (1) ROS production appears to be similar in 
both WT and KO PVAT, although the expression of nitrotyrosine, a marker for 
peroxynitrite appears higher in KO PVAT. (2) The level of NO appeared to be similar in 
both types of PVAT, although there was a significant reduction in the levels of phospho- 
eNOS and proportion of eNOS phosphorylated in KO PVAT when quantified by Western 
blotting. (3) There was a reduced relaxation to sodium nitroprusside in KO aortic rings, 
which indicates dysfunctional medial smooth muscle.  
4.4.1 Role of AMPK in regulation of ROS release from PVAT 
Many studies have now established that AMPK is a critical regulator of vascular redox 
balance. AMPK has been reported to abolish the formation of ROS by NADPH oxidase 
and induce NO production by eNOS (Fisslthaler and Fleming, 2009). Silencing of the 
AMPKα1 subunit isoform has also been reported to be associated with reduced expression 
of MnSOD, catalase, γ-glutamylcysteine synthase and thioredoxin, in endothelial cells 
(Colombo and Moncada, 2009). Conversely, activation of AMPK by AICAR or AMP can 
suppress the production of O2
.-
 stimulated by phorbol esters or fMLP (Formyl-Methionyl-
Leucyl-Phenylalanine) in neutrophils (Alba et al., 2004). Furthermore, activation of AMPK 
by rosiglitazone effectively attenuated the generation of ROS in HUVECs exposed to a 
high glucose concentration (Ceolotto et al., 2007). Not only this, AMPK can also influence 
the cellular redox balance via inhibition of prostacyclin synthase in endothelial cells by 
prevention of tyrosine nitration through upregulation of UCP-2 (Xie et al., 2008). As 
AMPK is expressed in all layers of the vascular wall including PVAT, it is plausible that 
AMPK is also involved in regulation of the redox state of the PVAT itself. 
PVAT is known to release ROS such as O2
.-
 (Ketonen et al., 2010). This chapter aimed 
firstly to investigate the role of AMPK in regulation of ROS production by looking at 
levels of O2
.-
 and peroxynitrite. Using confocal microscopy, experiments using DHE 
fluorescence as a measurement of O2
.-
 showed that there was no difference in the levels of 
O2
.- 
between WT and KO PVAT (Figure 4-1). The absence of a difference may be 
attributed to the DHE which is known to produce multiple fluorescent products with 
overlapping emission spectra, only one of which is specific to O2
.-
 (Fink et al., 2004, Zhao 
et al., 2003). DHE can be oxidized by oxidants other than O2
.-
, such as H2O2 and 
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cytochrome C which can produce excitation emissions that are relatively near the 
excitation emission of DHE. Therefore, the detection system used in this study will have 
captured the composite spectra of non-specific DHE products and therefore the intensity 
values reported may reflect not just O2
.-
 production by the PVAT but other radicals as well 
(Zhao et al., 2005). The issue of the DHE signal being nonspecific was investigated by 
incubating the PVAT with the superoxide scavenger SOD to enable O2
.-
 specific 
fluorescence to be estimated. There was a reduction in the intensity in both WT and KO 
PVAT which was inconsistent and variable and which suggests perhaps a low production 
of extracellular O2
.-
 that cannot be estimated by using unconjugated SOD. It has been 
reported that O2
.-
 has a restricted ability to diffuse through cell membranes and so 
endogenous SOD is largely confined to intracellular compartments (Szabo et al., 2007).  
Application of unconjugated SOD which has a limited permeability makes the 
interpretation of the current data difficult as it may have been unable to access the site of 
O2
.-
 generation. Alernatively, the current data suggest the need for more quantitative tools 
which are more specific for detecting O2
.-
 and also using a more permeable form of SOD 
such as polyethylene glycolated SOD (Laurindo et al., 2008, Beckman et al., 1988).  
Despite the findings that PVAT NO and O2
.-
 levels were similar in both WT and KO 
PVAT, the content of peroxynitrite (detected as nitrotyrosine) was greater in the KO PVAT 
(Figure 4-2), suggesting an imbalance in the NO pathway. Peroxynitrite is a strong oxidant 
and nitrating compound formed from the extremely rapid reaction between O2
.-
 and NO. 
The cellular source of NO is various NOS isoforms, whereas O2
.-
 sources include the 
mitochondrial electron transport chain, NADPH oxidase and xanthine oxidase. Moreover, 
a deficiency in NO substrate (L-arginine) or cofactors (tetrahydrobiopterin) can lead to 
uncoupling of NOS and a shift towards generation of O2
.-
 which will lead to oxidative 
stress (Liaudet et al., 2009). It is worth noting that the reaction of NO with O2
- 
depends on 
the ratio of superoxide to NO which means that peroxynitrite production does not depend 
on enhanced NO or O2
.- 
generation and that the generation of peroxynitrite under normal 
physiological conditions occurs when there are equal levels of both NO and O2
.- 
 (Pacher et 
al., 2007).  More importantly, the rate of the formation of peroxynitrite is greater than the 
rate of superoxide decomposition by SOD (Liaudet et al., 2009). Therefore, any minimal 
changes in the rate of NO and O2
.-
 generation can result in a substantially larger increase in 
the rate of peroxynitrite formation meaning that undetectable differences in NO and 
superoxide which were observed in this study, could manifest as significant differences in 
nitrotyrosine levels (Pacher et al., 2007). 
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In this study, nitrotyrosine levels were greater in aortic KO PVAT. A possible explanation 
of the difference is that mouse aortic PVAT has a similar morphology and gene expression 
profile to BAT, suggesting it performs similar functions (Frontini and Cinti, 2010, 
Fitzgibbons et al., 2011), which was also observed in chapter 3. In contrast to WAT, BAT 
is rich in mitochondria, reflected by the high metabolic activity and is a potent source of 
oxygen radicals (Cannon and Nedergaard, 2004, Lopez-Torres et al., 1991). Generation of 
oxygen radicals may contribute to an increased capacity to generate peroxynitrite (Radi et 
al., 2002). Deletion of AMPKα1 subunit in aortic PVAT was associated with increased 
nitrotyrosine expression, potentially due to augmented peroxynitrite production secondary 
to a disrupted metabolic and redox balance in the absence of AMPK.  
4.4.2 Effect AMPKα1 deletion on eNOS and NO levels 
Previous studies have demonstrated that eNOS is also expressed in white adipose tissue 
(Motoshima et al., 2004, Boyle et al., 2008). Another study using an immunohistochemical 
approach has reported eNOS staining within PVAT surrounding saphenous vein 
(Dashwood et al., 2007). The findings from the current study support previous data that 
PVAT (Figure 4-1A&B), and eNOS in the PVAT produce NO (Figure 4-4). The current 
study also showed that the levels of eNOS are downregulated in KO PVAT suggesting a 
potential link between AMPKα1 subunit and eNOS function in the PVAT. However, data 
from confocal analysis of DAF-2 fluorescence indicated no difference in the NO 
production between WT and KO PVAT. Furthermore, the production of NO by PVAT was 
supported using L-NNA which reduced NO-dependent fluorescence in both types of 
PVAT, albeit non-significantly and SOD, which caused a non-significant enhancement in 
NO-fluorescence (Figure 4-4). The absence of any difference in the NO fluorescence 
between WT and KO despite KO PVAT showing reduced levels of eNOS phosphorylation 
may be explained in two ways. Firstly, the NO fluorescence detected using DAF-2DA in 
the KO mouse may be a compensatory NO production from other NOS isoforms such as 
iNOS. Secondly, DAF-2DA is associated with high background fluorescence, believed to 
result from inherent fluorescent properties of the inactivated DAF-2 probe and its reaction 
products (Rodriguez et al., 2005). Low NO levels being produced in the PVAT may be 
obscured by background fluorescence and make the detection of any difference between 
KO and WT more difficult.  
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4.4.3 PVAT anticontractile effect in response to NO donor 
As the AMPKα1 KO exhibited reduced expression of eNOS and enhanced expression of 
peroxynitrite, which suggests a redox status imbalance, this study further aimed to examine 
the functional properties of the PVAT by looking at the PVAT anticontractile effect. Dose 
response curves to sodium nitroprusside which is known to act via endothelium-
independent generation of NO (Tesfamariam and Halpern, 1988) were constructed in WT 
and KO aortic rings with and without PVAT. In both WT and KO (Figure 4-5), the 
relaxation response to sodium nitroprusside was not altered by the presence of PVAT, as 
shown in another study (Gao et al., 2007). However, in vessels lacking PVAT, the 
maximum relaxation response to nitroprusside in WT aortic rings was significantly greater 
than that in KO aortic rings (Figure 4-5C). The explanation for this may be a dysfunctional 
vascular smooth muscle layer due to AMPKα1 subunit ablation and that AMPKα1 
expression in VSMCs is essential for NO-mediated relaxation. Although this study 
reported reduced eNOS expression in the PVAT, the regulatory role of AMPK on eNOS 
activity and the magnitude of contribution of NO produced by eNOS in the PVAT to the 
endothelium independent anticontractile mechanism of the PVAT needs to be characterised 
further. Therefore, application of SOD and or L-NAME in functional studies such as 
myography would be a suitable approach to investigate this mechanism. Furthermore, as 
the response to SNP is very low, it is possible to test the effect of PVAT NO using another 
nitric oxide donor such as MAHMA NONOate ( 6-(2-Hydroxy-1-methyl-2-
nitrosohydrazino)-N-methyl-1-hexanamine, NOC-9).  
4.5 Conclusion  
Comparison of PVAT from AMPKα1 KO and WT mice revealed no significant difference 
in O2
.-
 or NO availability, although nitrotyrosine expression was higher and there was 
reduced eNOS phosphorylation in KO aortic PVAT. Although functional studies did not 
show any significant effect of PVAT on sodium nitroprusside induced relaxation, the 
contribution of PVAT-derived NO on vascular relaxation and the anticontractile effect of 
PVAT cannot be ruled out and needs further investigation.  
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5.1 Introduction  
There is abundant evidence in the literature reported that obesity is a leading cause of 
insulin resistance, type 2 diabetes mellitus and increased blood pressure; all are major risk 
factors for cardiovascular disease (Gledhill et al., 2007). Generally, high-fat diet leads to 
adipocyte hypertrophy and the development of a low grade pro-inflammatory state 
(Jorgensen et al., 2004). As a result, there is increasing accumulation of macrophages and 
other leukocytes, particularly in obese adipose tissue (Weisberg et al., 2003). The function 
of adipocytes in storage of TAGs is also impaired, resulting in ectopic fat deposition in 
liver and skeletal muscle (Jorgensen et al., 2004). Furthermore, circulating adipose-derived 
pro-inflammatory cytokines, FAs and metabolites of this ectopic lipid are increased 
(Jorgensen et al., 2004). Excessive caloric intake is associated with increased secretion of 
proinflammatory adipokines such as TNF-α, leptin, IL-6, resistin, RBP4, lipocalin 2, IL-
18, ANGPTL2 and reduced antinflammatory adipokines such as adiponectin and omentin 
(Nakamura et al., 2014). These changes reported in HFD may extend to PVAT and trigger 
both structural and functional changes which result in dysfunctional vasculature (Maenhaut 
and Van de Voorde, 2011). 
Many studies have reported that the vasorelaxant function of PVAT is impaired in the 
presence of many pathophysiological conditions. Gao et al showed that the anticontractile 
effect of PVAT was reduced in spontaneously hypertensive rats (Lu et al., 2011a) and 
increased in streptozotocin-induced diabetic rats (Lee et al., 2009b). As obesity is 
associated with increased PVAT mass, it would be conceivable to expect an increased 
anticontractile effect of the PVAT due to enhanced PVAT-derived relaxing factors being 
released. However, it is now believed that obesity triggers structural and functional 
changes in PVAT which contribute to a loss or attenuation of the anticontractile effect. The 
loss of anticontractile effect has been reported in many studies. Chatterjee and co-workers 
reported that human coronary perivascular adipocytes exhibit a reduced state of adipocytic 
differentiation as compared with adipocytes derived from subcutaneous and visceral 
(perirenal) adipose depots. Secretion of adiponectin was significantly reduced, whereas 
that of proinflammatory cytokines interleukin-6, interleukin-8, and monocyte 
chemoattractant protein-1, was markedly increased in perivascular adipocytes (Chatterjee 
et al., 2009). It has been reported that the anticontractile effect of PVAT can be restored 6 
months following bariatric surgery to encourage weight loss and that this corresponded to a 
significant reduction in TNF-α and macrophage infiltration in the PVAT.  
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It should be emphasized that not only obesity, but other pathological insults such as 
hypertension and balloon inflation during percutaneous intervention may trigger changes 
within the PVAT. It has been reported that PVAT generates complement 3 (C3) which 
stimulates fibroblast migration and differentiation via JNK activation (Ruan et al., 2010). 
This effect was thought to contribute to adventitial remodelling and increased vascular 
stiffness reported in the deoxycorticosterone acetate–salt hypertensive rat (Ruan et al., 
2010). Furthermore, PVAT-released adipocytokines may enhance neointimal formation 
after vascular wire injury. In another study, transplantation of thoracic PVAT from donor 
mice fed a high-fat diet to the carotid arteries of recipient low-density lipoprotein receptor 
knockout mice also fed a high-fat diet was undertaken, followed by induction of 
intravascular wire injury after 2 weeks. The transplanted thoracic PVAT accelerated 
neointimal formation, adventitial angiogenesis, and macrophage infiltration (Manka et al., 
2014). Furthermore, the same study reported that transplanted PVAT from MCP-1-
deficient mice significantly reduced adventitial angiogenesis and neointimal hyperplasia 
with effects on macrophage infiltration (Manka et al., 2014). Indeed, PVAT inflammation 
induced by either HFD and/or intravascular wire injury contributes to vascular dysfunction 
including affecting the anticontractile activity of PVAT.   
Although it is known that the anti-contractile properties of PVAT are lost in obese patients 
and animal models (Greenstein et al., 2009), the underlying mechanism of PVAT 
dysfunction remains elusive. AMPK maintains energy homoeostasis (Carling et al., 2011) 
and is involved in regulation of glucose, lipid and protein metabolism (Hardie, 2008). 
These basic functions are known to be dysregulated in obesity and metabolic syndrome in 
which the activity of AMPK is diminished (Ruderman et al., 2013). An impaired AMPK 
function associated with obesity has been reported with reduced eNOS activity and 
upregulation of mTOR which contributes to vascular remodelling and endothelial 
dysfunction (Ma et al., 2010). Furthermore, endothelial dysfunction in obesity can be 
reversed by AMPK activation, which increases phosphorylation of eNOS and enhances 
NO bioavailability; an effect which involved adiponectin (Deng et al., 2010). Another 
study demonstrated that PVAT-derived adiponectin can induce PVAT-dependent 
hyperpolarisation of vascular smooth muscle cells via AMPK (Weston et al., 2013), and 
thus reduced AMPK activation could also modify the PVAT effect on vascular 
contractility.  
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In spite of the fundamental role AMPK plays in regulation of cellular and whole-body 
energy demands, the effect of a HFD, a major cause of obesity and its complications 
(Hariri and Thibault, 2010, Woods et al., 2003b), on AMPK in the PVAT has not been 
comprehensively investigated. The effect of diet-induced obesity on AMPK has most 
frequently been studied in endothelium and VSMCs (Ma et al., 2010, Weston et al., 2013, 
Rubin et al., 2005, Nagata et al., 2004, Igata et al., 2005). These types of studies have 
yielded consistent results, showing that AMPK acts as a protective mechanism against 
diet-induced obesity and vascular injury. To date, no study has investigated the role of 
PVAT AMPK in the response to HFD and vascular injury. Therefore, we hypothesised that 
AMPK expressed in PVAT would act as a protective mechanism against diet-induced loss 
of anticontractile effect and wire-induced injury. 
Aim of the study  
 To determine whether high HFD could affect AMPK function and thus the anti-
contractile properties of PVAT in mice aortae, and if so, to investigate the potential 
mechanisms involved. 
 To determine the whether wire-induced injury could affect AMPK function in the 
PVAT and thus the antiprolefertive response in mice carotid artery. 
5.2 Method and results 
5.2.1 High fat diet increased the weight of both wild type and 
AMPKα1 knockout  
Wild type (WT) (n =20) and AMPKα1 knockout (KO) (22) were divided into two groups 
and fed either a normal diet (ND) or a high fat diet (HFD) for 12 weeks starting at age 8 
weeks. Body weight was measured at the start of the study and at the time of culling. At 
the start of the experiment, there was no difference in the weight between WT and KO 
mice for each group (Figure 5-1). After 12 weeks, there was a significant increase in the 
weight of WT mice on ND (16.9 ±2.9 g (n=10) compared to 33.2 ± 3.1 g (n=11)) in HFD 
group. Similarly, HFD increased the weight of KO mice to 33.4 ± 5.5 g (n=11) compared 
to 13.6 ± 2.3 g (n=10) in KO mice fed ND. Overall, both WT and KO HFD groups gained 
more than 50% weight in comparison with the respective ND groups. Figure 5-2 represents 
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the percentage of weight gain in the HFD group in comparison with normal diet (ND) 
group. 
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Figure ‎5-1 The average baseline weight of WT and KO mice before starting the HFD. 
Wild type (WT) (n =20) and AMPKα1 knockout (KO) (n =22) were allocated randomly to ND and 
HFD groups and the weight of mice in each  group was measured prior to starting ND or HFD. 
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Figure ‎5-2 Weight gain in response to high-fat diet in wild type and AMPKα1 knockout mice.  
Body weights were recorded at the beginning and at the end of the 12 wks of the study. 
Percentage weight gain was calculated for normal diet group and HFD group in both WT and KO. 
**p<0.01 vs WT HFD, n = 10-11, **p<0.01 vs KO HFD, n = 10-12. 
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5.2.2 Effect of high-fat diet on vascular contraction 
The contractile response of thoracic aortic segments with or without attached PVAT from 
WT and KO mice on ND or HFD was measured in response to 3x10
-8
M of U46619 (Figure 
5-3). Aortic segments with and without PVAT were dissected from WT and KO mice in 
ND and HFD groups, cut into 2 mm segments and mounted on two 40 μm diameter wires 
in a small artery wire myograph as described in Section 2.5. Arterial rings were maintained 
in Krebs’ solution at 37 °C and gassed continuously with 95 % O2 and 5 % CO2. Following 
a 30 minute equilibration period, the arterial rings were exposed to 1 g tension for 30 min. 
Viability of arterial segments was measured with 40 mM KCl. Following this, the vessels 
were washed and then pre-constricted with U46619 for a further 30 minutes. Maximum 
contraction to U46619 was then recorded in grams and comapred between groups. The 
contraction of WT aorta without PVAT in ND group was 1.2 ± 0.3 g (n = 7) and was not 
significantly different from that reported in PVAT-free vessels from the HFD group (1.2 ± 
0.2 g; n = 7). The contraction in WT aorta with intact PVAT from HFD group was (1.4 ± 
0.3 g; n = 6) which was higher than that reported in the ND group (1.1 ± 0.1 g; n = 7) but 
did not reach statistical significance. There was no significant difference in contraction to 
U46619 in PVAT-free vessels from AMPKα1 KO mice in either the ND and HFD group 
(1.3 ± 0.2 g; n = 8 vs 1.4 ± 0.2 g; n = 6). Similarly, there was no statistical significance 
between vessels with intact PVAT in either the ND and HFD KO mice groups. The 
contraction in the ND group of KO mice with intact PVAT was 1.6 ± 0.2 g (n = 8) which 
was slightly higher than that in the KO HFD group (1.4 ± 0.2 g; n = 7; p = ns vs HFD 
intact PVAT arteries). Although the results did not show a significant difference between 
ND and HFD groups, the trend toward an enhanced contractile response in WT PVAT-
intact vessels from mice fed a HFD was observed. 
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Figure ‎5-3 Effect of high-fat diet on thromboxane A2 receptor agonist U46619 (3x10
-8
 M) 
induced contraction. 
Endothelium denuded, thoracic aortae with and without PVAT from WT and KO were dissected 
from ND and HFD groups and stimulated with U46619 for approximately 30 min and contraction 
measured on a myograph.  
 
5.2.3 Effect of high-fat diet on the anticontractile effect of PVAT 
At the end of the diet period, the anticontractile responses of the thoracic aorta to 
cromakalim were determined in WT and KO as described in section 2.5. Briefly, WT and 
KO thoracic aortae with and without PVAT from ND and HFD mice were preconstricted 
to U46619 and cumulative dose-response curves to increasing concentrations of 
cromakalim were constructed. In the ND group, the maximum relaxation to 10
-4
M 
cromakalim produced by aortic rings from WT mice with intact PVAT (83.3 ± 3.6%, n=7; 
Figure 5-2A) was significantly greater than that produced by aortic rings without PVAT 
(27.6 ± 2.8%, n=7). At the end of 12 week of HFD, the maximal responses to cromakalim 
in intact PVAT aortic rings was 54.3 ± 3.5%; n = 7 in comparison with rings lacking 
PVAT from the same group (25.9 ± 4.6%; n = 7; Figure 5-2 B). Overall, in comparison 
with ND, HFD reduced the maximum response in aortic rings with intact PVAT by 
approximately 30%, while there was no effect in vessels without PVAT (Figure 5-2C), 
suggesting partial dysfunction of the PVAT caused by HFD which attenuates the 
anticontractile effect.  
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In the AMPKα1 KO mice, maximal responses to cromakalim were not significantly 
different between vessels with or without intact PVAT in both ND and HFD diet groups. 
The maximum responses were: 32.01 ± 4.02% vs. 21.7 ± 5.3%; n=7; p=ns with ND 
(Figure 5-3A) and 35.3 ± 4.4% vs. 33.5 ± 8.6%; n=7; p=ns with HFD (Figure 5-3B) 
respectively. Comparison between ND and HFD groups showed no significant difference 
(Figure 5-3C).  
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Figure ‎5-4 Effect of HFD on cromakalim-induced relaxation in WT thoracic aorta.  
Dose-response curves to cromakalim were produced by wire myography in thoracic aortic rings 
with (+) and without (-) PVAT from WT mice fed ND or HFD. All vessels were without endothelium. 
(A) Dose-response curves to cromakalim in WT ND. (B) Dose-response curves to cromakalim in 
WT HFD. (C) Effect of HFD on cromakalim induced relaxation. ***p<0.001 vs ND PVAT(-), n = 6; 
***p<0.01 vs HFD PVAT(-), n = 6; ***p<0.001 vs ND PVAT(+). 
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Figure ‎5-5 Effect of HFD on the cromakalim-induced relaxation in AMPKα1 KO thoracic 
aorta.  
Dose-response curves to cromakalim were produced by wire myography in thoracic aortic rings 
with (+) and without (-) PVAT from KO mice fed ND (n = 6) or HFD (n = 6). All vessels were without 
endothelium. (A) Dose-response curves to cromakalim in KO ND. (B) Dose-response curves to 
cromakalim in KO HFD. (C) Effect of HFD on cromakalim induced relaxation.   
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5.2.4 Effect of high-fat diet on the morphology of PVAT 
To determine the effect of HFD on PVAT phenotype, WT and KO thoracic aortic rings 
from ND and HFD were processed, cut and stained as detailed in Section 2.4. thoracic 
arteries with intact PVAT were excised immediately after death and placed in 10% zinc 
formalin overnight. Arteries were processed through a gradient of alcohols to Histoclear 
and embedded vertically in paraffin wax before being sectioned on a microtome at  5 μm. 
H&E staining was performed and sections visualised by light microscopy. The results 
shown in Figure 5-6 indicated that 12 weeks of HFD had obvious effects on adipocyte 
phenotypic features in both WT and KO PVAT. In both groups, aortic PVAT was 
composed of adipocytes with the morphological features of brown adipocytes with 
multiple lipid vacuoles and central nucleus. The WT and KO adipocytes from the HFD 
group were hypertrophied with some scattered WAT adipocytes present in the PVAT 
dissected from KO mice (Figure 5-6D). 
Wild type 
AMPKα1 KO
Normal diet (Chow) High-fat diet 
C
A B
D
 
Figure ‎5-6 Effect of high-fat diet on thoracic PVAT phenotype from both WT and KO mice.  
Sections of WT and KO thoracic aortic rings were harvested from mice fed normal diet (chow) or 
high fat diet and stained with H&E. Nuclei appear blue/purple whereas cytoplasm is stained pink. 
Scale‎bar;‎20‎μm. Representative micrographs are shown. 
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To further test the effect of HFD on the phenotype of the PVAT, quantitative analysis of 
levels of the brown adipose tissue marker UCP-1 was performed. Expression of UCP-1 
was measured by Western blot analysis as detailed in Section 2.7. Briefly, WT and KO 
PVAT samples harvested from mice fed ND or HFD were dissected free and lyastes 
prepared. Protein estimation analysis from these lysates was performed and protein was 
added at 10 μg per well. Immunoblotting was performed with antibodies against UCP-1 
and GAPDH which was used as a loading control. Membrane visualisation of 
immunolabelled bands was carried out using an Odyssey Sa Infrared Imaging System (LI-
COR, USA) linked with Odyssey Sa Infrared Imaging System software (LI-COR, USA) 
(all antibody dilutions found in Table 2.5). The results showed that HFD increased the 
level of UCP-1 in both WT and KO PVAT in comparison with ND derived PVAT relative 
to GAPDH levels. In WT, HFD exhibited increased levels of UCP-1 (1.2 ± 0.03 vs 0.7 ± 
0.1 in ND). Similarly, the level of UCP-1 was significantly elevated by HFD in KO PVAT 
(1.3 ± 0.1 vs 0.83 ± 0.1 in ND).  
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Figure ‎5-7 Effect of HFD on UCP-1 levels in PVAT.  
Tissue lysates were prepared from thoracic aortic PVAT dissected from WT and KO mice fed ND 
or HFD and Western blotting was performed. UCP-1 level is presented as a ratio relative to the 
density of the GAPDH band to adjust for protein loading. The immunoblot shown is representative 
of (n= 4).  *p<0.05 vs WT PVAT (ND); *p<0.05 vs KO PVAT (ND).  
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5.2.5 Effect of high-fat diet on AMPK level and activity 
To examine the effect of HFD on AMPK level and activity, WT and KO thoracic aortic 
rings from both ND and HFD groups were analysed by immunohistochemistry for total 
and phospho-AMPKα (Thr172). Aortic rings dissected from WT and KO fed on ND or 
HFD were processed, cut and stained as detailed in Section 2.3.3. In brief, WT and KO 
thoracic aortae were excised immediately after death and placed in 10% acetic zinc 
formalin overnight. Arteries were processed through a gradient of alcohols to Histoclear 
and embedded vertically in paraffin wax before being cut into 5 μm sections. Polymer-
based immunohistochemistry was used to evaluate expression of total and phospho-
AMPKα in PVAT from WT and KO mice fed on ND or HFD. Figure 5-8 shows 
photomicrographs of total AMPKα in ND and HFD groups. Although there was an 
obvious reduction in staining intensity of total AMPKα and phospho-AMPKα in KO 
PVAT in comparsion with WT PVAT, there was no significant difference caused by HFD 
in either strain.  Immunohistochemical staining of total AMPKα in both WT and KO aortic 
PVAT showed no difference in the staining intensity in WT (Figure 5-8A&D) and KO 
(Figure 5-8 G&J). Similarly, staining for phospho-AMPKα showed almost similar staining 
intensity in WT of the HFD group in comparison with WT of the ND group (Figure 5-
9A&D). Thoracic aortic rings of KO mice of both ND and HFD group did not show any 
obvious difference in phospho-AMPKα level (Figure 5-9G&J).   
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Figure ‎5-8 Effect of HFD on AMPKα levels in WT and KO PVAT.  
Representative histological sections of WT and KO thoracic aorta with intact PVAT from normal 
diet (ND) and high fat diet (HFD) mice stained with anti-AMPKα‎antibodies‎and‎counterstained‎with‎
haematoxylin. (A,D,G,J) Positive staining is indicated by brown colour. (B,E,H,K) Negative control 
represents aortic rings with anti-AMPKα‎ primary antibodies only; (C,F,I,L) Blank (untreated) 
represents‎aortic‎section‎without‎treatment.‎Scale‎bar‎20μm. 
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Figure ‎5-9 Effect of HFD on phospho-AMPKα levels in WT and KO PVAT.  
Representative histological sections of WT and KO thoracic aorta with intact PVAT from normal 
diet (ND) and high fat diet (HFD) mice stained with anti-phospho-AMPKα‎(Thr172) antibodies and 
counterstained with haematoxylin. (A,D,G,J) Positive staining is indicated by brown colour. 
(B,E,H,K) Negative control represents aortic rings with anti-AMPKα‎ primary‎ antibodies‎ only;‎
(C,F,I,L)‎Blank‎(untreated)‎represents‎aortic‎section‎without‎treatment.‎Scale‎bar‎20μm. 
 
 
To further clarify the effect of HFD on AMPK level and activity, quantitative analysis of 
levels of total and phosphorylated form of AMPK was performed. Briefly, WT and KO 
PVAT samples harvested from mice fed ND or HFD were dissected free and lyastes was 
prepared. Protein estimation analysis from these lysates was performed and protein was 
added at 10 μg per well. Immunoblotting was performed with antibodies against total and 
phospho-AMPK, and total and phospho-ACC and GAPDH which was used as a loading 
control. Membrane visualisation of immunolabelled bands was carried out using an 
Odyssey Sa Infrared Imaging System (LI-COR, USA) linked with Odyssey Sa Infrared 
Imaging System software (LI-COR, USA). The results are illustrated in Figure 5-10. HFD 
significantly reduced the level of total AMPKα of WT PVAT (1.1 ± 0.24 vs 1.6 ± 0.2 in 
ND). Similar findings were observed in the level of phospho-AMPKα which was reduced 
significantly in HFD from 1.13 ± 01 down to to 0.9 ± 0.2. However, HFD had no effect on 
either total or phospho-AMPKα in KO mice (Figure 5-10 B&C). When measured as a ratio 
of phospho- to total-AMPKα and phospho-AMPK to total ACC, there were also significant 
reductions in response to HFD in WT but not KO mice (Figure 5-10 D&E). 
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Figure ‎5-10 Effect of high-fat diet on phosphorylation and activity of the AMPK in the PVAT.  
Lysates of PVAT from WT and KO mice fed ND and HFD were immunoblotted with the indicated 
antibodies. (A) Representative immunoblots are shown. (B,C) Quantitative analysis of 
immunoblots, expressed as the ratio of the phosphorylated‎(B)‎and‎total‎form‎of‎AMPKα‎divided‎by‎
GAPDH (C). (D) Quantitative analysis of immunoblots, expressed as the ratio of the 
phosphorylated‎ form‎ of‎ the‎ enzyme‎ divided‎ by‎ total‎ AMPKα.‎ (E)‎ Quantitative‎ analysis‎ of‎
immunoblots, expressed as the ratio of the phosphorylated form of ACC divided by total ACC. 
*p<0.05 vs WT PVAT (HFD), n = 3; **p<0.01 vs WT PVAT (HFD), n = 3; **p<0.01 vs KO PVAT 
(ND).  
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5.2.6 Effect of HFD on the inflammatory phenotype of PVAT 
To test the effect of HFD on the inflammatory phenotype of the PVAT in both WT and KO 
mice, immunohistochemical staining with anti-MAC2 antibodies was performed. In brief, 
aortic rings from WT and KO mice fed ND or HFD and spleen were dissected and placed 
in 10% acetic zinc formalin overnight. Arteries were processed through a gradient of 
alcohols to Histoclear and embedded vertically in paraffin wax and cut into 5 μm sections. 
Sections of spleen were also prepared. Immunohistochemistry was used to evaluate the 
level MAC2 in PVAT from WT and KO mice fed on ND or HFD and spleen was used as a 
positive control. Histological analyses revealed considerable macrophage infiltrates in 
PVAT of KO mice compared to WT fed on ND (Figure 5-11 D&F). 12 weeks of HFD was 
accompanied by increased macrophage infiltration in WT PVAT compared to ND fed mice 
(p = 6, p<0.05; Figure 5-11 H). There was no significant difference in the intensity of 
MAC2 the staining in KO PVAT between the ND and HFD group (Figure 5-11 F&G). 
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Figure ‎5-11 Effect of high-fat diet on inflammatory phenotype of WT and KO PVAT.  
Representative histological sections of WT and KO thoracic aorta with intact PVAT from normal 
diet (ND) and high fat diet (HFD) mice stained with anti-MAC2 antibodies and counterstained with 
haematoxylin. Images shown are representative (A). (A,B,C) WT spleen anti-MAC2 antibody. (D) 
WT PVAT of ND mice; (E) WT PVAT of HFD; (F) KO PVAT from ND mice; (G) KO PVAT from HFD 
mice. Data were expressed as percentage of stained cells to total nuclear area in the section. **p 
<0.01 vs WT PVAT (ND); *p<0.05 vs WT PVAT (ND). 
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5.2.7 Effect of High-fat diet on adiponectin release 
To examine the effect of HFD on adiponectin release from PVAT, adiponectin in 
conditioned media samples from WT and KO PVAT from ND and HFD groups were 
analysed by ELISA. PVAT samples were collected from WT and KO mice fed ND or HFD 
and incubated in Krebs solution for 1 hour at 37 ̊C and ELISA was performed as described 
in section 2.5. There was a significant reduction (approximately 70%) in the adiponectin in 
CM collected from WT PVAT of HFD mice compared to ND mice (n = 6, p<0.01; Figure 
5-12). Similarly, there was a significant decrease in CM collected from KO mice fed ND in 
comparison with WT mice fed ND (n = 6, p<0.01; Figure 5-12). However, HFD had no 
effect on adiponectin secretion by PVAT of KO mice compared with ND (n = 6, p =ns). 
 
W
T 
(N
D
)
W
T 
(H
FD
)
K
O
 (N
D
)
K
O
 (H
FD
)
0
5
10
15
20
25
**
**
*
A
d
ip
o
n
e
c
ti
n
(n
g
/m
L
)
 
Figure ‎5-12 Effect of HFD on adiponectin release.  
CM samples were collected from WT and KO PVAT from mice fed ND or HFD (n = 6) and 
adiponectin ELISA was performed. **p<0.01 vs WT ND CM, *p<0.05 vs WT CM. 
 
5.2.8 Effect of vascular injury on the PVAT phenotype 
To test the hypothesis that PVAT contributes to the vascular response to wire injury and 
investigate the role of AMPK in this response, right and left carotid arteries from WT and 
KO mice were utilised. The vessels utilised in this study were used in a previous study 
performed in our lab. This study involved induction of vascular injury using a wire inserted 
into the left carotid artery (LCA) in both WT and KO mice. Right carotid artery was not 
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injured and used as a control . After a week of wire injury, mice were sacrificed and 
carotid arteries with surrounding PVAT were dissected. 
Firstly, the morphology of PVAT was evaluated using H&E which showed that in both 
WT and KO carotid arteries, the vessel was surrounded by BAT like adipocytes with the 
characteristic multiple lipid vacuoles and central nuclei (Figure 5-13). Although there was 
marked intimal thickening in both WT and KO LCAs and although the thickening was 
more pronounced in the KO derived LCAs, there was no phenotypic change in the 
surrounding adipocytes. The difference in the intimal thickening was not evaluated as it 
was not part of the current study. 
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Figure ‎5-13 Effect of wire injury on carotid PVAT phenotype from both WT and KO mice.  
Representative H&E stained sections harvested from WT and KO right carotid arteries (RCA) and 
left carotid arteries (LCA). Representative images are shown. Nuclei appear blue/purple whereas 
cytoplasm‎is‎stained‎pink.‎Scale‎bar;‎20‎μm. 
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5.2.9 Inflammatory response of WT and KO PVAT to vascular 
injury 
To test the hypothesis that PVAT contributes to the vascular response to wire injury and to 
investigate the involvement of AMPK in regulation of this response, WT and KO carotid 
arteries with intact PVAT were utilised. As stated previously, wire injury was performed in 
LCA from both WT and KO and RCA was used as a control of the experiment in both 
types of mice. After a week of wire injury, mice were sacrificed and carotid arteries with 
surrounding PVAT were dissected. Immunohistochemistry using anti-MAC2 antibodies 
was performed to quantify PVAT macrophage infiltration.  
LCAs from both WT and KO mice exhibited an obvious intimal thickening. In WT, 
vascular injury was associated with significant macrophage infiltration in LCA in 
comparison with control RCA (n = 4-5, **p<0.01; Figure 5-14 E). Although there was no 
significant difference in MAC2 between RCA and LCA of KO mice, there was a trend 
towards increased inflammatory infiltration (Figure 5-14 E; n = 3-4, p = ns).  
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Figure ‎5-14 Inflammatory response of WT and KO PVAT to vascular injury.  
Representative histological sections of WT and KO right and left carotid arteries with intact PVAT 
stained with anti- MAC2 antibody and counterstained with haematoxylin. Figures shown are 
representative (A). (A) Control WT RCA stained anti-MAC2 antibody. (B) 1 week post wire induced 
injury WT LCA. (C) Control KO RCA stained anti-MAC2 antibody. (D) 1 week post wire induced 
injury KO LCA .WT PVAT of HFD (F) KO PVAT from ND mice (G) KO PVAT from HFD mice. Data 
were expressed as percentage of stained cells to total nuclear area in the section. **p <0.001 vs 
WT RCA. 
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5.3  Discussion  
This study investigated the effect of HFD on PVAT regulation of conduit artery tone in 
WT and AMPKα1 KO mice. The novel finding of the current research was that the anti-
contractile effect of PVAT was significantly diminished in WT mice fed a HFD compared 
to those maintained on chow diet. The loss of anti-contractile function could be due in part 
to a reduction in PVAT-derived adiponectin release, due to AMPK dysfunction and/or 
inflammation of the PVAT.  
5.3.1 Effect of HFD on anticontractile effect of PVAT 
In the present study, thoracic aortae with intact PVAT and endothelium removed showed 
the greatest contractile response to U46619 in WT HFD group fed HFD in comparison 
with the ND group, although the difference was not statistically significant. The contractile 
response in vessels with intact PVAT in KO was similar in both control and HFD mice. 
Additionally, there was no difference in contraction in vessels with the PVAT removed 
across all groups. The endothelium-independent relaxation response to cromakalim was 
significantly reduced in HFD WT compared to ND arteries. The response of PVAT-free 
vessels was similar in both ND and HFD group. However, in KO mice there was no 
difference in relaxation between PVAT intact and removed vessels or in animals fed ND or 
HFD KO. Combination of both the U46619 and cromakalim experiments suggest that 
vascular dysfunction is at the level of the PVAT rather than medial layer and that AMPK 
might act as a protective mechanism as the anticontractile response was not completely lost 
in obese WT mice fed HFD.  
The current results are consistent with previous studies reporting that PVAT-mediated 
anticontractile effect is impaired in HFD models (Fesus et al., 2007, Ma et al., 2010, 
Greenstein et al., 2009, Gao et al., 2005a, Owen et al., 2013, Nakagawa et al., 2002, Payne 
et al., 2010, Marchesi et al., 2009). Gao and co-workers reported that the anticontractile 
effect is lost in obese rats due to reduced release of relaxing factor despite the increased 
amount of PVAT around rat aorta (Gao et al., 2005a). A loss of the anticontractile effect of 
PVAT was also reported in obese New Zealand mice (NZO) model which was 
characterised by metabolic syndrome and larger amounts of PVAT. The lost function was 
suggested to be due to changes in the expression of PVAT-derived factors other than 
adiponectin (Fesus et al., 2007). In the Ossabaw swine model and using a proteomic 
profiler, there was an up-regulation of 186 PVAT-derived proteins which was associated 
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with increased coronary contractility and these included transforming protein RhoA and 
calpastatin (Owen et al., 2013).  
5.3.2 Eeffect of HFD on PVAT phenotype 
The mechanisms underlying the effect of AMPK in regulating adipose tissue mass are 
poorly characterised. Adipose tissue mass expansion occurs as a consequence of either an 
increase in adipocyte number as a result of enhanced adipogensis, an increase in cell size 
due to fat deposition in pre-existing cells, or a combination of both. It has been reported 
that the increase in adipose tissue mass in AMPKα2 knockout mice was due to an 
increased triglyceride accumulation in the preexisting adipocytes rather than an increase in 
cell number or differentiation as no changes in the expression of adipocyte transcription 
factors, PPARγ, C/EBPα, or the mature adipocyte markers, including aFABP/aP2, were 
reported (Villena et al., 2004). The model used in the current study is a global AMPKα1 
knockout mouse and the findings indicate that adiponectin was reduced by HFD although 
no attempt was made to examine the transcription factor involved in regulation of cell 
differentiation such as PPARγ.  
The study also looked at the effect of HFD on the brown adipose tissue marker UCP-1. As 
a general rule, prevention of the development of obesity is dependent on energy 
expenditure. The uncoupling of oxidative phosphorylation in BAT by UCP-1 plays a 
critical role in protecting the body from hypothermia or a hyperlipidaemic diet (Glavind-
Kristensen et al., 2004, Cannon and Nedergaard, 2004). It was reported that increased 
expression of UCP-1 was associated with a decrease in the ATP/ADP and ATP/AMP 
ratios in the subcutaneous white fat of transgenic mice, increased activity of AMPK and 
enhanced oxidation of FA (Rossmeisl et al., 2004). Furthermore, it is well known that HFD 
increase UCP-1 mRNA and protein expression in BAT (Garcia-Ruiz et al., 2015). 
Therefore, it is plausible to think that HFD will result in an increased expression of UCP-1 
in PVAT as a mechanism of dissipating energy and that this will be associated with 
increased AMPK activity in WT but not in AMPKα1 KO. Indeed, the results from the 
current study revealed an enhanced level of UCP-1 not only in WT but also KO in 
response to HFD (Figure 5-7) and was associated with reduced AMPK activity (Figure 5-
10). The enhanced UCP-1 level in PVAT in both WT and KO in response to HFD can be 
explained by UCP-1 expression being regulated by many other mechanisms. It has been 
reported that the expression of UCP-1 can be increased in response to fatty acids (Cannon 
and Nedergaard, 2004). Another mechanism which can be proposed is involvement of 
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thyroid hormones (Guerra et al., 1996). Thyroid hormones (THs) are well known 
regulators of body energy expenditure (Klieverik et al., 2009). Treatment with THs has 
been reported to increase UCP-1 expression in BAT in rats as a result of binding to TH-
responsive elements in the UCP1 promoter (Guerra et al., 1996). As thoracic PVAT 
exhibits BAT like features, it would be logical to think that the increased UCP-1 in both 
WT and KO occurs in response to circulating THs. Therefore, investigation of THs levels 
would be beneficial to assess the mechanism on UCP-1 elevation.  
5.3.3 Effect of HFD on inflammatory phenotype of PVAT 
Another question addressed in the current study was whether AMPK could affect the 
inflammatory phenotype of PVAT in response to HFD. The results showed increased 
macrophage infiltration indicated by increased MAC2 expression in HFD exposed WT 
mice. The increased MAC2 level in WT PVAT in the HFD group was associated with 
reduced AMPK activity in the PVAT (Figure 5-11). Therefore, it can be speculated that 
AMPK acts as a protective mechanism against inflammation and this effect is lost due to 
HFD-induced obesity. However, KO PVAT exhibit increased MAC2 expression under 
both ND and HFD conditions. These results further support the protective anti-
inflammatory role of AMPK in the PVAT and that the absence of any difference between 
ND and HFD groups in the KO mice may be due to that fact the PVAT of ND KO mice is 
already maximally inflitrated or as a result of a compensation mechanism by AMPKα2 
complexes preventing further inflammatory cell infiltration which needs further 
investigation. Indeed, these results support previous studies that demonstrated the loss of 
the anicontractile effect of PVAT in obesity (Marchesi et al., 2009, Rebolledo et al., 2010, 
Bailey-Downs et al., 2013, Chatterjee et al., 2009, Wang et al., 2012). HFD-induced 
obesity as discussed previously can impair PVAT anticontractile effect via promoting a 
marked proinflammatory shift in cytokines and chemokines which is associated with 
oxidative stress in the PVAT (Bailey-Downs et al., 2013). PVAT inflammation and 
oxidative stress can lead to endothelial dysfunction and decreased NO bioavailability and 
increased superoxide generation by uncoupled endothelial NO synthase in PVAT 
(Marchesi et al., 2009). Moreover, HFD induced PVAT dysfunction via increased 
macrophage accumulation in the PVAT and vascular oxidative stress (Wang et al., 2012). 
It has been reported that human coronary PVAT collected from organ donor candidates 
exhibits an enhanced release of IL-6, IL-8 and MCP-1 and reduced adipocyte 
differentiation (Chatterjee et al., 2009). These results indicate that inflammatory cytokines 
released by PVAT act as chemoattractants for macrophages and aggravating inflammation. 
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In contrast to the previous studies, Fitzgibbons and coworkers have shown that thoracic 
PVAT exhibits a very low grade of inflammation after 13 weeks of HFD. They proposed 
that the lack of effect was due to its similarities with BAT and because BAT-like adipose 
tissue is resistant to HFD-induced inflammatory changes (Fitzgibbons et al., 2011). When 
contrasting the Fitzgibbons findings to the current study, althought it used similar HFD 
period, it can be argued that Fitzgibbons et al study is conducted in a completely different 
mouse strain (C57BL6/J) and the low level of inflammation detected in this study may be 
related to the type of HFD used in the study. 
Another important leading cause of PVAT anticontractile dysfunction is that HFD causes a 
rise in the inflammatory adipocytokine leptin and chemokine MIP1α concomitant with a 
decrease in the expression of adiponectin, PPARγ and FABP4 (Chatterjee et al., 2009). 
Although, the current study did not address adipokine leptin and inflammatory cytokines, 
the results showed reduced release of adiponectin from PVAT in WT and KO exposed to 
HFD. The findings from the current study support the previous evidence that 2 weeks HFD 
is associated with significant reduction of adiponectin expression (Chatterjee et al., 2009). 
In contrast to the Chatterjee study and the findings from the current study, Ketonen et al 
reported completely different results. They reported that 8 months of HFD in C57BL6/J 
mice had no effect on the adiponectin expression in the thoracic PVAT (Ketonen et al., 
2010). Although both studies utilised the same mouse strain, the completely different 
results can be attributed to type of diet used and that the period of feeding used in 
Ketonen’s study may lead to adiponectin being upregulated to overcome HFD induced 
PVAT dysfunction.  
Several lines of evidence reported that AMPK activation is associated with increased 
secretion or expression of adiponectin by suppression of inflammatory cytokines such as 
TNF-α and IL-6 (Lihn et al., 2004, Sell et al., 2006, Tsuchida et al., 2005). Activation of 
AMPK with AICAR in human adipose tissue was associated with degradation of TNF-α 
and increase adiponectin gene expression (Lihn et al., 2004). TNF-α and IL-6 are known 
shown to have inhibitory effects on adiponectin gene expression and release (Fasshauer et 
al., 2002, Fasshauer et al., 2003). Moreover, TNF-α has been suggested to play a central 
role in regulating adiponectin levels (Greenberg et al., 1991). It can be speculated that the 
decrease in TNF-α protein may be involved in the up-regulation of adiponectin mRNA 
levels (Lihn et al., 2004). Sell et al reported activation of AMPK by AICAR and 
troglitazone was associated with reduction of IL-6, IL-8, MIP-1α/β, and MCP-1 and 
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upregulation of adiponectin expression (Sell et al., 2006). Similar findings demonstrate that 
the expression of inflammatory genes inculding TNF-α, MCP-1, and macrophage antigen-
1 in WAT was reduced in response to PPARα agonist rosiglitazone (Tsuchida et al., 2005). 
The increase in the expression of macrophage markers reported in HFD and KO animals 
may be due to loss of AMPK antifilammatory activity leading to upregulation of 
inflammatory cytokines such as TNFα and IL-6 and downregulation of adiponectin. 
Therefore, investigation of cytokine expression in PVAT would be beneficial to further 
characterise the role of AMPK.  
5.3.4 AMPK protects PVAT againest endovascular injury 
Obesity-induced inflammation in periadventitial adipose tissue is associated with 
upregulation of inflammatory adipocytokines and downregulation of the antiinflammatory 
adipocytokine adiponectin (Takaoka et al., 2009). These changes were associated with 
enhanced neointima formation after endovascular injury. Endothelial injury induces 
adhesion and migration of leukocytes, macrophages, and bone marrow–derived progenitor 
cells into the vessel wall (Beckman et al., 1990, Sata et al., 2000). Furthermore, pro-
inflammatory cytokines have a fundamental role in mediating the initiation and 
progression of vascular lesion formation (Serrano et al., 1997, Libby, 2002, Beckmann et 
al., 1994, Xie et al., 2008).  
Takaoka et al provide direct evidence that PVAT may protect against neointimal formation 
after angioplasty in lean status and that inflammatory changes in the periadventitial fat may 
have a direct role in the pathogenesis of vascular disease accelerated by obesity. They also 
suggested that adiponectin released from PVAT may play a protective role in neointima 
formation of the adjacent artery after vascular injury in lean mice (Takaoka et al., 2009). In 
this study, PVAT removal enhanced neointimal hyperplasia following endovascular injury 
in the femoral artery. Transplantation of subcutaneous fat from a normal mouse to 
surround the injured artery significantly reduced neointimal formation. These results 
demonstrate that PVAT may possess a protective role in neointimal hyperplasia (Takaoka 
et al., 2009).  
In line with the previous findings, the protective effect of exogenous adipose tissue was 
lost when transplanted subcutaneous adipose tissue was derived from obese mice. This is 
likely related to phenotypic changes in adipose tissue associated with obesity. These 
changes include reduced production of anti-inflammatory adiponectin and increased pro-
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inflammatory adipokines; IL-6, MCP-1, TNF-α and PAI-1 in subcutaneous adipose tissue-
conditioned medium from obese mice compared with that from normal mice (Takaoka et 
al., 2010). In the same study, the conditioned medium derived from the subcutaneous 
adipose tissue of normal mice attenuated VSMC proliferation stimulated by platelet-
derived growth factor (PDGF)-BB (Takaoka et al., 2010). On the other hand, the 
conditioned medium from obese mice increased VSMC proliferation, which was 
attenuated by pretreatment with anti-TNF-α antibodies. Furthermore, the conditioned 
medium of adiponectin-deficient subcutaneous adipose tissue enhanced VSMC 
proliferation. These findings reveal that TNF-α secreted from adipose tissue increased 
VSMC growth, and that adiponectin secreted from adipose tissue inhibited VSMC growth 
in response to PDGF-BB stimulation (Takaoka et al., 2010).  
In the current study, the role of AMPK in regulation of PVAT inflammatory phenotype in 
response to intravascular wire injury was investigated. PVAT in both WT and KO carotid 
arteries composed of brown adipocytes with its multiple lipid vacuoles and central nuclus 
(Figure 5-13). These data support the findings reported by Cinti et al who reported that 
PVAT surrounding carotid artery possess the characteristic of BAT (Cinti, 2011). It also 
supported our view in chapter 3 that AMPK has no effect on the morphological feature of 
the PVAT. One week after wire injury induced in both WT and KO LCAs, there was an 
obvious intimal thickening in both strains and it was associated with increased macrophage 
infiltration in both intima and PVAT (Figure 5-14). It is worth noting that the thickening of 
the intima was visually more in the KO LCA in comparison with WT LCA, although no 
measurement was done. However, these data need further investigation. The results of 
current analysis show increased MAC2 expression in both WT and KO. The expression of 
MAC2 was more pounced in WT LCA in comparison with its control RCA. Additionally, 
there was a trend toward increased expression in KO LCA in contrast to RCA. The lack of 
statistical difference in KO derived vessels suggests that loss of AMPK is associated with 
increased inflammation of PVAT in KO of control and injured vessels and also that AMPK 
might act as protective mechanism against vascular intimal thickening associated with 
vascular injury. It is known that activation of AMPK in VSMCs reduced intimal 
hyperplasia by either inducing cell cycle arrest by upregulation of p53-p21 which inhibits 
VSMCs proliferation (Igata et al., 2005) or reducing protein synthesis mediated via 
inhibition of mTOR (Kim et al., 2014, Inoki et al., 2003). Furthermore, the implication of 
PVAT AMPK came from study by Ma et al who reported that PVAT can induce vascular 
dysfunction via dysregulation of the AMPK/mTOR signalling pathway in diet-induced 
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obese rat. They demonstarted that incubation of mesenteric arterial rings with periaortic fat 
from HFD rats caused attenuated endothelium-dependent relaxation and down-regulation 
of AMPK and eNOS in the aorta with a concurrent up-regulation of mTOR. This effect 
was absent in periaortic fat from rats on a chow diet. In the same study, co-culture of 
vascular SMCs with periaortic adipocytes from HFD animals also reduced AMPK 
phosphorylation and increased mTOR phosphorylation (Ma et al., 2010). 
The findings from the current study revealed that adiponectin release was reduced in KO 
mice and this was associated with reduced expression of AMPK in PVAT (Figure 5-12). 
Therefore, it can be speculated that AMPKα1 deletion in PVAT leads to a reduction in the 
adiponectin release and loss of the protective function of the PVAT. The results in WT 
wire-injured LCA can be explained due to inflammation of the PVAT causedby vascular 
injury with increased macrophage infiltration and associated expression of inflammatory 
cytokines and reduction of antiinflammatory factors such as adiponectin. Current results 
support the evidence from other experiments that adiponectin suppresses cell proliferation 
induced by a low dose of oxidized low density lipoprotein (Motoshima et al., 2004). 
Exogenous adiponectin suppressed PDGF-BB-induced VSMC proliferation via AMPK 
activation (Igata et al., 2005). The AMPK pathway is also involved in the effect of 
adiponectin to inhibit the expression and activity of iNOS, secretion of adventitial 
antiinflammatory factors, division, proliferation and translation of adventitial fibroblasts, 
change of adventitial fibroblasts to myofibroblasts, and oxidative/nitrative stress which 
reduce atherosclerotic plaque area and stabilize atherosclerotic plaque (Cai et al., 2008). 
Thus, changes in adiponectin secretion by inflamed PVAT could also influence the reponse 
to vascular injury. 
5.4 Conclusion 
Taken together, HFD and wire injury are associated with increased macrophage infiltration 
and reduced AMPK activity in thoracic and carotid PVAT. Marked reduction in AMPK 
activity in WT PVAT, accompanied with the reduction in the release of adiponectin in 
HFD and KO animals may explain the impaired vascular function including loss of an 
anticontractile effect antiathergenic function. Further studies are needed to investigate the 
expression of different adipokines and cytokines released by PVAT exposed to HFD and 
intravascular injury.   
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6.1 The hypothesis 
The concept that adipose tissue is a functional endocrine organ involved in energy 
haemostasis was a huge step toward a greater understanding of the molecular basis of 
obesity and its co-morbidities. The link between obesity and CVD is further supported by 
Yudkin et al who speculated that PVAT might be the element that links obesity, insulin 
resistance and vascular disease due to its detrimental effects on blood vessels in obese 
people (Yudkin et al., 2005). PVAT is now considered a highly active endocrine organ that 
releases a variety of adipocytokines, and other factors which influence vascular tone in a 
paracrine manner. Under normal physiological conditions, PVAT can release 
adipocytokines which can attenuate contractility of the underlying vessel. The precise 
mechanism is still undefined, although some evidence suggests that PDRF may induce the 
anti-contractile effect via both endothelium-dependent and -independent mechanisms (Gao 
et al., 2007). Both mechanisms have been reported to involve AMPK, the cellular energy 
regulator. AMPK activation can induce vasodilation via phosphorylation and activation of 
endothelial NO synthase (eNOS) at Ser1179 (Morrow et al., 2003, Davis et al., 2006) and 
Ser663 (Chen et al., 2009) to increase NO production and vascular relaxation (Morrow et 
al., 2003, Davis et al., 2006). AMPK can also induce endothelium-independent relaxation 
via reduced sensitivity of myosin light-chain kinase (MLCK) to intracellular calcium 
(Horman et al., 2008). Although AMPK is expressed throughout the vessel wall, its role in 
the regulation of PVAT had not been investigated prior to this study. Therefore, the 
primary hypothesis was that AMPK is required for PVAT to function normally and that the 
α1 isoform is the most important isoform in mediating PVAT function. Therefore, the aim 
of this thesis was to investigate the role of AMPKα in the regulation of PVAT anti-
contractile function using a mouse with a global AMPKα1 isoform knockout. 
The data reported in this study demonstrate that PVAT has a profound anti-contractile 
effect on mouse thoracic aorta. The effect may be due to release of a transferable factor 
and that factor is likely to be adiponectin, release of which is regulated by the activity of 
AMPKα1. Furthermore, AMPK activity may regulate adiponectin secretion by either 
directly targeting its release from adipocytes and/or indirectly by its anti-inflammatory 
function which would limit the suppression of adiponectin expression. The studies in this 
thesis demonstrate that in mouse aortic rings, adiponectin augments relaxation to 
cromakalim in an endothelium-independent manner although other effects of adiponectin 
on the endothelium cannot be ruled out. Indeed, although aortic rings in this study were 
mechanically denuded, endothelial cells in vessels within the vasa vasorum will not be 
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affected and adiponectin could affect endothelial functiojn in these microvessels. The 
current research also reported that HFD-induced obesity is associated with a profound 
reduction in PVAT-mediated anti-contractile effects. Furthermore, HFD- induced obesity 
was associated with reduced AMPK activity, increased macrophage infiltration and a 
marked decrease in adiponectin release, all of which may contribute to dysfunctional 
PVAT.  
6.2 The anticontractile effect of PVAT under basal 
conditions 
Most blood vessels are surrounded by PVAT which may be predominantly WAT or a 
combination of BAT and WAT. The majority of the experiments in the thesis used conduit 
vessels, (thoracic aorta) which are surrounded by a mixture of WAT and BAT. The overall 
results suggest that brown PVAT can release adiponectin under the basal (unstimulated) 
state and that this may act as a PVAT-derived anticontractile factor (PDRF). Furthermore, 
AMPK regulates the secretion and/or function of this PVAT-derived adiponectin 
(Almabrouk et al., 2016).  
6.3 U46619 as contractile agent  
Like white PVAT, brown PVAT can also release factors and has anti-contractile effects on 
the surrounding vessels as reported in both rat (Lohn et al., 2002, Gao et al., 2007) and 
human internal thoracic aortas (Gao et al., 2005b). The anticontractile effect of the PVAT 
has been reported to different contractile agents including angiotensin II, 5-HT, 
phenylephrine (Lohn et al., 2002) and U46619 (Verlohren et al., 2004). These spasmogens 
are known to induce different types of contraction. Phenyephrine induces tonic 
contractions or initial vasoconstrictions followed by diameter oscillations (Inoki et al., 
2003). Angiotensin II causes a biphasic contraction which rises rapidly and transiently and 
peaks in a few minutes, before declining to a lower steady level (Hardie, 2016). 5-HT 
induces a strong contraction which lasts for a long time in rat thoracic aorta (Ratz and 
Flaim, 1984). However, U46619 causes a tonic vascular contraction which is associated 
with a reduction in the diameter of the artery. In the case of U46619, the contraction 
induced is stable and the PVAT anticontractile effect is sub-maximal. Therefore, U46619 
was utilised as contractile agent in this project to allow the effects of PVAT on relaxation 
to several vasodilators to be studied. Indeed, the use of U46619 only in the current thesis is 
a potential limitation as the effects of AMPK ablation may be specific to mechanisms after 
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U46619 -mediated contraction. Therefore, it would be beneficial to further test the 
hypothesis using different physiological constrictor agents to establish if PVAT from WT 
and KO animals had similar effects. 
6.4 Endothelium-independent relaxation to AICAR and 
PVAT  
The endothelium-independent relaxation to the AMPK activator AICAR has been 
documented in many animal models and vessels types, including mice aorta (Goirand et 
al., 2007), swine carotid artery (Rubin et al., 2005) and rat aorta (Majithiya and Balaraman, 
2006). In these models, in addition to removal of endothelium, PVAT was also dissected 
during preparation of the vessels for functional studies. Removal of endothelium did not 
affect the relaxation response induced by AICAR. Indeed these observations indicate a 
direct effect of AMPK activation in VSMCs. While the findings in the current study 
confirm these previous observations, they also provide evidence that the presence of PVAT 
enhances the relaxation induced by AICAR in an endothelium-independent manner. 
Furthermore, the enhanced response is mediated by transferable factor(s) the action of 
which may involve AMPK as the effects were lost in KO mice (Figure 3-8) . As reported 
previously, AMPK is expressed in all layers of blood vessel including PVAT. Therefore, it 
is plausible that AICAR will also activate AMPK in the PVAT which makes delineating 
the contribution of AMPK in the PVAT more difficult as the markers of AMPK activation 
(phosphorylation at both AMPK activation site Thr172 and AMPK downstream target 
Ser79 on acetyl-CoA carboxylase) responded in the same dose-dependent manner to 
AICAR. Indeed, treatment of PVAT alone with AICAR can be a solution; however, the 
decision about the basal activity of AMPK becomes more difficult.  
6.5 Relaxation to cromakalim and the role of KATP 
channels 
The role of KATP channels in the anti-contractile effect of PVAT was first proposed by 
Lohn et al (Lohn et al., 2002). They proposed that PVAT releases a transferable factor that 
acts via tyrosine kinase-dependent activation of KATP channels in the medial layer and was 
blocked by glibenclamide (Lohn et al., 2002). In the current research, the primary aim was 
to investigate the role of AMPK in the PVAT. Therefore, cromakalim was used to examine 
the relaxing ability of PVAT. Cromakalim is known to induce vascular relaxation by 
activation of KATP and hyperpolarisation of vascular myocytes (Cook et al., 1988). In the 
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current experiments, PVAT enhanced the relaxation response to cromakalim in an 
endothelium-independent manner in WT mice (Figure 3-9A). These effects were lost in the 
KO mouse-derived arteries (Figure 3-9B). Indeed, the findings from this study indicated 
the involvement of KATP in the anticontractile effect of PVAT (Lohn et al., 2002), and 
further suggest a possible regulatory role of AMPK. In general, the contraction of vascular 
smooth muscle is closely related to the status of myocyte membrane potential. 
Depolarisation of the myocyte cell membrane leads to opening of L-type voltage-
dependent Ca
2+
 channels causing Ca
2+
 influx into the cell and myocyte contraction. On the 
other hand, hyperpolarisation induced by opening of K
+
 channels decreases L-type Ca
2+
 
channel opening time and keeps the myocytes relaxed (Nelson and Quayle, 1995). 
Furthermore, KATP channels are activated in response to a reduction in intracellular 
ATP/ADP ratio, which help the myocytes to regulate the efflux of K
+ 
depending on their 
metabolic state (Nelson and Quayle, 1995). Indeed, these findings have made defining the 
role of AMPK in the PVAT more difficult as AMPK activation can occur in response to 
Ca
2+
 and a change in the ATP/ADP ratio as previously reported (reviewed in Hardie, 
2008). Although, the role of KATP has been tested by examination of AMPK activity in 
cultured VSMCs treated with increasing concentrations of cromakalim, the role of AMPK 
activation in VSMCs cannot be completely excluded as there was a reduction in the 
relaxation response in KO vessels without PVAT in comparison with WT PVAT-free 
vessels. Additionally, it is known that tonic vascular myocytes have negative membrane 
potentials (Nelson and Quayle, 1995) that are close to the activation threshold of Kv 
channels. Opening of cell membrane K
+
 channels allows K
+
 efflux, keeping the myocyte 
hyperpolarised and preventing further influx of Ca
2+
 into the cells and that may control the 
activation of AMPK in VSMCs.  
Taken together, these studies indicate that the activation of KATP in vascular myocytes, in 
addition to cromakalim, may be mediated by a transferable factor released from PVAT 
(adiponectin) and that AMPK is involved in this process by either controlling release of 
adiponectin and/or activation of KATP in vascular myocytes.  
6.6 Adiponectin as ADRF? 
In an attempt to determine the chemical nature of ADRF, the effects of adiponectin on 
whole vessels and cultured VSMCs were investigated. A previous study by Greenstein et 
al speculated that adiponectin was the PVAT-derived anticontractile factor in human 
vessels, since an adiponectin blocking peptide abolished the anticontractile effects of 
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PVAT. However, the mechanism proposed in their study involves activation of eNOS in 
the endothelium and subsequent release of NO (Greenstein et al., 2009). The role of 
adiponectin in endothelium-independent relaxation has been investigated in other studies 
which reported the involvement of both AMPK and BKCa (Weston et al., 2013, Lynch et 
al., 2013). In the current study, the importance of adiponectin to the anti-contractile effect 
of PVAT was illustrated as PVAT from AMPKα1 knockout mice had an impaired anti-
contractile effect in functional studies and this corresponded with reduced adiponectin 
content and release. Application of globular adiponectin enhanced the vasorelaxant effect 
of both WT and KO thoracic aortae (Figure 3-27). Furthermore, by using a KATP channel 
opener in vessel tension experiments, the current study suggests that the attenuated 
relaxation in KO arteries may be attributed to the adiponectin deficiency in KO PVAT and 
that adiponectin-induced hyperpolarisation in WT occurs as a result of opening of KATP 
channels in the medial layer. The role of KATP channels could be confirmed using a 
selective blocker such as glibenclamide and/or measuring membrane potential in VSMCs 
treated with adiponectin. The role of KATP channels could also be studied using specific 
KATP channel knockout model animals. It is worth noting that a specific KATP channel KO 
has been reported by targeting Sur2 or Kir6.1 subunit (Nichols et al., 2013). 
As application of globular adiponectin enhanced the cromakalim-induced relaxation in 
both wild type and AMPKα1-deficient vessels, four conclusions can be drawn. Firstly, the 
attenuated relaxation response in the KO occurred as result of dysfunctional adiponectin 
release from PVAT and that the downstream effectors in vascular smooth muscle are intact 
and still able to respond to adiponectin. Secondly, the expression of adiponectin receptors 
in the medial layer might be not affected by AMPKα1 deletion, although the expression of 
these receptors has not been investigated in the current study. Thirdly, adiponectin can 
activate KATP in the myocytes directly and induce hyperpolarisation and relaxation. The 
direct KATP activation by adiponectin has been reported previously in nerve cells (Hoyda 
and Ferguson, 2010). However, there are many different types of KATP channels with 
variable expression and tissue localisation (Ko et al., 2008). Furthermore, the role of KATP 
in the PVAT anti-contractile effect has been previously proposed by Lohn et al without 
defining the ADRF released by PVAT (Lohn et al., 2002). Finally, the enhanced relaxation 
in both WT and KO arteries in response to globular adiponectin suggests a possible direct 
action of adiponectin on vascular myocytes mediated by activation of MLCK which needs 
to be further clarified.  
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Together, these data indicate that non-stimulated PVAT releases adiponectin and that 
adiponectin (and perhaps other PVAT-derived factors) can activate KATP channels on the 
myocytes. It is likely in the mouse aorta that adiponectin is the ADRF. Hence, the anti-
contractile effect of adiponectin is apparently via two different mechanisms: firstly, by 
activating the KATP channels on the myocytes to cause hyperpolarisation; secondly, it may 
also trigger inhibition of MLCK and/or activation of MLCP in VSMCs. 
6.7 Proposed mechanism of relaxation 
The release of ADRF has been reported to be dependent on Ca
2+
 and is regulated by 
intracellular signalling pathways involving tyrosine kinase and protein kinase A, 
independent of perivascular nerve endings (Dubrovska et al., 2004). There are very few 
studies where the role of AMPK in the release of ADRFs has been investigated. A study by 
Lihn et al indicated that the AMPK activator AICAR stimulated adipose tissue AMPKα1 
activity and adiponectin gene expression and reduced the release of TNF-α and IL-6 (Lihn 
et al., 2004). These cytokines have been shown to have inhibitory effects on adiponectin 
gene expression and release (Fasshauer et al., 2002, Maeda et al., 2002, Greenberg et al., 
1991), meaning that activity of AMPK in the PVAT could regulate adiponectin expression 
(Lihn et al., 2004). Similarly, the PPARγ agonist troglitazone which also activates AMPK 
has a positive effect on adiponectin expression in mature adipocytes (Phillips et al., 2003). 
The current study supports previous evidence as the KO PVAT exhibited a profound 
reduction in adiponectin release as confirmed by both array and ELISA (Figures 3-22 and 
3-23). However, other studies using cultured 3T3-L1 adipocytes found that prolonged 
exposure to AMPK activating agents actually causes a significant reduction in adiponectin 
protein content of the adipocytes (Huypens et al., 2005). Therefore, it can be proposed that 
AMPK modulates adiponectin release by directly affecting its secretion by PVAT or 
indirectly via alleviating PVAT inflammation. Figure 6-1 illustrates the proposed 
mechanism by which PVAT AMPK modulates vascular function.   
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Figure ‎6-1 The proposed anticontractile mechanism of perivascular adipocytes on vascular 
myocytes.  
AMPK: AMP-activated protein kinase; AdipoR1: Adiponectin receptor 1; KATP: ATP-sensitive 
potassium channel; MLCK: Myosin light chain Kinase; MLCP: Myosin light chain phosphatase.  
 
 
6.8 Mechanism of PVAT dysfunction in obesity 
In chapter 5, an investigation of the effects of obesity on PVAT function was examined, 
assessing the contribution of AMPK in more detail. The current investigation using ELISA 
showed that the levels of adiponectin were significantly lower in PVAT and CM from 
HFD-fed mice as compared with ND group (Figure 5-12). It has been reported previously 
that adiponectin released from PVAT has a profound vasorelaxant effect on nearby arteries 
(Greenstein et al., 2009), and that data presented in this thesis confirms that the PVAT anti-
contractile effect is impaired in obese mice compared to healthy controls (Figure 5-4). The 
macrophage infiltration in the obese PVAT as reported in the current study (Figure 5-11) 
and previous reports (Aghamohammadzadeh et al., 2015) and the reduced activity of 
AMPK in obese and AMPKα1 knockout PVAT (Figure 5-10) suggests that higher levels of 
inflammatory mediators such as cytokines and superoxide in the PVAT may have adverse 
vasoactive effects on adjacent vasculature.  
Obesity is associated with chronic low-grade inflammation in adipose tissue that can be 
extended to PVAT. HFD leads to an increase in adipose tissue mass that initially occurrs as 
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a result of cell hyperplasia mediated by the recruitment and proliferation of adipogenic 
progenitors such as IGF-I, IGF binding proteins, TNFα, angiotensin II, and 
MCSF(Hausman et al., 2001). Later, increased fatty acid deposition in adipocytes is 
associated with cell death. Cell death with the release of inflammatory cytokines leads to 
rerecruitment of inflammatory cells and to adipose tissue dysfunction (Cinti et al., 2005). 
Obesity causes major changes in cellular phenotype of adipose tissue that can be detected 
systemically or within local adipose tissue. HFD-induced obesity induces a shift in the 
PVAT secretory function profile from anti-inflammatory profile to pro-inflammatory 
profile by releasing cytokines and chemokines which are linked with oxidative stress in 
PVAT (Bailey-Downs et al., 2013). HFD-induced obesity is associated with enhanced 
production of proinflammatory adipokines, such as TNF-α, leptin, resistin and decreased 
production of anti-inflammatory adipokines, such as adiponectin (Chatterjee et al., 2009, 
Arita et al., 1999, Serne et al., 2007). In another study, HFD increased mesenteric PVAT 
macrophage content and vascular oxidative stress in mice (Wang et al., 2012). Human 
adipocytes show an increase in proinflammatory cytokines expression in obese states (IL-
6, IL-8, and MCP-1) and reduced adipocytic differentiation (Chatterjee et al., 2009). These 
data suggest that inflammatory cytokine release by PVAT could attract macrophages to the 
depot further aggravating inflammation and PVAT dysfunction. 
Several signalling pathways have been suggested in pro-inflammatory adipocytokine-
induced adipose tissue inflammation. Cytokines such as TNF-α and IL-1β signalling 
pathway involves activation of pro-inflammatory transcription factors ERK, p38 and JNK 
MAP kinases and the NF-kB (Salt and Palmer, 2012). Factors such as leptin and IL-6 
signalling involves JAK/STAT pathway (Richard and Stephens, 2014). In obesity, These 
signalling pathways result in upregulation of chemokines, including MCP-1 which 
stimulates  macrophages infiltration to the site of inflammation (Gesta et al., 2007). 
Obesity-associated inflammation may also involve other chemokine receptors and ligands, 
including MIP-1, RANTES and MCP-2 (Kitade et al., 2012). Macrophage infiltration into 
adipose tissue also occures in response to adipocyte death as demonstrated by Cinti et al 
(Cinti et al., 2005) or in response to increased caloric intake (increased FA) (Nguyen et al., 
2007). The recruitment of macrophages in response to FA occurs as a result of activation 
of TLR (Toll-like receptor) family which in turn trigger proinflammatory pathways and 
induces cytokine expression (Shi et al., 2006). 
 Chapter 6 – General Discussion 
 
 
161 
 
Adipose tissue macrophages in healthy mice have the genetic features of M2 macrophages 
with anti-inflammatory properties, which may protect adipocytes from inflammation. 
HFD-induced obesity causes a shift in the macrophage polarity to an M1 pro-inflammatory 
state that contributes to insulin resistance (Lumeng et al., 2007). It is worth noting that 
adiponectin induces anti-inflammatory function by polarisin adipose tissue macrophages 
into M2 macrophages with characteristic anti-inflammatory markers (Ohashi et al., 2010). 
Recruited macrophages can induce an inflammatory reaction via activation of NLRP3 
inflammosome which results in maturation and release of cytokines IL-1β and IL-18 
(Vandanmagsar et al., 2011). 
There is much evidence demonstrating AMPK is anti-inflammatory and acts as a protective 
mechanism against inflammation (Salt and Palmer, 2012). Several mechanisms have been 
proposed. Activation of AMPK can abolish the production of pro-inflammatory cytokines 
such as TNF-α, IL-1β and IL-6 in macrophages (Galic et al., 2011, Yang et al., 2010, Jeong 
et al., 2009, Sag et al., 2008) and IL-6 and IL-8 in adipocytes (Lihn et al., 2008). AMPK 
activation was also shown to increase expression of anti-inflammatory cytokine IL-10 in 
macrophages (Galic et al., 2011, Sag et al., 2008). Activation of AMPK by AICAR in 
cultured adipocytes has been shown to promote adiponectin gene expression, while 
attenuating the release of TNF-α and IL-6 (Lihn et al., 2004). Similarly, activation of 
AMPK by berberine attenuates the expression of proinflammatory genes such as TNF-α, 
IL-1β, IL-6, MCP-1, iNOS, and COX-2 in adipose tissue (Jeong et al., 2009). Activation of 
NLRP3 inflammasome in myeloid cells by metformin has been reported to reduce release 
of IL-1β and IL-18 in monocyte-derived macrophages, an effect which may involve 
AMPK (Lee et al., 2013).  
In addition, in healthy WT animals, there was preservation of PVAT anticontractile 
function after removal of the endothelium, thus supporting the data reported by Gao et al 
(Gao et al., 2007) that PVAT effect is not dependent on the presence of endothelium. In the 
HFD model, there was partial preservation of the anti-contractile capacity in WT but not 
KO mice in the absence of endothelium. These observations could be attributed to the 
protective mechanism of AMPK against inflammatory insults and/or contribution of other 
vasodilators released from PVAT such as H2S.  
Taken together, in obesity, increases in the amount of PVAT and in the expression pattern 
of adipokines and other PVAT-derived factors may shift the normal paracrine influence of 
PVAT from a net vasorelaxant role to an oxidative, pro-inflammatory, and contractile 
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status. This shift towards the dominance of vasoconstrictor and inflammatory factors, 
together with the lack of normal functioning AMPK in obesity could provide the link 
between obesity and the functional and structural changes observed in CVD.   
Obesity
Relaxation 
dysfunction
Increase in PVAT mass
Adipocytes hypertrophy 
Inflammation  & macrophage infiltration 
Oxidative stress
Increase cytokines release such as TNFα
& IL-6.
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AMPK activity
Dysfunctional PVAT 
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Decreased 
adiponectin 
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Normal AMPK 
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Normal PVAT 
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Figure ‎6-2 Hypothesis of the mechanism of PVAT dysfunction in obesity and the role of 
AMPK. 
 
6.9 Potential physiological relevance and clinical 
implications 
Findings generated in this thesis have physiological, pathophysiological and therapeutic 
implications. The results of the current thesis provide evidence that supports a potential 
role for PVAT in regulation of vascular contraction mediated via AMPK in situ, a 
vasoprotective function for AMPK in maintaining normal PVAT function in regulating 
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vasomotor responsiveness in healthy vasculature, and a potential therapeutic target for 
AMPK in treatment of vascular dysfunction associated with obesity and CVD.  
6.9.1 Basal AMPK activity may act as vasculoprotective 
mechanism  
The findings in this thesis indicate that basal AMPK activation is depressed in PVAT of 
both obese and KO mice relative to lean and WT animals, respectively (Figure 5-10). Since 
the reduction of AMPK in PVAT is associated with dysfunctional vasomotor function in 
obese and KO animals, it can be assumed that activation of AMPK at basal conditions will 
act as a protective mechanism against vascular insult, maintaining a healthy vascular 
function or perhaps help in alleviating the consequence of any pathological conditions that 
trigger vascular dysfunction.  
The protective function of the AMPK has been reported before in endothelium and 
VSMCs. It has been reported that deletion of AMPKα2 subunit is associated with 
endothelial dysfunction (Wang et al., 2010b) and increased vascular smooth muscle 
contraction (Wang et al., 2011b). The study by Meijer et al investigated the effect of 
PVAT on the insulin-induced vasodilatation in muscular resistance arteries and showed 
that insulin causes dilation in AMPKα2 intact vessels while deletion of AMPKα2 caused 
insulin to induce vasoconstriction. Furthermore, the vasoralxant effect of PVAT was 
diminished in obese mice and that inhibition of JNK restored insulin-induced vasodilation 
in an adiponectin-dependent manner (Meijer et al., 2013). The current research reported 
different subunit contribution to the anti-contractile effect of PVAT. The difference in the 
findings may be related to the mice strain or to the type of vessels they utilise. 
Additionally, it might be related to the insulin signalling pathway which might be 
dependent of AMPKα2.    
Another study reported that endothelial dysfunction was more pronounced in AMPK α1 
deficient mice chronically treated with angiotensin II compared to WT mice and that the 
AMPK α1 in WT retain certain degree of endothelial function in mice treated with 
angiotensin II (Schuhmacher et al., 2011). Data from the current thesis suggest that 
AMPKα1 may partially preserve PVAT anticontractile effects in case of endothelial injury 
via modulation of adipocytokine production and release. These findings suggest that 
AMPK plays a vascular protective role under normal physiological conditions and protects 
against vascular tone dysfunction induced by cardiovascular pathologies.  
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However, the results using a global AMPK knockout model are not conclusive, as this 
model is also associated with other metabolic and physiological dysfunction that might 
lead to altered vasomotor impairment independently of the AMPK catalytic subunit 
ablation in the vessel or PVAT itself (Viollet et al., 2003, Jorgensen et al., 2004, Andreelli 
et al., 2006). Furthermore, it is difficult to determine the extent of α2 subunit compensation 
in the absence of the other alpha subunit.  Indeed, the findings of the current research do 
appear to add to the previous evidence regarding the protective role for AMPK in 
maintaining normal vasomotor function, although continued investigation is mandatory to 
confirm the current data. If AMPK does play a role in regulating physiological responses 
to different stimuli in health, it is plausible to think that the depression of AMPK activity 
in blood vessels including PVAT in obesity contributes to the dysfunctional vascular 
phenotype in these animals. 
6.9.2 Activation of AMPK in PVAT is a Potential therapeutic target 
Currently, the only therapeutic strategy that has been reported to improve survival in obese 
patients is weight-reducing surgery. However, its higher cost makes it less efficient. Based 
on the current findings and evidence in literature, PVAT function is essential to maintain 
normal vascular haemostasis. If this is the case, any therapeutic strategy that can prevent 
inflammation and beneficially manipulate secretory function at the adipocyte level would 
be attractive.  
Many studies have investigated the therapeutic benefit of AMPK-targeted compounds on 
the vascular tone in animal disease models. α-lipoic acid, a potent antioxidant used in 
treatment of diabetic neuropathy, has been found to alleviate endothelial dysfunction in 
obese rats (Lee et al., 2005). Another natural compound known as berberine was found to 
protect endothelial cells from hyperglycaemia and enhance vasodilation via AMPK 
activation (Wang et al., 2009c). Furthermore, in vivo administration of metformin has been 
found to enhance acetylcholine-induced relaxation and decrease endothelium-derived 
contracting factor (EDCF)-mediated contraction in OLEFT rat mesenteric rings 
(Matsumoto et al., 2008). Similarly, cultured SCAT derived from obese women and 
stimulated with AICAR showed enhanced adiponectin and GLUT4 expression and reduced 
TNF-α, IL-8 and IL-6 secretion (Lihn et al., 2004, Lihn et al., 2008).  
Interestingly, a synthetic small-molecule adiponectin receptor agonist (adipoRon) has been 
synthesised and was found to have similar effects to adiponectin on muscle and liver. 
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AdipoRon alleviates obesity-associated insulin resistance and glucose intolerance in obese 
rodent model db/db mice, and prolonged the lifespan of db/db mice on a high-fat diet. This 
effect involves activation of AMPK and PPAR-α pathway (Okada-Iwabu et al., 2013). 
Perhaps most exciting is a recent report on adipoRon where it was found to induce 
vasodilation in rat cerebral and coronary arteries. However, the effect was endothelium-
independent and also independent from AMPK, K
+
 efflux and any decrease in intracellular 
Ca
2+
 (Hong et al., 2016). AdipoRon is a promising therapeutic approach for the treatment 
of obesity-related diseases such as type 2 diabetes. 
The current evidence supports that PVAT have the capacity to act in a paracrine manner, 
on the circulation, the function of which it modulates via complex mechanisms which 
involves AMPK. The alterations in the anticontractile function of PVAT associated with 
obesity, metabolic syndrome, hypertension, or atherosclerosis are correlated with an 
imbalance in the secretion of adipokines such as adiponectin, inflammation and oxidative 
stress, resulted in vascular dysfunction. The sequence and the trigger of this 
phathophysiology are unclear, and the main events reported in this thesis, appear to be the 
PVAT infiltration by macrophage and reduced AMPK expression. A better understanding 
of PVAT physiology may allow for the design of therapies for vascular dysfunction and of 
strategies for directing these therapies to PVAT. Furthermore, the current findings provide 
meaningful data to justify follow-up in vivo studies to evaluate the role of AMPK 
activation in both physiological and pathophysiological state. Furthermore, more human 
studies are certainly needed in order to definitively define the role of PVAT AMPK in 
cardiovascular disease. 
6.10 Limitations 
Despite the research advances, AMPK remains a challenging system to study due to its 
multiple interactions with other molecules at both cellular and whole body level and its 
ubiquitous distribution. Furthermore, the lack of specific tools currently available to study 
this enzyme in adipose tissue including PVAT is one limitation that exists with this field of 
research. Although models of global AMPKα1 and α2 knockout have been generated, their 
application in identifying a specific role for PVAT AMPK in regulating vascular function 
is limited as these models are usually associated with metabolic and physiological 
dysfunction. Recently, adipose tissue-specific AMPKα1 and α2 knockout mouse models 
have been generated and used to investigate the role of AMPK in lipolysis and FA 
metabolism in adipose tissue under physiological conditions (Giordano et al., 2005).  This 
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model may be more useful for providing insight regarding the vascular effects of PVAT 
AMPK, as these animals should exhibit major reductions in PVAT AMPK activity (AMPK 
α1 is the predominant isoform expressed in PVAT). 
6.11 Concluding remarks   
The results presented in this thesis have increased our understanding of signalling 
pathways involved in regulation of vascular contractility by providing insight on a novel 
mechanism and regulator of vascular tone in both health and disease state. Furthermore, 
the data presented in this thesis provides not only supporting evidence about the function 
of adiponectin as a potential physiological modulator of vascular tone but also helps the 
understanding of the molecular mechanisms behind the vasculoprotective effects of this 
adipokine and its interaction with AMPK.  
It is, however, important to consider that the mechanisms proposed in this thesis and other 
research are ex vivo/in vitro studies and, thus, the physiological and clinical relevance of 
these results remains to be further investigated. Therefore, it is essential to continue to 
investigate the basic signalling mechanisms by which PVAT controls vascular 
haemostasis, as understanding the fundamental mechanism of AMPK vasomotor signalling 
pathways and their functional outcomes will broaden the understanding of regulation of 
vascular haemodynamic control. Furthermore, it will facilitate the development of potential 
novel therapeutic approaches that can be used to tackle vascular dysfunction associated 
with obesity and its complications. 
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